<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75889</article-id><article-id pub-id-type="doi">10.7554/eLife.75889</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer’s disease mouse model</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-263641"><name><surname>Lonnemann</surname><given-names>Niklas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7285-9995</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263640"><name><surname>Hosseini</surname><given-names>Shirin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7949-862X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263642"><name><surname>Ohm</surname><given-names>Melanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286110"><name><surname>Geffers</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263643"><name><surname>Hiller</surname><given-names>Karsten</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-263644"><name><surname>Dinarello</surname><given-names>Charles A</given-names></name><email>cdinare333@aol.com</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-109528"><name><surname>Korte</surname><given-names>Martin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6956-5913</contrib-id><email>m.korte@tu-bs.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Cellular Neurobiology, Zoological Institute</institution><addr-line><named-content content-type="city">Braunschweig</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03d0p2685</institution-id><institution>Neuroinflammation and Neurodegeneration Group, Helmholtz Centre for Infection Research</institution></institution-wrap><addr-line><named-content content-type="city">Braunschweig</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution>BRICS - Braunschweig Integrated Centre of Systems Biology</institution><addr-line><named-content content-type="city">Braunschweig</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution>Genome Analytics Group, Helmholtz Center for Infection Research</institution><addr-line><named-content content-type="city">Braunschweig</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03d0p2685</institution-id><institution>Department of Computational Biology of Infection Research, Helmholtz Centre for Infection Research</institution></institution-wrap><addr-line><named-content content-type="city">Braunschweig</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02hh7en24</institution-id><institution>Department of Medicine, University of Colorado Denver</institution></institution-wrap><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Department of Medicine, Radboud University, Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nijmegen</named-content></addr-line><country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hu</surname><given-names>Xiaoyu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Tsinghua University</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Chin</surname><given-names>Jeannie</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Baylor College of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e75889</elocation-id><history><date date-type="received" iso-8601-date="2021-11-26"><day>26</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-08-29"><day>29</day><month>08</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-11-26"><day>26</day><month>11</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.11.26.470085"/></event></pub-history><permissions><copyright-statement>© 2022, Lonnemann et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Lonnemann et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75889-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-75889-figures-v2.pdf"/><abstract><p>The anti-inflammatory cytokine interleukin-37 (IL-37) belongs to the IL-1 family but is not expressed in mice. We used a human IL-37 (hIL-37tg) expressing mouse, which has been subjected to various models of local and systemic inflammation as well as immunological challenges. Previous studies reveal an immunomodulatory role of IL-37, which can be characterized as an important suppressor of innate immunity. Here, we examined the functions of IL-37 in the central nervous system and explored the effects of IL-37 on neuronal architecture and function, microglial phenotype, cytokine production and behavior after inflammatory challenge by intraperitoneal LPS-injection. In wild-type mice, decreased spine density, activated microglial phenotype and impaired long-term potentiation (LTP) were observed after LPS injection, whereas hIL-37tg mice showed no impairment. In addition, we crossed the hIL-37tg mouse with an animal model of Alzheimer’s disease (APP/PS1) to investigate the anti-inflammatory properties of IL-37 under chronic neuroinflammatory conditions. Our results show that expression of IL-37 is able to limit inflammation in the brain after acute inflammatory events and prevent loss of cognitive abilities in a mouse model of AD.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>neurodegeneration</kwd><kwd>neuroinflammation</kwd><kwd>memory</kwd><kwd>hippocampus</kwd><kwd>cytokine</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB854</award-id><principal-award-recipient><name><surname>Korte</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Expression of an interleukin that is immune suppressive (IL-37) in mice is able to limit inflammation in the brain after acute inflammatory events and prevent loss of cognitive abilities in a mouse model of AD.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Neuroinflammation is characterized by glial cell activation and is mediated via pro-inflammatory signals (<xref ref-type="bibr" rid="bib69">Ji et al., 2014</xref>; <xref ref-type="bibr" rid="bib120">Rivest, 2009</xref>). In general, acute inflammation is the initial response of the immune system and is characterized by activation of immune cells, rapid production of various cytokines and chemokines, and phagocytic mechanisms. Although these processes are important to combat pathogens, persistent inflammation can lead to a pathophysiological state that results in tissue damage and loss of function. It is well known that during inflammation, pro- and anti-inflammatory cytokines interact and influence the outcome. Examples of pro-inflammatory cytokines include interleukin (IL)–1β and tumor necrosis factor α (TNF-α), both of which elicit a strong acute inflammatory response (<xref ref-type="bibr" rid="bib35">Dinarello, 1996</xref>; <xref ref-type="bibr" rid="bib84">Leal et al., 2013</xref>). In contrast, anti-inflammatory cytokines such as IL-4, IL-10 (<xref ref-type="bibr" rid="bib33">De Beaux et al., 1996</xref>; <xref ref-type="bibr" rid="bib93">Marie et al., 1996</xref>), or IL-37 (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>) inhibit the action of pro-inflammatory cytokines and hence limit inflammation (<xref ref-type="bibr" rid="bib24">Cavaillon, 2001</xref>). In the CNS, long-term activation of glial cells leads to neuroinflammation, which is an important hallmark of many neurological disorders, including Alzheimer’s disease (AD), Parkinson’s disease or multiple sclerosis (<xref ref-type="bibr" rid="bib69">Ji et al., 2014</xref>). In particular, AD is the most common form of dementia characterized by amyloid-β plaques and neurofibrillary tangles in the brain tissue. Patients with AD suffer from memory loss, speech disorders, confusion, problems with attention, and spatial orientation. Currently, there are no effective treatment strategies to combat AD despite the considerable clinical need.</p><p>Innate immune responses and neuroinflammation are thought to contribute significantly to the progression of AD (<xref ref-type="bibr" rid="bib136">Tan et al., 2007</xref>). Therefore, regulatory cytokines that can reduce inflammation in the CNS are of therapeutic value (<xref ref-type="bibr" rid="bib11">Banchereau et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Cavalli et al., 2016</xref>). Nevertheless, it remains unclear which of the regulatory mediators act adversely or beneficially at each stage of the neuroinflammatory process (<xref ref-type="bibr" rid="bib69">Ji et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Grace et al., 2014</xref>; <xref ref-type="bibr" rid="bib74">Kigerl et al., 2009</xref>).</p><p>For example, the release of IL-1β under pathological conditions can lead to deficits in learning and memory processes as well as in long-term potentiation (LTP) (<xref ref-type="bibr" rid="bib9">Avital et al., 2003</xref>; <xref ref-type="bibr" rid="bib57">Hein et al., 2010</xref>; <xref ref-type="bibr" rid="bib139">Tong et al., 2012</xref>). In addition, pro-inflammatory cytokines such as TNF-α and interferon-γ (IFN-γ) have been associated with impairments in hippocampal neuron structure and function during viral infection (<xref ref-type="bibr" rid="bib62">Hosseini et al., 2018</xref>). It is important to note that in chronic inflammation, the homeostasis of pro- and anti-inflammatory mediators is completely disturbed and must be therapeutically directed at attenuating persistent inflammatory processes. Among the important pro-inflammatory mediators, both IL-1α and IL-1β play a role in autoinflammatory, autoimmune, infectious, and degenerative diseases (<xref ref-type="bibr" rid="bib36">Dinarello, 2009</xref>; <xref ref-type="bibr" rid="bib37">Dinarello, 2010</xref>; <xref ref-type="bibr" rid="bib38">Dinarello et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Gabay et al., 2010</xref>; <xref ref-type="bibr" rid="bib128">Sims and Smith, 2010</xref>). Although IL-1α and IL-1β are encoded by different genes, both cytokines are structurally related proteins that bind to the type I interleukin 1 receptor (IL-1R1) and elicit similar innate responses. However, IL-1α is constitutively present in healthy cells but is only released under cell stress conditions, as is the case during inflammation. Moreover, because it is constitutively present, IL-1α acts rapidly to trigger local inflammation. In contrast, IL-1β is not present in the healthy state; the IL-1β precursor is not active but requires processing by caspase-1, an intracellular protease, resulting in conversion to an active cytokine that is secreted (<xref ref-type="bibr" rid="bib50">Garlanda et al., 2013</xref>).</p><p>Unlike most members of the IL-1 family that induce inflammation, this important cytokine family also includes two members (IL-37 and IL-38) that act as anti-inflammatory signalling agents and are thought to dampen an ongoing innate immune response (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Dinarello, 2018</xref>). In particularly, IL-37 serves as a potent mediator to limit the inflammatory responses (<xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>; <xref ref-type="bibr" rid="bib23">Caraffa et al., 2018</xref>). Therefore, a transgenic mouse model expressing the human splice variant IL-37b (hIL-37tg) was developed (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>) and showed potent anti-inflammatory and beneficial effects in a wide variety of different pathological conditions in different organs (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib10">Ballak et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Coll-Miró et al., 2016</xref>; <xref ref-type="bibr" rid="bib95">McNamee et al., 2011</xref>; <xref ref-type="bibr" rid="bib158">Yousif et al., 2011</xref>). The transgenic mouse was generated to allow continuous expression of IL-37 in almost all cells. This was achieved by using the full-length cDNA of IL-37b through the CMV promoter (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>). It is important to note that these IL-37tg mice did not exhibit an abnormal phenotype and reproduced normally (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib39">Dinarello et al., 2016</xref>). IL-37 has been described as a protein that binds to the IL-18 receptor (IL-18R) and, unlike IL-18, does not elicit a pro-inflammatory immune response but prevents it and is even involved in an anti-inflammatory response (<xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>). IL-37 binds the alpha chain of the IL-18R and additionally interacts with IL-1R8 (also known as TIR8 or SIGIRR) rather than recruiting the beta chain of the IL-18R (as is the case with IL-18 binding) (<xref ref-type="bibr" rid="bib109">Nold-Petry et al., 2015</xref>). This co-localization was also demonstrated in mouse cells (<xref ref-type="bibr" rid="bib109">Nold-Petry et al., 2015</xref>). Other studies showed the mRNA of IL-18Rα and SIGIRR receptors on astrocytes and microglia (<xref ref-type="bibr" rid="bib3">Andre et al., 2005</xref>). Notably, IL-18Rα has been shown to be expressed on astrocytes and microglia, and IL-18 is produced only by microglial cells, suggesting a signalling cascade running mainly through microglia with respect to IL-18 and IL-37 (<xref ref-type="bibr" rid="bib3">Andre et al., 2005</xref>; <xref ref-type="bibr" rid="bib141">Tsilioni et al., 2019</xref>). In addition, two recent studies focusing on the central and peripheral nervous systems have demonstrated the therapeutic potential of IL-37 in autism spectrum disorders (ASD) and multiple sclerosis (MS) (<xref ref-type="bibr" rid="bib141">Tsilioni et al., 2019</xref>; <xref ref-type="bibr" rid="bib28">Cavalli et al., 2019</xref>). <xref ref-type="bibr" rid="bib141">Tsilioni et al., 2019</xref> have demonstrated a reducing effect of inflammation on IL-37 expression in cultured human microglia.</p><p>An important factor for the expression of IL-37 related to the instability sequence was also discovered in a mouse cell line. <xref ref-type="bibr" rid="bib21">Bufler et al., 2004</xref> showed that despite strong activation of the CMV promoter, expression of IL-37 could not be detected (<xref ref-type="bibr" rid="bib21">Bufler et al., 2004</xref>). It was also shown that the specific mRNA was rapidly degraded. However, a significant and rapid increase in IL-37 mRNA could be achieved by an LPS stimulus (<xref ref-type="bibr" rid="bib21">Bufler et al., 2004</xref>). Similarly, administration of recombinant IL-37 frequently exhibited beneficial effects on the outcome of various animal models of human diseases (<xref ref-type="bibr" rid="bib25">Cavalli et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Coll-Miró et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Moretti et al., 2014</xref>; <xref ref-type="bibr" rid="bib151">Wu et al., 2014</xref>). In addition, IL-37 has been shown to regulate cellular metabolism after an inflammatory stimulus (<xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>). In the last decade, metabolic changes have been described as an important determinant of immunological processes, as shown in macrophages after LPS stimulation (<xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>; <xref ref-type="bibr" rid="bib111">O’Neill and Hardie, 2013</xref>). The LPS-induced increase in mTOR phosphorylation and decreased AMP-activated protein kinase activity were reversed by expression of IL-37 (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib10">Ballak et al., 2014</xref>; <xref ref-type="bibr" rid="bib109">Nold-Petry et al., 2015</xref>; <xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>).</p><p>In the present study, we used hIL-37tg mice to investigate the effect of IL-37 expression on the acute inflammatory processes induced by LPS or IL-1β administration. In addition, we crossed the APP/PS1 mouse model of AD with hIL-37tg mice to investigate the role of IL-37 expression during the chronic state of neuroinflammation and the consequences for the progression of AD pathology.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Primary microglia from IL-37tg mice exhibit an inflammatory-suppressive response after LPS challenge in vitro</title><p>To investigate the effect of IL-37 on microglial cell activation, the release of the pro-inflammatory cytokines IL-6, IL-1β, and TNF-α was analyzed after LPS stimulation of wild-type (WT) and IL-37 transgenic microglial cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Primary microglial cells from IL-37tg mice showed decreased pro-inflammatory cytokine release after stimulation by LPS.</title><p>(<bold>A</bold>) WT and IL-37tg primary microglial cells (P3-5) were plated and stimulated without LPS or with LPS. Cells were treated for 6 hr (<bold>B</bold>) and 24 hr (<bold>B–E</bold>). Cells from homozygous transgenic animals released less pro-inflammatory cytokines IL-6 (<bold>C</bold>), TNF- (<bold>D</bold>) and IL-1β (<bold>E</bold>) under different LPS concentration (B-E n=4–9). (<bold>F</bold>) IL37 mRNA was analyzed in IL-37tg microglial cells at specific intervals after addition of LPS. (<bold>G</bold>) Levels of IL-6 were measured from the same cells as in (<bold>F</bold>) and were detectable only after 24 hr (n=3). (<bold>H</bold>) Levels of IL-6 were measured in WT after addition of increasing concentrations of recombinant IL-37b and 100 ng LPS (H n=6–18). Data are presented as mean ± SEM. * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001 compared to WT. (B+F + H: 1-way ANOVA with multiple comparison; C-E+G: t-test).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Release of pro-inflammatory cytokines by microglia after LPS stimulation.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Pro-inflammatory cytokine release by primary astrocytes after LPS stimulation.</title><p>(<bold>A–B</bold>) Primary astrocytes respond to an LPS stimulus (100 ng/ml for 24 hr) with increased levels of the pro-inflammatory cytokines IL-6 (<bold>A</bold>) and TNF-α (<bold>B</bold>). In contrast to microglial cells, astrocytes from hIL-37tg mice showed no reduction in these two pro-inflammatory cytokines (n=5-10).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Release of pro-inflammatory cytokines by astrocytes after LPS stimulation.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig1-figsupp1-v2.tif"/></fig></fig-group><p>First, IL-6 secretion in heterozygous (IL-37<sup>wt/tg</sup>) and homozygous (IL-37<sup>tg/tg</sup>) IL-37 transgenic primary microglia was analyzed and compared to IL-6 secretion of WT microglia upon LPS stimulation. The results showed that the amounts of IL-6 secreted by microglial cells from homozygous IL-37 transgenic (IL-37<sup>tg/tg</sup>) mice were significantly reduced compared to microglial cells from control mice after 24 hr of stimulation with 100 ng/ml and 1 µg/ml LPS and additionally also 6 hr after stimulation with 1 µg/ml LPS (F(2,11)=7.941 p=0.007; p=0.007; p=0.054; F(2,11)=3.915 p=0.052; p=0.043; p=0.359; F(2,9)=12.74 p=0.002; p=0.004; p=0.009) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Microglial cells from heterozygous IL-37 transgenic mice (IL-37<sup>wt/tg</sup>) also showed decreased IL-6 secretion, but only after 6 hr of stimulation with 1 µg/ml LPS (F(2,9)=12.74 p=0.002; p=0.009) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Thus, the immunosuppressive effect of transgenic expression of IL-37 on primary microglia was demonstrated only in this experiment by differences between hetero- and homozygous IL-37 transgenic mice. All subsequent experiments were analyzed using homozygous (IL-37<sup>tg/tg</sup>) IL-37 transgenic mice (referred to as IL-37tg). Further analysis also confirmed the reduction in inflammatory mediators by measuring the release of IL-6 when other concentrations of the inflammatory stimulus were examined (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) and could be extended by the significantly reduced release of TNF-α (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) and IL-1β (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), compared with primary microglial cells from control mice (IL-6: p=0.1007; p=0.0024; p=0.0001; TNF-α: p=0.0038; p&lt;0.0001; p&lt;0.0001; IL-1β: p=0.0295; p=0.0001; p&lt;0.0001). Remarkably, LPS stimulation caused a detectable increase in the level of transgenic <italic>IL37</italic> mRNA after 1 hr, which remained elevated in the following hours up to 24 hr post stimulation (F(7,15)=2.629 p=0.05509; p=0.0171, p=0.0086, p=0.0238) (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). As mentioned previously, the amount of IL-6 protein in the supernatant of the same cultures was significantly reduced when IL-37tg microglial cells were compared to identically stimulated control cells (p&lt;0.0001) (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Examining inflammatory responses in primary astrocytes as a different group of glial cells, we did not detect decreased levels of IL-6 and TNF-α in IL-37tg cells 24 hr after LPS stimulation (100 ng/ml) compared with WT primary astrocytic cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>), confirming the importance of anti-inflammatory IL-37 signaling, which may proceed via microglia but not astrocytes.</p><p>To investigate the potential effect of recombinant IL-37 (rIL-37) in inhibiting LPS-induced release of proinflammatory cytokines (here IL-6) by microglia, primary WT microglial cells were pretreated with either 100 ng/mL or 500 ng/mL rIL-37 for 2 hr and then stimulated with increasing concentrations of LPS. Pretreatment with rIL-37 was chosen because microglial cells from IL-37tg mice had very low basal expression of IL-37 even in the absence of LPS (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Therefore, the response of WT microglial cells to LPS in the presence of different concentrations of rIL-37 was examined here. After LPS induction, microglial cells pretreated with the higher concentration of rIL-37 showed a significant decrease in the release of IL-6 compared with cells pretreated with rIL-37 vehicle (PBS) (F(2,30)=5.135 p=0.0121; p=0.0133; F(2,30)=3.512 p=0.0426; p=0.0498) (<xref ref-type="fig" rid="fig1">Figure 1H</xref>).</p><p>Taken together, these results indicate that microglial cells in particular release lower levels of pro-inflammatory cytokines upon acute inflammatory stimulation in the presence of IL-37.</p></sec><sec id="s2-2"><title>Metabolomic profiling of microglial cells from IL-37tg mice reveals an attenuated metabolic response associated with inflammation after LPS stimulation in vitro</title><p>Recent studies have discovered several metabolic intermediates that contribute directly to immune function. Among them, the TCA cycle-related metabolites succinate and itaconate are novel markers associated with pro-inflammatory macrophage activation and function (<xref ref-type="bibr" rid="bib56">He et al., 2021</xref>; <xref ref-type="bibr" rid="bib97">Michelucci et al., 2021</xref>; <xref ref-type="bibr" rid="bib99">Mills et al., 2021</xref>). To address the question of whether microglial cells expressing the anti-inflammatory cytokine IL-37 are further capable of modulating inflammation-related metabolic changes, we performed intracellular metabolomic analysis of control and IL-37tg microglial cells treated with 10 ng/ml LPS for 24 hr. As expected, many metabolites were significantly elevated in LPS-treated control cells, including itaconate and succinate, both metabolic markers for proinflammatory activation of macrophages (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib97">Michelucci et al., 2021</xref>; <xref ref-type="bibr" rid="bib137">Tannahill et al., 2013</xref>). Levels of both metabolites were significantly less elevated in IL-37tg microglial cells, indicating an attenuated pro-inflammatory response at the metabolic level (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>) (itaconate F(1,20)=174.9 p&lt;0.0001; p&lt;0.0001; p&lt;0.0001; F(1,20)=27.55 p&lt;0.0001; p&lt;0.0001; succinate F(1,20)=98.40 p&lt;0.0001; p&lt;0.0001; p=0.0005; F(1,20)=17.01 p=0.0005; p&lt;0.0001). This is consistent with the profiles of other metabolites of central carbon metabolism showing modest effects after LPS treatment (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We conclude that IL-37tg microglial cells release lower levels of pro-inflammatory cytokines than control cells after LPS stimulation and that IL-37 expression in microglial cells limits LPS-induced pro-inflammatory metabolic reprogramming.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Primary microglial cells isolated from IL-37tg mice exhibited reduced levels of inflammation-associated intracellular metabolites after stimulation with LPS.</title><p>WT and IL-37tg microglia were stimulated with 10 ng/ml LPS (based on highly sensitive metabolomics assessments). Metabolomic analysis was performed on these cells. (<bold>A</bold>) Heatmap of identified significantly altered metabolites after or without LPS stimulation (described as Z-score). (<bold>B–C</bold>) Significant effects in WT, treated with LPS, were seen with respect to itaconate (<bold>B</bold>) and succinate (<bold>C</bold>), whereas these changes were significantly reduced in IL-37tg microglial cells treated with LPS compared with WT cells (n=11). Data are presented as mean ± SEM. *** p&lt;0.001 (two-way ANOVA with multiple comparison).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Inflammation-associated intracellular metabolites in primary microglia after LPS stimulation.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig2-v2.tif"/></fig></sec><sec id="s2-3"><title>Microglial activation and inflammatory responses are reduced after LPS challenge in IL-37tg mice</title><p>To test whether the anti-inflammatory properties of IL-37 on microglial cells observed in vitro studies, are similar in vivo, we intraperitoneally injected adult (3–8 month-old) homozygous IL-37tg mice (referred to as IL-37tg) and age-matched control animals with either saline (vehicle control group) or LPS (2x0.5 mg/kg) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Both experimental groups showed significant weight loss in response to systemic LPS injection, but the effect was significantly higher in control mice than in IL-37tg mice (weight loss F(1,17)=220.5 p&lt;0.0001; p&lt;0.0001; p&lt;0.0001; F(1,41)=1.486 p=0.2299; p=0.0139) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We next examined the effect of systemic administration of LPS on neuroinflammation by using brain homogenates for ELISA assays and also by isolating microglia from the brains of controls and LPS-treated animals for FACS analyzes. Control mice treated with LPS had a significantly higher percentage of CD68-expressing microglial cells (gated on the CD11b<sup>+</sup>/CD45<sup>low</sup> population) (CD68 F(1,6)=19.52 p=0.0045; p=0.0017; p&gt;0.9999; F(1,6)=48.42 p=0.0004; p=0.0001) (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>) compared to the cells of control animals treated with saline. Similarly, IL-1β levels in the brain of LPS-treated WT mice were significantly higher than those of saline-treated WT controls (IL-1β F(1,7)=9.399 p=0.0182; p=0.0244; p=0.7541; F(1,7)=3.182 p=0.0935; p=0.0366) (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Remarkably, IL-37tg animals showed no significant changes in CD68-expressing microglia and IL-1β levels when challenged with LPS in the same manner compared with matched controls (<xref ref-type="fig" rid="fig3">Figure 3C–E</xref>). Further analysis of pro-inflammatory cytokines IL-6 and TNF-α showed no significant changes between WT and IL-37tg mice treated with LPS and control groups, but a trend toward higher levels of IL-6 was observed in WT brain homogenates after LPS challenge (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>). Further investigation of cell populations in the brains of WT and IL-37tg mice after LPS stimulation underscored the importance of the IL-37 response, particularly in microglial cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A-E</xref>), whereas macrophages (gated on the CD11b<sup>+</sup>/CD45<sup>high</sup> population) showed no changes in CD68-expressing cells after LPS stimulation or between genotypes (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F-H</xref>). In addition, analysis of cell numbers in all experimental groups revealed a generally high number of microglial cells in the brain of the animals (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D and K</xref>) and, in contrast, very low numbers of macrophages (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2G and K</xref>) and leukocytes (gated on the CD11b<sup>-</sup>/CD45<sup>high</sup> population) (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2J-K</xref>), again highlighting the important role of microglia in this scenario.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>IL-37tg mice showed decreased pro-inflammatory cytokine release and less activated microglia after the stimulus of LPS.</title><p>(<bold>A</bold>) WT and IL-37tg mice were stimulated with saline or LPS. (<bold>B</bold>) IL-37tg animals exhibited significantly less weight loss compared to WT mice. However, IL-37tg mice also had a significant weight change compared to saline treated mice (n=10–22). Microglial cell activation was analyzed by FACS method. (<bold>C–D</bold>) Microglial cells were identified as CD11b<sup>+</sup> and CD45<sup>low</sup> cells and analyzed for CD68 expression. IL-37tg mice had a lower percentage of cells with CD68 expression compared with WT mice after LPS stimulation (n=4) (<bold>C–D</bold>). (<bold>E</bold>) In addition, WT mice exhibited a significant increase in IL-1β levels after LPS treatment, whereas IL-37tg mice did not (n=6–8). (<bold>F–I</bold>) Morphological analysis of microglial cells showed an increased number of IBA-1-positive cells in WT animals treated with LPS compared with saline-treated animals. In contrast, there is no increased IBA-1-positive cell number in IL-37tg animals after LPS stimulation (n=9–18; n=18–30 cells for processes). (<bold>J</bold>) Representative images of IBA-1-positive cells (red) and DAPI (blue); scale bar 40 µm. Data are shown as mean ± SEM. * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001, (B-I: 2-way ANOVA with multiple comparison).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Neuroinflammatory status of mouse brain after systemic LPS challenge.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Pro-inflammatory cytokines in brain lysates after peripheral LPS challenge.</title><p>(<bold>A–B</bold>) Pro-inflammatory cytokines IL-6 and TNF-α were measured in brain lysates from mice treated with LPS or saline (control). WT Mice showed slightly increased levels of IL-6 after LPS compared with mice treated with saline, whereas hIL-37tg mice did not show increased IL-6 levels (<bold>A</bold>) (n=7-10); TNF-α levels were not altered in both WT and hIL-37tg mice after LPS challenge (<bold>B</bold>) (n=3-5).</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Pro-inflammatory cytokines in mouse brain after systemic LPS challenge.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>FACS analysis of brain cells after peripheral LPS administration.</title><p>(<bold>A–B</bold>) Fluorescent activated cell sorting (FACS) method was used to analyze microglial activation with respect to CD68 expression (n=4). In forward/side scatter (FSC/SSC), the region of interest (ROI) was selected (<bold>A</bold>) and analyzed for two monocyte markers (CD11b and CD45) (<bold>B</bold>). (<bold>C–J</bold>) CD68 expressing cells were analyzed in microglia (CD11b<sup>+</sup>/CD45<sup>low</sup>) (<bold>C–E</bold>), macrophages (CD11b<sup>+</sup>/CD45<sup>high</sup>) (<bold>F–H</bold>), and leukocytes (CD11b<sup>-</sup>/CD45<sup>high</sup>) (<bold>I–J</bold>). (<bold>K</bold>) The number of cells in the different populations is shown in the experimental groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig3-figsupp2-v2.tif"/></fig></fig-group><p>The activation feature of microglial cells is reflected in the total number of microglial cells in the brain parenchyma and the number of primary processes of these CNS resident immune cells. For example, a higher number of IBA-1-positive cells and a reduced number of primary processes correlate with increased microglial activation (<xref ref-type="bibr" rid="bib54">Hanisch and Kettenmann, 2021</xref>; <xref ref-type="bibr" rid="bib113">Papageorgiou et al., 2015</xref>; <xref ref-type="bibr" rid="bib148">Wolf et al., 2017</xref>). Therefore, we performed immunostaining with the known microglial marker IBA-1 on brain sections obtained from the animals of both genotypes treated with either saline or LPS (<xref ref-type="fig" rid="fig3">Figure 3F–J</xref>). A significant increase in the number of IBA-1 positive cells was observed in the CA1 subregion of the hippocampus and in the cortex of LPS-treated animals compared with saline-treated control animals. However, in the IL-37tg mice, LPS did not result in a significant increase in the number of microglial cells (IBA-1 CA1 F(1,25)=5.222 p=0.0311; p=0.0024; p&gt;0.9999; F(1,34)=4.951 p=0.0328; p=0.0027;; IBA-1 Cx F(1,25)=15.97 p=0.0005; p=0.0002; p=0.3234; F(1,34)=5.159 p=0.0296; p=0.0054) (<xref ref-type="fig" rid="fig3">Figure 3F and H</xref>). Further analysis of the number of microglial primary processes showed no differences between animals in the control and the IL-37tg groups treated with either saline or LPS, except that microglial primary processes were significantly increased in the cortex of IL-37tg mice treated with LPS compared with saline-treated IL-37tg mice, which may indicate more branched microglial features (processes CA1 F(1,46)=1.066; p&gt;0.9999; p=0.6229; processes Cx F(1,104)=9.865; p=0.1401; p=0.0232) (<xref ref-type="fig" rid="fig3">Figure 3G1</xref>). Overall, these results demonstrate the anti-inflammatory effect of IL-37 expression on brain after LPS challenge, possibly mediated via microglial cells.</p></sec><sec id="s2-4"><title>IL-37tg mice are protected from functional and structural neuronal deficits after LPS challenge</title><p>Neuroinflammation has been shown to impair hippocampal network function (<xref ref-type="bibr" rid="bib62">Hosseini et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Beyer et al., 2020</xref>). Because previous studies indicate a significant induction of neuroinflammation after systemic LPS challenge, we hypothesized that IL-37 might also have a beneficial effect on hippocampal network function and structure. Therefore, as described above, we injected control and IL-37tg animals with either saline or LPS for subsequent analysis of neuronal function and structure. We, first examined long-term synaptic plasticity, the ability of synapses to change their transmission strength, which is considered a cellular correlate of learning and memory processes (<xref ref-type="bibr" rid="bib16">Bliss and Collingridge, 1993</xref>). To this end, we induced long-term potentiation (LTP) at the Schaffer collateral CA3 to CA1 pathway in the hippocampus. After 20 minutes of baseline recording, we observed significantly impaired LTP in the acute hippocampal slices of control mice treated with LPS compared to saline (F(1,28)=4.459 p=0.0438) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In contrast, IL-37tg animals treated with LPS did not show comparable deficits in synaptic plasticity compared to saline treated IL-37tg animals (F(1,23)=0.0849 p=0.7734) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). These differences were also evident in the maintenance phase of LTP (last 5 min of the measurement) (last 5 min F(1,22)=7.887 p=0.0102; p=0.0043; p&gt;0.9999) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>IL-37tg mice showed rescued synaptic plasticity and restored loss of spine density after stimulation by LPS compared with WT animals.</title><p>(<bold>A</bold>) WT animals stimulated with LPS showed significant impairment of theta burst stimulation-induced LTP (TBS) compared with WT, which were treated with saline. (<bold>B</bold>) In contrast, IL-37tg mice showed no significant impairment of LTP after LPS treatment. (<bold>C</bold>) Mean LTP magnitude (average of 55–60 min after TBS) was significantly lower in WT mice treated with LPS, while IL-37tg mice showed no significant differences (n of mice 3–4; n of acute slices 11–17). (<bold>D–F</bold>) Spine density in apical dendrites of the CA1 hippocampal neurons and in the superior DG neurons was significantly decreased in WT mice treated with LPS, whereas spine density of IL-37tg animals treated with LPS was not affected (n of mice 3–4; n of dendrites 13–25) (<bold>D and E</bold>). (<bold>F</bold>) Representative images of dendritic spines of hippocampal CA1 neurons in the tested groups were shown; scale bar 5 µm. (<bold>G</bold>) WT acute slices stimulated with LPS showed significant impairment of TBS-induced LTP compared with WT acute slices treated with ACSF. (<bold>H</bold>) In contrast, acute slices from IL-37tg mice showed no significant impairment of LTP after LPS treatment. (<bold>I</bold>) Mean LTP magnitude (mean of 55–60 min after TBS) was significantly lower in acute slices from WT mice treated with LPS, whereas slices from IL-37tg mice showed no significant differences (n of mice 3–4; n of acute slices 14–17). Data are presented as mean ± SEM. * p&lt;0.05, *** p&lt;0.001, (A-I: two-way ANOVA with multiple comparison).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Assessment of synaptic plasticity after LPS challenge.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig4-v2.tif"/></fig><p>To assess the effects of IL-37 on neuronal structure, we analyzed the dendritic spine density of hippocampal neurons from all experimental groups. Dendritic spines are small protrusions representing the postsynaptic part of excitatory synapses and were counted on the apical dendrites of CA1 neurons as well as on the dendrites of dentate gyrus neurons. A significant decrease in the density of dendritic spines of CA1 pyramidal neurons and dentate gyrus cells was observed in control mice treated with LPS compared with saline-treated mice (spines CA1 F(1,32)=22.81 p&lt;0.0001; p&lt;0.0001; p=0.1145; F(1,44)=26.68 p&lt;0.0001; p&lt;0.0001; spines DG F(1,26)=3.307 p=0.0805; p=0.0062; p&gt;0.9999; F(1,36)=0.529 p=0.4718; p=0.0295) (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>).</p><p>Similar to the LTP data, the density of dendritic spines of neurons from IL-37tg animals was unchanged when LPS- and saline-injected mice were evaluated (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>). In conclusion, these results demonstrate a negative effect of systemically administered LPS on synaptic plasticity that can be restored by IL-37.</p><p>Given the possibility that peripheral immune cells in IL-37tg mice also produce IL-37 after LPS challenge and already attenuate the systemic immune response, the question arose whether IL-37 would have a similar protective effect directly in the CNS after LPS stimulation. To accurately demonstrate the beneficial effect of IL-37 in the CNS without the influence of peripheral cells, another electrophysiological experiment was performed.</p><p>Here, acute hippocampal slices from control and IL-37tg animals were prepared and stimulated with LPS (10 µg/ml) in ACSF for 2 hr after a resting period before recording. In the control groups, the sections were kept in ACSF only. These further results indicated that direct IL-37 expression in the acute slices of IL-37tg mice appears to be sufficient to reverse the impairments in LTP after LPS administration. This is because, in contrast to the significant impairment of LTP after LPS administration in acute hippocampal slices of control mice (LTP WT F(1,30)=4.925 p 0.05) (<xref ref-type="fig" rid="fig4">Figure 4G</xref>), no impairment of LTP was observed in acute slices of IL-37tg mice when treated with LPS (LTP IL-37tg F(1,26)=0.0139 p=0.9069) (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). This effect was also evident in the data for the last 5 min of the measurement, which represents the maintenance phase of LTP (last 5 min F(1,27)=4.613 p=0.0409; p=0.0285; p 0.9999) (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). These results clearly demonstrate that local IL-37 expression in the brain can prevent the deleterious effects of LPS on neuronal function.</p></sec><sec id="s2-5"><title>Recombinant IL-37 reduces inflammatory response in vivo and alleviates short-term memory impairment induced by pro-inflammatory cytokine stimulation</title><p>To investigate the anti-inflammatory properties of the recombinant IL-37 (rIL-37) protein in vivo, wild-type mice were pretreated with either 300 ng rIL-37 per animal (i.p.) or an equivalent amount of vehicle (saline, control group) for 3 consecutive days. On day 4, animals were injected with 60 ng i.p. IL-1β or saline as control (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). After another 24 hr, the animals were trained and tested with the Y-Maze behavioral test to assess short-term memory based on the mice’s natural willingness to explore a new area. The score for spontaneous alternation depends on the mouse’s tendency to seek out a less recently entered arm of the maze. Therefore, this test also measures spatial hippocampus-dependent memory function.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Injection of recombinant IL-37 into WT mice showed restoration of cognitive deficits and reduced release of pro-inflammatory cytokines after IL-1β-mediated immunostimulation.</title><p>(<bold>A</bold>) WT mice were pretreated with either saline or rIL-37 for three consecutive days and then injected with saline or IL-1β. (<bold>B</bold>) WT mice pretreated with saline and then stimulated with IL-1β failed to perform the Y-maze test, whereas WT mice pretreated with rIL-37 and then stimulated with IL-1β performed the test without deficits (n=4). (<bold>C and D</bold>) Although the pro-inflammatory cytokine levels of IL-6 and IL-1α were significantly increased in stimulated WT mice pretreated with rIL-37 compared with the control group, the mice treated with rIL-37 showed a significant decrease in cytokine levels after immunostimulation with IL-1β compared with saline treated group (n=4–6). Data are presented as mean ± SEM. ** p&lt;0.01, *** p&lt;0.001, (B-D: two-way ANOVA with multiple comparison).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Suppressive effect of rIL-37 on the inflammatory response induced by IL-1β.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Pro-inflammatory cytokines in brain lysates after peripheral pretreatment with recombinant IL-37 followed by LPS challenge.</title><p>(<bold>A–C</bold>) IL-1β (<bold>A</bold>), IL-6 (<bold>B</bold>), and TNF-α (<bold>C</bold>) measured in control and LPS-treated WT or rIL-37-pretreated WT mice (n=3-4).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Pro-inflammatory cytokine levels induced by LPS in the brain of rIL-37 treated mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig5-figsupp1-v2.tif"/></fig></fig-group><p>In the absence of rIL-37 pretreatment, we detected a significant performance deterioration in IL-1β-injected mice compared to the corresponding saline-injected control group (Y-Maze F(1,6)=18.25 p=0.0052; p=0.0046; p=0.7313) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In contrast, pretreatment with rIL-37 protected the mice from the behavioral deficits induced by IL-1β administration (F(1,6)=9.899 p=0.0199; p=0.0024). To analyze the inflammatory mediators in the CNS of these animals, the levels of the pro-inflammatory cytokines IL-6 and IL-1α were measured in brain lysates. We observed that animals stimulated with rIL-1β showed significantly elevated levels of both cytokines compared with the corresponding controls (IL-6 F(1,16)=264.6 p&lt;0.0001; p&lt;0.0001; p&lt;0.0001; F(1,16)=10.27 p=0.0055; p=0.0004; IL-1α F(1,16)=132.0 p&lt;0.0001; p&lt;0.0001; p&lt;0.0001) (<xref ref-type="fig" rid="fig5">Figure 5C–D</xref>). However, pretreatment with rIL-37 resulted in significantly lower levels of IL-6 and IL-1α in the brains of rIL-1β immunostimulated mice (F(1,16)=17.47 p=0.0007; p=0.0003) (<xref ref-type="fig" rid="fig5">Figure 5C–D</xref>). Taken together, these data indicate the beneficial effects of IL-37 expression on cognitive function in immunostimulated mice.</p><p>To investigate the possible preventive effect of rIL-37 on LPS-induced neuroinflammation, in addition to IL-1β-immunostimulation, WT mice were pretreated with either 100 ng rIL-37 per animal (i.p.) or an equivalent amount of vehicle (saline, control group) for 3 consecutive days. On day 3 and 4, the animals were injected twice with LPS (0.5 mg/kg) and 3 hr after the last injection, the level of proinflammatory cytokines in the brain was measured (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A-C</xref>). The results showed that although injection of LPS in the saline-treated mice resulted in a significant increase in the levels of IL-1β (p&lt;0.01), IL-6 (p=0.04), and TNF-α (p&lt;0.004), only the production of IL-1β was significantly increased in the mice receiving rIL-37 (p=0.001), and the levels of TNF-α (p=0.97) and IL-6 (p=0.63) were not significantly increased in the brains of the mice pretreated with rIL-37 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A-C</xref>). These results also highlight the protective role of rIL-37 in modulating LPS-induced proinflammatory cytokines.</p></sec><sec id="s2-6"><title>IL-37 shows beneficial effects on neuronal deficits and microglia activation in APP/PS1-IL37tg animals</title><p>Our results demonstrated the protective properties of IL-37 on microglial activation, production of pro-inflammatory mediators, impairment of cognition, and disruption of long-term potentiation (LTP) after acute immunostimulatory challenge. To investigate the potential of IL-37 to attenuate chronic inflammation, we next analyzed transgenic APP/PS1 mice, which serve as a widely used animal model for Alzheimer’s disease (<xref ref-type="bibr" rid="bib67">Jankowsky et al., 2004</xref>), and crossed this mouse strain with hIL-37tg animals (<xref ref-type="fig" rid="fig6">Figure 6A</xref>; <xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>APP/PS1-IL37tg double transgenic mice showed lower pro-inflammatory cytokine expression and reduced activation of microglia, as well as lower numbers of amyloid plaques compared with APP/PS1 mice.</title><p>(<bold>A</bold>) WT, APP/PS1, and APP /PS1-IL37tg mice were analyzed at 6, 9–12, and 20–23 months of age. (<bold>B–C</bold>) Pro-inflammatory cytokine levels of IL-6 and IL-1β (although for IL-1β was not statistically significant) were increased in 9–12 months old APP/PS1 mice compared with WT mice, whereas APP/PS1-IL37tg mice showed no increase in pro-inflammatory cytokines (n=6–10). (<bold>D–G</bold>) Microglial cells were identified as CD11b<sup>+</sup> and CD45<sup>low</sup> cells and analyzed for CD68 expression. Nine to 12-month-old APP/PS1 mice showed a significantly increased percentage of cells with CD68 expression compared with WT mice, whereas APP/PS1-IL37tg mice did not show a significant increase (<bold>D and F</bold>). Although 6- and 20–23 month-old APP/PS1-IL37tg mice had a significantly higher amount of CD68-expressing cells compared with WT mice, the percentage of CD68-expressing cells was reduced compared with APP/PS1 animals (6 months: n=4–6; 9–12 months: n=3–6; 20–23 months: n=3–7). (<bold>H–J</bold>) Plaque analysis showed significantly lower plaque burden (<bold>I</bold>) and reduced plaque size (<bold>J</bold>) in the hippocampal (Hp) and cortex (Cx) regions compared between APP/PS1-IL37tg mice and APP/PS1 (n=27–42). Representative image of Congo red staining in 30 µm sections; scale bar 500 µm (<bold>H</bold>). (<bold>K–M</bold>) Aβ uptake by microglial cells by measuring single cells in FACS system. Gating strategy for positive Cx3CR1-GFP cells and positive staining for MXO4 (<bold>K–L</bold>). Quantified analysis of Aβ uptake showing significantly higher uptake in APP/PS1-IL37tg cells compared with APP/PS1 cells (n=5–11) (<bold>M</bold>). Data are presented as mean ± SEM. * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001 compared to WT, # p&lt;0.05, ## p&lt;0.01, ### p&lt;0.001 compared to APP/PS1. (B-G and M: one-way ANOVA with multicolumn comparison; I-J: t-test).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Neuroinflammatory status in the brain of APP/PS1 mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Congo red staining of brain sections from APP/PS1 and APP /PS1-IL37 mice.</title><p>(<bold>A–B</bold>) Plaque staining in the cortex area of APP/PS1 mice (<bold>A</bold>) and APP/PS1-IL37tg mice (<bold>B</bold>). A single plaque is shown in the lower right inset. (<bold>C–D</bold>) Plaque staining in the hippocampal region of APP/PS1 mice (<bold>C</bold>) and APP/PS1-IL37tg mice (<bold>D</bold>). Individual plaques are shown in the lower left inset (scale bar 200 µm).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>FACS analysis of microglial cells regarding their Methoxy-X04 uptake.</title><p>(<bold>A–C</bold>) Gating strategy of CX3CR1-GFP+cell. (<bold>D–E</bold>) Gating strategy for MX04-(neg) and MX04+(pos) cells depending on the Pacific-Blue-Methoxy-X04 signal. (<bold>G–I</bold>) Cell counts of MX04- and MX04 + cells in WT, APP/PS1 and APP/PS1-IL37tg (n=5-11).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig6-figsupp2-v2.tif"/></fig></fig-group><p>First, we examined the levels of pro-inflammatory cytokines in the brains of 9–12 month-old control, APP/PS1 and APP/PS1-IL37tg transgenic mice (<xref ref-type="fig" rid="fig6">Figure 6B–C</xref>). Compared with control, APP/PS1 animals exhibited significantly higher IL-6 levels and a slight increase in IL-1β levels, although this was not statistically significant, whereas APP/PS1-IL37tg mice showed no increase in IL-6 and IL-1β levels. Moreover, the levels of these pro-inflammatory cytokines were significantly reduced in APP/PS1-IL37tg compared with APP/PS1 mice (IL-1β F(2,19)=5.224 p=0.0156; p=0.0903; p=0.248; p=0.0046; IL-6 F(2,21)=3.6 p=0.0452; p=0.022; p=0.5264; p=0.0466) (<xref ref-type="fig" rid="fig6">Figure 6B–C</xref>). We then examined microglial cell activation by FACS analysis. For this purpose, the percentage of microglial cells expressing the activation marker CD68 (<xref ref-type="bibr" rid="bib71">Jurga et al., 2020</xref>; <xref ref-type="bibr" rid="bib129">Smith and Koch, 1987</xref>; <xref ref-type="bibr" rid="bib143">Verbeek et al., 1995</xref>) (identified as a CD11b<sup>+</sup>/CD45<sup>low</sup> cell population in the brain) was analyzed at different ages of mice (<xref ref-type="fig" rid="fig6">Figure 6D–G</xref>).</p><p>In the brains of 9–12 month-old animals, the frequency of CD68<sup>+</sup> microglia isolated from APP/PS1 mice was significantly increased compared to age-matched WT, while the brains of APP/PS1-IL37tg mice did not show significantly increased numbers of CD68<sup>+</sup> microglial cells (FACS 9–12 m F(2,11)=14.39 p=0.0008; p=0.0008; p=0.0529; p=0.0494) (<xref ref-type="fig" rid="fig6">Figure 6D and F</xref>). The microglial cell population isolated from the brains of 6- and 20–23 month-old APP/PS1 and APP/PS1-IL37tg showed an increased proportion of CD68<sup>+</sup> cells compared to those of WT controls (FACS 6 m F(2,12)=13.45 p=0.0009; p=0.0007; p=0.0263; p=0.0985; FACS 20–23 m F(2,12)=13.38 p=0.0009; p=0.0007; p=0.0359; p=0.0383) (<xref ref-type="fig" rid="fig6">Figure 6E and G</xref>). However, APP/PS1-IL37tg had a significantly lower percentage of cells expressing CD68 compared to APP/PS1 mice (<xref ref-type="fig" rid="fig6">Figure 6F–G</xref>). We then examined amyloid-β (Aβ) plaque load as a hallmark of Alzheimer’s disease in the hippocampus and cortex (<xref ref-type="fig" rid="fig6">Figure 6H–J</xref>) of APP/PS1 (<xref ref-type="fig" rid="fig6">Figure 6H</xref> left panel) and APP/PS1-IL37tg animals (<xref ref-type="fig" rid="fig6">Figure 6H</xref> right panel). We observed that APP/PS1-IL37tg mice had significantly fewer plaques in both the hippocampus and cortex (<xref ref-type="fig" rid="fig6">Figure 6I</xref>) and that plaques were even smaller (<xref ref-type="fig" rid="fig6">Figure 6J</xref>) compared to APP/PS1 mice (plaque burden Hp t=2.403, df = 74 p=0.0187; Cx t=4.953, df = 63 p&lt;0.0001; plaque size Hp t=2.296, df = 74 p=0.0245; Cx t=5.949, df = 63 p&lt;0.0001) (<xref ref-type="fig" rid="fig6">Figure 6H–J</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A-D</xref>).</p><p>To further analyze whether the observed lower Aβ plaques in APP/PS1-IL37tg were due to higher Aβ uptake, an Aβ uptake assay was performed to examine phagocytic activity in APP/PS1 and APP/PS1-IL37tg mice carrying the CX3CR1-GFP gene (heterozygous) (<xref ref-type="bibr" rid="bib70">Jung et al., 2000</xref>). For this purpose, methoxy-XO4 staining was performed followed by FACS analysis. The CX3CR1-GFP transgenic mice express a microglia-specific green fluorescent protein in the CNS. To stain Aβ-plaques, animals were injected i.p. with 10 mg/kg methoxy-XO4 3 hr before the start of the experiment. After isolating the brain and performing a single-cell suspension, cells were measured in the FACS system and gated for Cx3CR1-positive cells (<xref ref-type="fig" rid="fig6">Figure 6K</xref>) and then further gated for the methoxy-XO4-positive population (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A-I</xref>). Data showed increased uptake of Aβ-particles by microglial cells from APP/PS1-IL37tg animals compared to those from APP/PS1 mice (F(2,22)=136.2 p&lt;0.0001; p&lt;0.0001; p&lt;0.0001; p=0.0026) (<xref ref-type="fig" rid="fig6">Figure 6L–M</xref>).</p><p>The APP/PS1 mouse model of Alzheimer’s disease shows cognitive deficits as early as 8 months of age (<xref ref-type="bibr" rid="bib67">Jankowsky et al., 2004</xref>; <xref ref-type="bibr" rid="bib110">O’Leary and Brown, 2009</xref>). To investigate whether IL-37 could positively affect learning and memory in this animal model, we performed the Morris water maze (MWM) behavioral test on 9–12 month-old control, APP/PS1, and APP/PS1-IL-37tg animals (<xref ref-type="fig" rid="fig7">Figure 7A</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). During the 8-day acquisition phase in the MWM, escape latency decreased progressively in all groups (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). However, APP/PS1 animals showed increased escape latency on day 1 and day 3–6 of the training phase compared to control mice (escape latency F(2,30)=10.5 p=0.0003; WT vs. APP/PS1 day 1 p=0.0463; day 3 p=0.007; day 4 p=0.0017; day5 p=0.0015; day 6 p=0.005) (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Subsequently, the reference memory test (probe trial) was performed on day 3 before the training and on day 9, 24 hr after the last training session. During the probe trials, the mice were tested without the presence of the escape platform. The percentage of time mice spent in each quadrant was measured, and preference for the target quadrant (TQ) was compared with the three non-target quadrants (NT). Control mice showed an explicit preference for the target quadrant at day 9 (t=11.45, df = 22 p&lt;0.0001), whereas in the comparison APP/PS1 animals showed no preference for any of the quadrants (t=0.9874, df = 18 p=0.3365) (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Remarkably, APP/PS1-IL37tg mice showed significantly higher preference for the target quadrant, similar to what was observed in control animals (APP/PS1-IL37tg PT t=3.705, df = 20 p=0.0014) (PT F(2,30)=8.415 p=0.0013; p=0.0009; p=0.0505) (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). In addition, heat maps of the different groups (1 example per group) were shown to better represent the performance of the animals in the reference memory test. These heat maps showed a prolonged time of control and APP/PS1-IL37tg mice in the target quadrant, whereas APP/PS1 mice did not show this preference (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>APP/PS1-IL37tg double transgenic mice showed improvements in behavioral tests and synaptic plasticity compared with APP/PS1 mice.</title><p>(<bold>A</bold>) WT, APP/PS1 and APP/PS1-IL37tg mice were analyzed at 9–12 months of age. (<bold>B–D</bold>) The cognitive deficits of APP/PS1 mice in the spatial learning test of the Morris Water Maze could be restored in APP/PS1-IL37tg animals. WT APP/PS1 and APP/PS1-IL37tg mice showed learning behavior during the training phase of the spatial learning test. APP/PS1 animals showed higher escape latency during acquisition on day 3–6 compared to WT mice (<bold>B</bold>). WT Mice and APP/PS1-IL37tg mice show a significant preference for the target quadrant (TQ), whereas APP/PS1 mice showed no preference (<bold>C</bold>). Representative heat maps of mice from each group demonstrated the results of the reference test (<bold>D</bold>) (n=10–12). (<bold>E–G</bold>) The LTP deficits in APP/PS1 mice could be rescued in APP/PS1-IL37tg mice in the induction phase (20–25 min). However, LTP deficits were not restored in APP/PS1-IL37tg animals in the maintenance phase (75–80 min) (n of animals 3–4; n of slices 12–18). (<bold>H–I</bold>) Dendritic spine density was significantly reduced in APP/PS1 animals compared to WT, whereas there was no significant reduction in spine density in APP/PS1-IL37tg (n=21–23), scale bar 5 µm. Data are presented as mean ± SEM. * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001 compared to WT, ^^ p&lt;0.01, ^^^ p&lt;0.001 compared to NT (non-target quadrants); (B+E: two-way ANOVA with multiple comparison; C: t-test; C-I: one-way ANOVA with multiple comparison).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Assessment of spatial learning and synaptic plasticity in APP/PS1 mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Age of the trained mice in the behavioral experiment.</title><p>Average age of each genotype trained in the Morris water maze is displayed (n=10-12).</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Age range of mice trained in the Morris water maze.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig7-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig7-figsupp1-v2.tif"/></fig></fig-group><p>The observed improvement of learning and memory in APP/PS1-IL37 transgenic mice prompted us to analyze whether hippocampal network function could also be improved by this genotype. Therefore, we measured synaptic plasticity at the Schaffer collateral pathway as described above in these animals. Acute hippocampal slices from APP/PS1 mice showed significant deficits in LTP compared to corresponding slices from age-matched control mice (F(2,45)=9.286 p=0.0004) (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). This was evident during both the induction (20–25 min of recording) and maintenance (75–80 min of recording) phases of LTP (first 5 min F(2,45)=7.09 p=0.0021; p=0.0016; last 5 min F(2,45)=9.354 p=0.0004; p=0.0014) (<xref ref-type="fig" rid="fig7">Figure 7F–G</xref>). Notably, the induction phase (but not the maintenance phase) of LTP was also indistinguishable in the slices from control and APP/PS1-IL37tg mice (first 5 min F(2,45)=7.09 p=0.0021; p=0.5444; last 5 min F(2,45)=9.354 p=0.0004; p=0.0023) (<xref ref-type="fig" rid="fig7">Figure 7F–G</xref>). Thus, it is clear that expression of IL-37 at 9 months of age in APP/PS1 mice can rescue the induction phase of LTP, which may be sufficient for the mice to perform spatial memory tasks.</p><p>To determine the rescued phenotypes observed in APP/PS1-IL37tg mice at the cellular level, neuronal morphology of the CA1 subregion of the hippocampus was analyzed in all experimental groups. A significant reduction in the density of dendritic spines was observed in 9–12 month-old APP/PS1 mice compared to age-matched control mice (dendritic spines F(2,63)=6.318 p=0.0032; p=0.0026) (<xref ref-type="fig" rid="fig7">Figure 7H–I</xref>). However, comparable dendritic spine density was detected between control and APP/PS1-IL37tg mice, indicating a rescue effect by IL-37 expression (dendritic spines F(2,63)=6.318 p=0.0032; p=0.0536) (<xref ref-type="fig" rid="fig7">Figure 7H–I</xref>). Taken together, these results suggest that expression of IL-37 in transgenic animals plays a protective role against chronic neuroinflammation by ameliorating the learning and memory deficits associated with the APP/PS1 mouse model and rescuing the underlying cellular correlates.</p></sec><sec id="s2-7"><title>RNA sequencing of microglia from IL-37tg mice reveals a slightly different gene expression profile after LPS challenge in vivo</title><p>Our results suggest that expression of IL-37 plays a protective role in both acute and chronic neuroinflammatory processes in the brain. Remarkably, in vitro experiments suggest that IL-37 exerts its anti-inflammatory effects most likely via microglial cells. To further investigate the function of microglia in this scenario, RNA sequencing was performed on microglial cells isolated from WT and IL-37tg mice treated with either saline or LPS. For this purpose, microglial cells were isolated using CD11b MicroBeads from WT and IL-37tg mice injected twice with saline or LPS 3 hr after the last injection, and then the mRNA expression profile of microglia was analyzed. The results showed that LPS challenge in vivo induced 11014 differentially expressed genes (DEGs) in microglial cells from WT and IL-37tg mice. The 500 most significantly expressed genes were shown in a heat map (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). This highlights the fact that even acute systemic LPS exposure leads to tremendous changes in the gene expression profile specifically in microglia, suggesting a strong communication between the peripheral immune system and the brain. Gene set enrichment analysis (GSEA) showed that LPS stimulated genes of both genotypes associated with interleukin-1 signaling (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). Although we did not detect significant changes in gene expression between WT and IL-37tg microglial cells after LPS stimulation (<xref ref-type="fig" rid="fig8">Figure 8C</xref>), some genes were identified that showed a slightly altered expression profile and have the potential to influence inflammatory outcome. Examples are: <italic>Saa2</italic>, which is highly expressed in response to inflammation and tissue injury (<xref ref-type="bibr" rid="bib156">Ye and Sun, 2015</xref>; <xref ref-type="fig" rid="fig8">Figure 8D</xref>), <italic>Vgf</italic>, which is expressed after nerve injury and inflammation in neurons of both peripheral and central nervous systems and contributes significantly to the inflammatory processes, as blockade of VGF reduces the secretion of pro-inflammatory cytokines (<xref ref-type="bibr" rid="bib22">Busse et al., 2014</xref>; <xref ref-type="fig" rid="fig8">Figure 8E</xref>), <italic>Bcl6b</italic>, which is involved in the regulation of inflammatory response and type 2 immune response (<xref ref-type="bibr" rid="bib81">Koyasu and Moro, 2011</xref>; <xref ref-type="fig" rid="fig8">Figure 8F</xref>), <italic>Il23a</italic>, which is associated with autoimmune cholangitis and inflammatory bowel disease (<xref ref-type="bibr" rid="bib2">Ando et al., 2012</xref>; <xref ref-type="fig" rid="fig8">Figure 8G</xref>), and <italic>Icam1</italic>, which plays a critical role in inflammatory processes and in the T-cell-mediated host defense system (<xref ref-type="bibr" rid="bib142">van de Stolpe and van der Saag, 1996</xref>; <xref ref-type="fig" rid="fig8">Figure 8H</xref>). These genes were upregulated in WT mice after LPS administration, whereas they were differentially expressed to a lesser extent in IL-37tg mice treated with LPS. In addition, some genes were downregulated in the microglial cells of WT mice challenged with LPS, which was the case to a lesser extent in IL-37tg mice. For example, the <italic>Tk2</italic> gene, the deficiency of which is highlighted in mitochondrial depletion syndrome (<xref ref-type="bibr" rid="bib160">Zhou et al., 2013</xref>; <xref ref-type="fig" rid="fig8">Figure 8I</xref>). The <italic>Kcnj9</italic> gene, which encodes the Na<sup>+</sup>/K<sup>+</sup>-ATPase pump and is important for brain function. Interestingly, this gene is significantly downregulated in schizophrenia (<xref ref-type="bibr" rid="bib89">Liu et al., 2019</xref>; <xref ref-type="fig" rid="fig8">Figure 8J</xref>). The <italic>Kif21b</italic> gene, a kinesin protein that promotes intracellular transport and controls microtubule dynamics. Downregulation of this gene results in neurodevelopmental abnormalities due to imbalanced canonical motor activity (<xref ref-type="bibr" rid="bib7">Asselin et al., 2020</xref>; <xref ref-type="fig" rid="fig8">Figure 8K</xref>). In addition to the above genes, some other important genes were equally regulated in both genotypes after LPS challenge, such as <italic>Gpr84</italic>, known to be regulated by pro-inflammatory cytokines such as TNF-α or IL-1 (<xref ref-type="bibr" rid="bib18">Bouchard et al., 2007</xref>; <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>), <italic>Mmp3</italic>, which is associated with brain inflammation and microglial activation (<xref ref-type="bibr" rid="bib76">Kim et al., 2005</xref>; <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B</xref>), <italic>Acod1</italic>, as a key regulator of immune metabolism in infection and inflammation (<xref ref-type="bibr" rid="bib152">Wu et al., 2020</xref>; <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>), and the IL-18 receptor (<italic>Il18r</italic>), indicating increased expression of the potential receptor for IL-37 in microglia after systemic LPS challenge (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1D</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>RNA sequencing of microglia isolated from WT and IL-37tg mice after LPS challenge in vivo.</title><p>(<bold>A</bold>) Heatmap shows z-normalized gene expression profiles of the 500 most highly regulated genes (out of 11014 genes with adjusted pValue &lt;0.05). Two clusters of co-regulated genes were identified, representing up- and down-regulated genes after LPS treatment. Each column shows expression data of individual mouse transcriptomes. (<bold>B</bold>) Gene Set Enrichment Analysis (GSEA) was performed for the 500 most up-regulated genes, which are also shown in the heat map. Each cluster (1 and 2) was tested for enriched gene sets defined by the Reactome Pathway Database (<ext-link ext-link-type="uri" xlink:href="https://reactome.org/">https://reactome.org/</ext-link>). The number of genes that could be linked to gene sets in the Reactome Pathway Database is indicated under each cluster name. The terms for the major gene sets are shown. The size of the circles corresponds to the ratio of genes found in each gene set. Significance of enrichment is expressed by a blue-red color code. (<bold>C</bold>) Differential expression comparing WT and IL-37tg after LPS stimulation is shown by the Volcano plot. Log<sub>2</sub>FC and the corresponding adjusted pValue are shown for each gene analyzed (18,049 in total). The dashed lines show the limits for significant gene regulation: –1 1, FDR &lt;0.05. (<bold>D–K</bold>) Changes in gene expression after LPS injection in WT and IL-37tg mice for candidate genes are shown (n=2-3).</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>RNA sequencing data of microglia isolated from mice after systemic LPS challenge.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>RNA sequencing of microglia isolated from WT and IL-37tg mice after LPS challenge in vivo.</title><p>(<bold>A–D</bold>) The changes in expression levels after LPS injection in WT and IL-37tg mice for the candidate genes are shown (n=2-3).</p><p><supplementary-material id="fig8s1sdata1"><label>Figure 8—figure supplement 1—source data 1.</label><caption><title>Expression levels of candidate genes in microglia isolated from mice after systemic LPS challenge.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-75889-fig8-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-75889-fig8-figsupp1-v2.tif"/></fig></fig-group><p>Although this mRNA expression assay for microglia showed that there were no significant differences between the overall gene profile of microglia from WT and IL-37 after LPS challenge, a specifically lower microglial response was nevertheless detectable in IL-37tg mice, which may shed light on the immunomodulatory role of IL-37 in acute and chronic neuroinflammation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The regulation of inflammation is an extremely complex and tightly controlled signaling event in which cytokines crucially modulate the process (<xref ref-type="bibr" rid="bib125">Shaikh, 2011</xref>). The interplay and balance between pro- and anti-inflammatory components are crucial for the delicate balance of inflammatory responses. Anti-inflammatory cytokines are known to limit persistent or excessive inflammation, but they may also be insufficient or overcompensated (<xref ref-type="bibr" rid="bib125">Shaikh, 2011</xref>; <xref ref-type="bibr" rid="bib72">Kasai et al., 1997</xref>; <xref ref-type="bibr" rid="bib103">Munoz et al., 1991</xref>). IL-37 is expressed in many human tissues and cells, especially in monocytes, tissue macrophages or dendritic cells (<xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>; <xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>; <xref ref-type="bibr" rid="bib122">Rudloff et al., 2017</xref>), where it is produced in response to inflammatory stimuli and may act as a self-protective mechanism against escalating inflammatory processes (<xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>). In this study, we showed that IL-37, an anti-inflammatory cytokine, is able to reduce both acute and chronic neuroinflammation and that the IL-37tg mouse model is a valuable animal model to study the details of neurodegenerative diseases caused by chronic inflammation.</p><p>The acute inflammatory response was analyzed in a mouse model of septic shock in which increased levels of IL-6, TNF-α, and IL-1β produced by activated microglia were detected (<xref ref-type="bibr" rid="bib85">Lemstra et al., 2007</xref>; <xref ref-type="bibr" rid="bib147">Widmann and Heneka, 2014</xref>). The ability of IL-37 to suppress pro-inflammatory cytokines induced by Toll-like receptors (TLR) was first demonstrated in mouse macrophages transfected with human IL-37 (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>) and recently described for TLR-induced activation of microglial cells (<xref ref-type="bibr" rid="bib32">Conti et al., 2020</xref>). Because there is no homologous gene for IL-37 in mice, transgenic mice expressing the human IL-37 gene were generated (IL-37tg) (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>). Here we showed the effect of IL-37 on CNS tissue resident macrophages (microglia) in terms of reducing inflammatory markers similar to those in the periphery. In contrast, no reduction was detected in primary astrocytes from IL-37tg mice, suggesting a specific modulatory role of microglia in this scenario. The timing of LPS stimulation is important because prolonged treatment of 24 hr results in higher cytokine release compared to 6 hr (<xref ref-type="bibr" rid="bib88">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib149">Wu et al., 2009</xref>).</p><p>Remarkably, the Warburg effect describes the change in metabolism toward the production of ATP from anaerobic glycolysis to oxidative phosphorylation observed in macrophages by increased mTOR levels and decreased AMPK activity after LPS stimulation (<xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>; <xref ref-type="bibr" rid="bib111">O’Neill and Hardie, 2013</xref>). It was shown that IL-37 can reverse the Warburg effect (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib10">Ballak et al., 2014</xref>; <xref ref-type="bibr" rid="bib109">Nold-Petry et al., 2015</xref>; <xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>) and, moreover, the metabolic cost of inflammation in plasma and muscle cells by reducing the concentration of succinate, a potent mediator in inflammatory states (<xref ref-type="bibr" rid="bib137">Tannahill et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Cavalli et al., 2017</xref>; <xref ref-type="bibr" rid="bib46">Fedotcheva et al., 2006</xref>; <xref ref-type="bibr" rid="bib98">Mills and O’Neill, 2014</xref>). In addition, macrophage activation has been found to increase the production of itaconate, which in turn inhibits succinate dehydrogenase (SDH), leading to an increase in succinate levels (<xref ref-type="bibr" rid="bib56">He et al., 2021</xref>; <xref ref-type="bibr" rid="bib112">O’Neill and Artyomov, 2019</xref>). Therefore, we focused here on two metabolites associated with inflammation in tissue macrophages. Our results showed that levels of itaconate and succinate decreased after LPS stimulation in primary microglia from IL-37tg animals. In conclusion, we demonstrated that the anti-inflammatory property of IL-37 is able to reduce inflammation in microglial cells in vitro. In addition, the restoration of metabolic cost plays a role in reversing cognitive decline in old age, as has been shown previously (<xref ref-type="bibr" rid="bib100">Minhas et al., 2021</xref>).</p><p>To confirm the anti-inflammatory effect of IL-37 in acute inflammatory conditions in vivo, further studies were performed by systemic LPS injection in control and IL-37tg animals. Inflammation and activation of microglia are crucial hallmarks of various neurological diseases (<xref ref-type="bibr" rid="bib117">Qin et al., 2007</xref>). On the one hand, activation of microglia is essential for homeostasis in the brain for an appropriate inflammatory response. On the other hand, overactivation of these processes can lead to neuronal damage (<xref ref-type="bibr" rid="bib117">Qin et al., 2007</xref>; <xref ref-type="bibr" rid="bib94">McGeer et al., 2005</xref>; <xref ref-type="bibr" rid="bib114">Polazzi and Contestabile, 2002</xref>). In acute inflammation, little LPS is likely to enter the brain because the blood-brain barrier (BBB) is intact (<xref ref-type="bibr" rid="bib105">Nadeau and Rivest, 1999</xref>). It is more likely that peripherally-induced neuroinflammation is an indirect effect (<xref ref-type="bibr" rid="bib117">Qin et al., 2007</xref>), in which LPS activates the inflammatory cascade that signals to the CNS via TLR and/or TNF-α receptors on the BBB (<xref ref-type="bibr" rid="bib117">Qin et al., 2007</xref>; <xref ref-type="bibr" rid="bib17">Block and Hong, 2005</xref>; <xref ref-type="bibr" rid="bib29">Chakravarty and Herkenham, 2005</xref>; <xref ref-type="bibr" rid="bib68">Ji et al., 2008</xref>; <xref ref-type="bibr" rid="bib75">Kim et al., 2000</xref>; <xref ref-type="bibr" rid="bib83">Laflamme et al., 2003</xref>; <xref ref-type="bibr" rid="bib150">Wu et al., 2011</xref>; <xref ref-type="bibr" rid="bib154">Yang et al., 2013</xref>). Systemic inflammation induces increased density and reactivity of microglial cells characterized by increased secretion of pro-inflammatory cytokines such as IL-1 (<xref ref-type="bibr" rid="bib147">Widmann and Heneka, 2014</xref>), changes in the morphological shape (retraction of the processes) (<xref ref-type="bibr" rid="bib154">Yang et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Kettenmann et al., 2011</xref>), greatly increased levels of surface proteins such as CD68 (<xref ref-type="bibr" rid="bib71">Jurga et al., 2020</xref>; <xref ref-type="bibr" rid="bib154">Yang et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Kettenmann et al., 2011</xref>), and increased density of IBA-1-positive cells (<xref ref-type="bibr" rid="bib154">Yang et al., 2013</xref>). In this study, we demonstrated that peripheral induced inflammation resulted in significantly increased numbers of IBA-1-positive cells and increased levels of CD68 and IL-1β in the CNS of control animals. In contrast, IL-37tg mice showed anti-inflammatory effects and did not exhibit an activated microglial phenotype in these features. However, the typical morphological changes described as retraction of processes (<xref ref-type="bibr" rid="bib154">Yang et al., 2013</xref>) were not observed in either genotype. IL-37 was originally described as a basic inhibitor of innate immunity with reduced pro-inflammatory cytokine levels in plasma (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>) and particularly in peripheral organs and in diseases such as endotoxemia, spinal cord injury, colitis, myocardial ischemia, obesity, and metabolic syndrome (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>; <xref ref-type="bibr" rid="bib10">Ballak et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Coll-Miró et al., 2016</xref>; <xref ref-type="bibr" rid="bib95">McNamee et al., 2011</xref>; <xref ref-type="bibr" rid="bib158">Yousif et al., 2011</xref>; <xref ref-type="bibr" rid="bib109">Nold-Petry et al., 2015</xref>). Our results clearly show that in vivo neuroinflammatory processes are reduced in acutely inflammatory challenged mice after transgenic IL-37 expression. IL-37 is a dual-function protein that has both intracellular and extracellular properties (<xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>). Intracellularly, IL-37 interacts with SMAD3, translocates to the nucleus and induces anti-inflammatory effects (<xref ref-type="bibr" rid="bib1">Amo-Aparicio et al., 2021</xref>; <xref ref-type="bibr" rid="bib126">Sharma et al., 2008</xref>). Extracellularly, IL-37 binds to the IL-18Rα and the co-receptor IL-1R8 (SIGGIR), resulting in a signaling cascade with anti-inflammatory effects (<xref ref-type="bibr" rid="bib109">Nold-Petry et al., 2015</xref>; <xref ref-type="bibr" rid="bib1">Amo-Aparicio et al., 2021</xref>). The differences between these two signaling pathways were demonstrated by <xref ref-type="bibr" rid="bib1">Amo-Aparicio et al., 2021</xref> in a spinal cord injury model (<xref ref-type="bibr" rid="bib1">Amo-Aparicio et al., 2021</xref>).</p><p>The resulting neuroinflammation and activation of microglial cells after peripheral LPS challenge also lead to functional and structural changes in the neuronal network, particularly affecting long-term potentiation (LTP) (<xref ref-type="bibr" rid="bib14">Beyer et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Commins et al., 2001</xref>; <xref ref-type="bibr" rid="bib34">Di Filippo et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Hennigan et al., 2007</xref>; <xref ref-type="bibr" rid="bib133">Strehl et al., 2014</xref>) and spine morphology with implications for dendritic spine density (<xref ref-type="bibr" rid="bib13">Beattie et al., 2002</xref>; <xref ref-type="bibr" rid="bib19">Boulanger, 2009</xref>; <xref ref-type="bibr" rid="bib66">Ikegaya et al., 2003</xref>; <xref ref-type="bibr" rid="bib80">Kondo et al., 2011</xref>; <xref ref-type="bibr" rid="bib91">Lucin and Wyss-Coray, 2009</xref>). Here, we showed that LTP was impaired in control animals after immunostimulation with LPS, whereas IL-37tg animals showed no defects in LTP. Loss of dendritic spines after LPS challenge was also restored in IL-37tg stimulated with LPS. These data indicate that deleterious neuronal changes known to be associated with acute inflammatory processes in the CNS are reduced in IL-37tg mice.</p><p>Our results suggest decreased neuroinflammation induced by systemic immune stimulation in the presence of IL-37. However, the anti-inflammatory effect of IL-37 in the CNS may be a secondary effect due to the reduction of the inflammatory response in the periphery. To identify the direct possibility of IL-37 expression in the CNS without peripheral influence, further electrophysiological experiments were performed with acute hippocampal slices from control and IL-37tg mice. Administration of LPS to the acute slices of IL-37tg mice suggests that IL-37 expression directly in the CNS may also be responsible for the reversal of neuronal impairments after peripheral LPS challenge. In addition, we confirmed the mechanisms of anti-inflammatory action in IL-37tg mice by using the recombinant IL-37 in WT mice. Recombinant human IL-37 has protective effects against endotoxemia, acute lung and spinal cord injury, asthma, and myocardial infarction (<xref ref-type="bibr" rid="bib25">Cavalli et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Cavalli and Dinarello, 2018</xref>; <xref ref-type="bibr" rid="bib30">Coll-Miró et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Moretti et al., 2014</xref>; <xref ref-type="bibr" rid="bib151">Wu et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Li et al., 2015</xref>; <xref ref-type="bibr" rid="bib92">Lunding et al., 2015</xref>; <xref ref-type="bibr" rid="bib155">Ye et al., 2014</xref>). Next, we investigated whether recombinant IL-37 has a similar effect on inflammatory processes in the CNS. Our results showed a reduction in pro-inflammatory cytokine levels in the brain. The consequences of acute peripheral immune stimulation by either LPS or IL-1β as a key cytokine triggering innate immune responses are the induction of pro-inflammatory cytokines leading to impaired learning and memory (<xref ref-type="bibr" rid="bib5">Arai et al., 2001</xref>; <xref ref-type="bibr" rid="bib52">Gonzalez et al., 2013</xref>; <xref ref-type="bibr" rid="bib119">Rachal Pugh et al., 2001</xref>; <xref ref-type="bibr" rid="bib127">Shaw et al., 2001</xref>; <xref ref-type="bibr" rid="bib130">Sparkman et al., 2005</xref>; <xref ref-type="bibr" rid="bib157">Yirmiya and Goshen, 2011</xref>). The effect of reduced neuroinflammation was analyzed on cognition and demonstrated by behavioral improvements in the Y-Maze test in animals pretreated with rIL-37. Spontaneous alternation behavior (SAB) in a symmetrical Y-shaped maze was used previously for pharmacological studies of short-term memory performance (<xref ref-type="bibr" rid="bib43">Drew et al., 1973</xref>; <xref ref-type="bibr" rid="bib64">Hughes, 2004</xref>; <xref ref-type="bibr" rid="bib79">Kokkinidis and Anisman, 1976</xref>; <xref ref-type="bibr" rid="bib135">Swonger and Rech, 1972</xref>). Systemic inflammation primarily affects attention and cognitive flexibility, including working memory, rather than associative learning. Low-dose injection of LPS, which elicits a very mild immune response and small changes (&lt;1 °C) in core body temperature, has been shown to severely impair working memory (<xref ref-type="bibr" rid="bib104">Murray et al., 2012</xref>). We therefore show that systemic injection of rIL-1β completely abolishes working memory. Consequently, rIL-37 was used as a preventive strategy by generating a certain level of IL-37 in the WT mice. Other studies using rIL-37 as a therapeutic intervention were performed, for example, after spinal cord injury by local administration of rIL-37 (<xref ref-type="bibr" rid="bib30">Coll-Miró et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Amo-Aparicio et al., 2021</xref>).</p><p>In this study, we specifically analyzed the activation status of microglial cells as a neuroinflammatory feature leading to structural changes in the neuronal network. Although our data suggest that IL-37 most likely transmits its signals via microglia, astrocytes also play an important role in maintaining neuronal circuits (<xref ref-type="bibr" rid="bib107">Nizami et al., 2019</xref>; <xref ref-type="bibr" rid="bib124">Schafer et al., 2012</xref>). Activated astrocytes express many complement factors that lead to synapse formation and elimination (<xref ref-type="bibr" rid="bib107">Nizami et al., 2019</xref>; <xref ref-type="bibr" rid="bib131">Stephan et al., 2012</xref>; <xref ref-type="bibr" rid="bib132">Stevens et al., 2007</xref>). Therefore, it would be of interest in future experiments to dissect the underlying mechanism of synapse elimination with respect to IL-37 expression including microglia and astrocytes.</p><p>To better predict the role of microglia in IL-37 signal transduction after immunostimulation, single-cell type RNA sequencing was performed. Analysis of mRNA gene expression profiles revealed that approximately 11014 genes were differentially expressed in microglia after systemic LPS administration, clearly confirming the close communication between the peripheral immune system and the CNS. Although no significant differences were found between the microglial gene profile of WT and IL-37tg mice, however, these data indicated the specific gene profile in the both genotypes after the LPS challenge. For example, some genes were up- or down-regulated in the WT mice, which was the case to a lesser extent in the IL-37tg mice. Among them were some important genes such as Saa2 (<xref ref-type="bibr" rid="bib156">Ye and Sun, 2015</xref>), Vgf (<xref ref-type="bibr" rid="bib22">Busse et al., 2014</xref>), Bcl6b (<xref ref-type="bibr" rid="bib81">Koyasu and Moro, 2011</xref>), Il23a (<xref ref-type="bibr" rid="bib2">Ando et al., 2012</xref>), Icam1 (<xref ref-type="bibr" rid="bib142">van de Stolpe and van der Saag, 1996</xref>), and Tk2 (<xref ref-type="bibr" rid="bib160">Zhou et al., 2013</xref>), which contribute to inflammatory responses and are involved in many inflammation-related diseases. Interestingly, peripheral LPS exposure led to downregulation of some genes such as Kcnj9 (<xref ref-type="bibr" rid="bib89">Liu et al., 2019</xref>) and Kif21b (<xref ref-type="bibr" rid="bib7">Asselin et al., 2020</xref>), the deficiency of which has been associated with the occurrence of neurological and neurodevelopmental disorders, again highlighting the importance of the immune system-brain axis. Moreover, peripheral LPS challenge induced the upregulation of some genes equally in both genotypes, such as <italic>Gpr84</italic> (<xref ref-type="bibr" rid="bib18">Bouchard et al., 2007</xref>), <italic>Mmp3</italic> (<xref ref-type="bibr" rid="bib76">Kim et al., 2005</xref>) which are associated with neuroinflammation and neurodegeneration. Or <italic>Acod1</italic>, which produces the immune metabolite itaconate that has been shown to be upregulated after LPS administration and to inhibit inflammatory signaling in monocytes (<xref ref-type="bibr" rid="bib152">Wu et al., 2020</xref>). Our mRNA gene expression analysis showed upregulation of <italic>Acod1</italic>, suggesting a link between the in vitro model (primary microglia) and the in vivo model here, because primary microglia showed upregulation of itaconate upon LPS treatment. Finally, RNA sequencing data showed upregulated gene expression of the IL-18 receptor, suggesting that expression of the IL-18 receptor on microglial cells may be responsible for IL-37 signal transduction by microglia in IL-37tg mice. It is worth noting that the lack of large differences in microglial gene expression profiles between WT and IL-37tg mice may be due to the timing of microglial isolation, because we isolated microglia 3 hr after the last LPS injection, which was also the case for the other experiments. However, the timing of gene regulation is different from that of protein synthesis. Therefore, it can be assumed that 3 hr after the last LPS injection, when we detected the deleterious effects, the transcripts of the responsible genes have already been degraded.</p><p>In the first part of this study, we showed that acute neuroinflammation, microglial activation, deficits in functional and structural plasticity, and impaired cognition induced by peripheral immune stimulation were attenuated or rescued in the presence of IL-37 (either transgene or recombinant). Moreover, these results suggest that rIL-37 may play an important future role as a therapeutic intervention in many neurological diseases associated with inflammatory responses. However, further experiments with recombinant IL-37 need to be performed to obtain a detailed picture of the mechanism underlying rIL-37 signaling. A recent study has shown that the efficacy of IL-37 is limited when administered systemically, suggesting a beneficial effect on local CNS cells rather than cells in the periphery (<xref ref-type="bibr" rid="bib1">Amo-Aparicio et al., 2021</xref>). Further experiments need to analyze therapeutic approaches for acute neuroinflammation, as it is not clear whether treating the peripheral immune response is sufficient to produce beneficial effects in brain tissue. Here, we show that local expression of IL-37 in the brain is sufficient to rescue LPS-induced LTP impairments. However, translation to brain impairments in acute systemic inflammation remains to be investigated with respect to systemic rIL-37 administration.</p><p>To analyze chronic neuroinflammation, we used APP/PS1 mice as a model for Alzheimer’s disease (AD). AD is the most common form of dementia, and in 2015, an estimated 46.8 million people worldwide were living with the dementia (<xref ref-type="bibr" rid="bib115">Prince, 2015</xref>). Research on AD has mainly focused on the long-lasting known pathological hallmarks namely beta-amyloid plaques and neurofibrillary tangles (<xref ref-type="bibr" rid="bib6">Ardura-Fabregat et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Glabe, 2005</xref>; <xref ref-type="bibr" rid="bib55">Hardy and Selkoe, 2002</xref>; <xref ref-type="bibr" rid="bib145">Wang et al., 2015</xref>). Recently, reports linking neuroinflammation to the pathogenic process of AD have been accumulating, showing that the brain can no longer be considered as an absolutely immune-privileged organ in disease progression (<xref ref-type="bibr" rid="bib6">Ardura-Fabregat et al., 2017</xref>; <xref ref-type="bibr" rid="bib145">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Heneka et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Heneka et al., 2014</xref>). In addition to the accumulation of amyloid-β (Aβ) during the progression of neuroinflammatory processes, pro-inflammatory cytokines such as TNF-α, IL-1β, or IL-6 have been shown to promote phosphorylation of tau (<xref ref-type="bibr" rid="bib15">Bhaskar et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Kitazawa et al., 2011</xref>; <xref ref-type="bibr" rid="bib118">Quintanilla et al., 2004</xref>; <xref ref-type="bibr" rid="bib153">Xu et al., 2021</xref>). In the present study, we focused on reducing the chronic neuroinflammatory response by decreasing microglial cell activation and proinflammatory mediators release and the subsequent effect on Aβ accumulation. For this purpose, we used the IL-37tg mouse line described above. To investigate the role of the anti-inflammatory cytokine IL-37 in chronic inflammation, we crossed the IL-37tg mouse with the APP/PS1 mouse. The APP/PS1 mouse line represents a reliable model that exhibits Aβ deposition as early as 6 months of age and has been reported to exhibit cognitive deficits starting at 8 months of age (<xref ref-type="bibr" rid="bib67">Jankowsky et al., 2004</xref>; <xref ref-type="bibr" rid="bib110">O’Leary and Brown, 2009</xref>; <xref ref-type="bibr" rid="bib49">Garcia-Alloza et al., 2006</xref>). Microglial cells, the resident immune cells of the brain, are described (along with astrocytes) as a major source of cytokines that have a significant and distinct impact on the neuroinflammation aspects in AD (<xref ref-type="bibr" rid="bib59">Heneka et al., 2015</xref>; <xref ref-type="bibr" rid="bib116">Prinz et al., 2011</xref>). It has been previously described that microglia respond to Aβ peptides, which might be able to trigger the inflammatory process in AD that contributes to microglial activation, release of pro-inflammatory cytokines and memory deficits (<xref ref-type="bibr" rid="bib145">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Heneka et al., 2015</xref>; <xref ref-type="bibr" rid="bib161">Zilka et al., 2012</xref>). Here, we show reduced pro-inflammatory cytokine levels for IL-1 and IL-6 in brain lysates from 9- to 12-month-old APP/PS1-IL37tg mice compared to APP/PS1 animals. In addition, microglial activation was significantly higher in APP/PS1 mice compared to control mice, whereas APP/PS1-IL37tg mice did not show a significant increase in microglial activation due to CD68 expression. Furthermore, we analyzed Aβ deposition in the brain tissue of APP/PS1 animals compared with APP/PS1-IL37tg mice. Overexpression of the anti-inflammatory cytokine IL-37 in APP/PS1 animals used in this study resulted in significantly higher plaque phagocytosis capacity, lower plaque burden, and smaller plaque size compared to APP/PS1 control mice. In conclusion, reduction of pro-inflammatory response or inhibition of excessive inflammation by IL-37 expression may lead to better Aβ uptake and may be involved in higher clearance of Aβ plaques.</p><p>It is noteworthy that previous studies have shown that IL-1β and IL-6 play an important role in the progression of AD, as both were released from microglial cells surrounding Aβ plaques in AD patients and animal models (<xref ref-type="bibr" rid="bib145">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Boutajangout and Wisniewski, 2013</xref>; <xref ref-type="bibr" rid="bib65">Hunter et al., 2012</xref>; <xref ref-type="bibr" rid="bib144">Vukic et al., 2009</xref>). Furthermore, IL-1β and IL-6 are described to play complex roles in regulating cognitive function in AD (<xref ref-type="bibr" rid="bib157">Yirmiya and Goshen, 2011</xref>; <xref ref-type="bibr" rid="bib145">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib78">Kitazawa et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Dugan et al., 2009</xref>; <xref ref-type="bibr" rid="bib146">Weaver et al., 2002</xref>). The present results showed an impairment of spatial memory in 9- to 12-month-old APP/PS1 mice compared with control animals. However, APP/PS1-IL37tg mice showed partially rescued spatial memory performance compared with APP/PS1 mice. In addition, APP/PS1-IL37tg mice did not exhibit any impairment during the reference memory test. Given the observed impairment in spatial learning in APP/PS1 animals, we further analyzed synaptic plasticity by measuring LTP as a cellular correlate of learning and memory in all groups. The findings demonstrated that the maintenance and induction phases of LTP were impaired in APP/PS1 mice compared to control animals. In contrast, the induction phase of LTP in APP/PS1-IL37tg mice was similar to that in control animals. However, the maintenance phase of LTP was also impaired in APP/PS1-IL37tg animals. These observations suggest that overexpression of IL-37 is sufficient to rescue the early phase of LTP (E-LTP; the first 20 min after stimulation), which is independent of protein synthesis. However, impaired late LTP in APP/PS1 mice, which requires regulation of gene expression at the transcriptional and translational levels (<xref ref-type="bibr" rid="bib8">Auffret et al., 2010</xref>), was not rescued by IL-37 overexpression. Interestingly, there is evidence that the water maze task can be efficiently solved despite late-LTP impairments in the CA1 or the CA3 hippocampal subregion (<xref ref-type="bibr" rid="bib12">Bannerman et al., 2012</xref>; <xref ref-type="bibr" rid="bib106">Nakazawa et al., 2002</xref>). In addition, neuronal morphology was analyzed to investigate whether structural cellular changes were the reason for the decline in LTP and cognitive function. When APP/PS1 mice were compared with control mice, it was found that APP/PS1 mice exhibited decreased spine density in the apical dendrites of CA1 pyramidal neurons. In contrast, APP/PS1-IL37tg did not show decreased numbers of dendritic spines.</p><p>In general, the putative mechanism of IL-37 signaling in neurodegenerative diseases is not clear. Translation to humans might suggest IL-37 as a biomarker for inflammatory diseases with changes in IL-37 levels in patients associated with these diseases (<xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>). IL-37 as a dual-acting cytokine during AD progression, we suggest that both intracellular and extracellular IL-37 signaling can reduce neuroinflammation and microglial activation. Because IL-37 is also produced by peripheral cells, this could lead to a reduced inflammatory response and a reduction in activated circulating immune cells, whether or not these peripheral immune cells enter the brain. In addition, it is not clear whether infiltrating immune cells have positive or negative effects on AD progression. There are some studies showing that phagocytic peripheral immune cells can infiltrate the brain and serve as a surrogate for microglial populations (<xref ref-type="bibr" rid="bib41">Dionisio-Santos et al., 2019</xref>; <xref ref-type="bibr" rid="bib47">Fiala et al., 2002</xref>; <xref ref-type="bibr" rid="bib96">Merlini et al., 2018</xref>; <xref ref-type="bibr" rid="bib138">Thériault et al., 2015</xref>; <xref ref-type="bibr" rid="bib140">Town et al., 2005</xref>).</p><p>In summary, during chronic neuroinflammation associated with Alzheimer’s disease, a significant deficit in synaptic plasticity (functional LTP and structural spine density) was documented, whereas rescue was observed in transgenic AD animals overexpressing the anti-inflammatory cytokine IL-37. In addition, a significant effect on the formation of amyloid-β plaques, a pathological feature of AD, was documented, suggesting that attenuation of neuroinflammation combined with increased clearance is sufficient to produce beneficial effects on learning and memory. Indeed, the results reported here demonstrate that expression of an anti-inflammatory IL-37 cytokine is able to reduce neuroinflammation and cognitive decline in a mouse model of Alzheimer’s disease. Furthermore, recent studies in spinal cord injury (<xref ref-type="bibr" rid="bib30">Coll-Miró et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Amo-Aparicio et al., 2021</xref>) and in a mouse model of multiple sclerosis (MS) <xref ref-type="bibr" rid="bib28">Cavalli et al., 2019</xref>; <xref ref-type="bibr" rid="bib123">Sánchez-Fernández et al., 2021</xref> have shown that IL-37 signaling has protective properties in two other neuroinflammatory models by both transgenic expression and recombinant delivery (<xref ref-type="bibr" rid="bib134">Su and Tao, 2021</xref>). Overall, the results of this study highlight the role of IL-37 in alleviating acute and chronic neuroinflammatory conditions and provide the basis for recombinant IL-37 as a potential future therapeutic approach. Furthermore, the IL-37tg mouse is a novel and important model system to explore therapeutic options while gaining mechanistic insights into human neurodegenerative diseases.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-IBA1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic Systems</td><td align="left" valign="bottom">Cat#234003, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10641962">AB_10641962</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Cy2 AffiniPure Goat Anti-Rabbit IgG (H+L) (Rabbit polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch Laboratories</td><td align="left" valign="bottom">Cat# 111-225-144, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338021">AB_2338021</ext-link></td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Cy3 AffiniPure Goat Anti-Mouse IgG +IgM (H+L) (Mouse polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch Laboratories</td><td align="left" valign="bottom">Cat#115-165-068, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338686">AB_2338686</ext-link></td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Cy3 AffiniPure Goat Anti-Rabbit IgG (H+L) (Rabbit polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch Laboratories</td><td align="left" valign="bottom">Cat#111-165-144, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338006">AB_2338006</ext-link></td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">mouse CD68-PE<break/>Clone REA835 (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-112-856</td><td align="left" valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">mouse CD11b-PerCP-Vio700<break/>Clone REA592 (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-113-809</td><td align="left" valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">mouse CD45-APC (mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-110-798</td><td align="left" valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Bovine Serum Albumin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A7906</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">CaCl<sub>2</sub></td><td align="left" valign="bottom">Applichem</td><td align="left" valign="bottom">Lot: 4U010421</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">cOmplete Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 04693116001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D9542</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">D-glucose</td><td align="left" valign="bottom">Roth</td><td align="left" valign="bottom">Art.-Nr. HN06.3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Evans Blue tetrasodium salt</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">Cat# 0845</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Fluoro-Gel mounting medium</td><td align="left" valign="bottom">Electron Microscopy Sciences</td><td align="left" valign="bottom">Cat# 17985–10</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">GBSS</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">G9779-500ML</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Gibco DMEM</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# 31885023</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Gibco Fetal Bovine Serum</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# 11573397</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Gibco HBSS 10 X</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# 14065049</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Gibco L-Glutamine</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# 15410314</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Glycine</td><td align="left" valign="bottom">Applichem</td><td align="left" valign="bottom">Cat# A1067</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">KCl</td><td align="left" valign="bottom">Applichem</td><td align="left" valign="bottom">Lot: 0000574737</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">KH<sub>2</sub>PO<sub>4</sub></td><td align="left" valign="bottom">Applichem</td><td align="left" valign="bottom">Lot: 4Q016683</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Methoxy-XO4</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab142818</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">MgSO<sub>4</sub></td><td align="left" valign="bottom">Applichem</td><td align="left" valign="bottom">Lot: 3E000057</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">NaCl</td><td align="left" valign="bottom">Applichem</td><td align="left" valign="bottom">Lot: 8Q012497</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">NaHCO<sub>3</sub></td><td align="left" valign="bottom">Roth</td><td align="left" valign="bottom">Art.-Nr. HN01.1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Permount Mounting Medium</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# SP15-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Poly-L-lysine solution</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">CAS# 25988-63-0</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant IL-37</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib101">Moretti et al., 2014</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant IL-1β</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib77">Kim et al., 2013</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Triton X-100 Molecular Biology grade BC</td><td align="left" valign="bottom">Applichem</td><td align="left" valign="bottom">Cat# A4975</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">Trypsin-EDTA Solution 10 X</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">CAS Nr. 9002-07-7</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">chemical compound, drug</td><td align="left" valign="bottom">TWEEN 20</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P9416</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">Biozym Blue Probe qPCR Kit Separate ROX</td><td align="left" valign="bottom">Biozym</td><td align="left" valign="bottom">Cat# 331456 S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">FD Congo-Red Solution Kit</td><td align="left" valign="bottom">FD NeuroTechnologies, Inc.</td><td align="left" valign="bottom">Cat# PS108</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">FD Rapid GolgiStain Kit</td><td align="left" valign="bottom">FD NeuroTechnologies, Inc.</td><td align="left" valign="bottom">Cat# PK401</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">High-Capacity cDNA Reverse Transcription Kit</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 4368814</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">Macherey-Nagel NucleoSpin RNA</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Product Code 15373604</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">pegGOLD TriFast</td><td align="left" valign="bottom">Avantor</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial assay or kit</td><td align="left" valign="bottom">ProtoScript II First Strand cDNA Synthesis Kit</td><td align="left" valign="bottom">New England Biolabs Inc.</td><td align="left" valign="bottom">Cat# E6560</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6;C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax mice</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Cat# 005864</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6 J OlaHsd mice</td><td align="left" valign="bottom">Harlan-Winkelmann or Janvier</td><td align="left" valign="bottom">Cat# 057 (H-W)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Human Interleukin-37 transgenic mice</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">ANY-maze</td><td align="left" valign="bottom">Stoelting</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014289">SCR_014289</ext-link> <break/><ext-link ext-link-type="uri" xlink:href="https://www.stoeltingco.com/">https://www.stoeltingco.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">Wane Rasband NIH, USA</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">IntraCell Version 1.5</td><td align="left" valign="bottom">(C)2000 Institute for Neurobiology Magdeburg</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">Prism 8</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">Video Mot 2</td><td align="left" valign="bottom">TSE Systems</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.tse-systems.com">https://www.tse-systems.com</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">G*Power Version 3.1.9.4</td><td align="left" valign="bottom">Heinrich Heine University Düsseldorf, Germany</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower.html">http://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower.html</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><p>All experiments were performed and analyzed blinded to the experimenter.</p><sec id="s4-1"><title>Animals</title><p>All animals used in this study were of either sex, equal distributed to the experiments with exception in the behavioral test were only males were used (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Mice were bred and kept at the animal facility of the TU Braunschweig under standard housing conditions in a 12:12 light:dark cycle at 22 °C with food and water available ad libitum. Transgenic mouse expressing human IL-37 (hIL-37tg mice, also referred as IL-37tg) were provided by Prof. Dr. Philip Bufler, Medical University of Munich. IL-37tg animals were originally generated by injecting fertilized eggs from C57BL/6 females with the pIRES IL-37 expression plasmid (<xref ref-type="bibr" rid="bib108">Nold et al., 2010</xref>). As a starting pair for these experiments here, a heterozygous female was mated with a heterozygous male. Resulting negative animals, heterozygous and homozygous IL-37tg animals were identified by PCR. The distinction between heterozygous and homozygous animals could be clearly analyzed based on the positive mRNA quantity. Further C57BL/6 J wild-type (WT) mice and APP/PS1ΔE9 (heterozygous breeding) mice were used. The latter mouse line was crossed with the hIL-37 line to create a double-transgenic mouse line (APP/PS1-IL37). In all experiments negative littermates and/or C57BL/6 wild-type mice were used as controls. All experimental procedures were authorized by the animal welfare representative of the TU Braunschweig and the LAVES (Oldenburg, Germany) (33.19-42502-04-16/2170).</p></sec><sec id="s4-2"><title>Lipopolysaccharide (LPS) administration</title><p>In all performed experiments related to any lipopolysaccharide (LPS) stimulus, the same LPS from <italic>Escherichia coli</italic> (<italic>E. coli</italic> O127:B8, Sigma Aldrich L 3129) was used. The systemic immune stimulation with LPS was performed by intraperitoneal injection. The body weight of the stimulated animals was monitored to determine the appropriate volume of LPS. Animals were either injected with 2x0.5 mg/kg LPS or 0.9% sodium chloride (NaCl) as a control.</p></sec><sec id="s4-3"><title>LPS administration during electrophysiological recordings</title><p>To investigate the acute effect of LPS-induced direct immunostimulation and subsequent local IL-37 expression in the CNS, LPS administration was performed during electrophysiological recordings. For this purpose, acute hippocampal slices from adult control and IL-37tg mice were pretreated with LPS (10 µg/ml) 2 hr before and throughout the recording period.</p></sec><sec id="s4-4"><title>Administration of recombinant IL-37 together with either IL-1β or LPS</title><p>Wild-type mice were injected intraperitoneally with 300 ng of recombinant IL-37 per mouse for 3 consecutive days, followed by an injection of 60 ng of recombinant IL-1β per mouse.</p><p>To test the preventive effect of rIL37 with LPS, WT mice received an intraperitoneal injection of 100 ng of rIL-37 or vehicle for three consecutive days. Two hours after the third injection, mice received an injection of either 0.5 mg/kg LPS or 0.9% sodium chloride (NaCl) as a control, followed by a second injection 24 hr later.</p></sec><sec id="s4-5"><title>Cell culture and LPS administration</title><p>Neonatal mouse brains (P3 – P5) were used for culture preparation as shown previously (<xref ref-type="bibr" rid="bib90">Lonnemann et al., 2020</xref>). Briefly, the meninges were removed and the brain transferred into HBSS 1 X on ice. Using a 10 ml pipette, the tissue was transferred into a sterile 50 ml conical tube and centrifuged at 2000 rcf for 5 min at 4 °C. The re-suspended pellet (in 5 ml fresh HBSS 1 X) was applied on a cell strainer (100 µm pores). Again after spinning as before the pellet was re-suspended in 10 ml culture media (DMEM +10% FCS+1% Penicillin/Streptomycin) and transferred into a T-75 flask. The mixed culture was incubated in the flask in an incubator at 10% CO<sub>2</sub> at 37 °C for 2–3 weeks. After 3 days incubation, the media was replaced 50% with fresh media. In the following every 7 days the media was replaced completely. After 2–3 weeks, the culture has reached confluence and the flasks were shaken at 180 rpm for 3 hr at 37 °C. The media including the microglia cells was collected without disrupting the astrocyte layer on the bottom of the flask and was centrifuged at 3000 rpm for 10 min at room temperature (RT). Microglia cells were plated in 96-well plate with a density of 6x10<sup>4</sup> cells/well and were treated with different concentrations of LPS for 24 hr. In the last hour of the treatment, ATP (5 mM) was added to the cells.</p><p>To prepare a primary astrocyte culture, neonatal mouse brains (P3-4) were used. After removal of the brain, the hippocampus and meninges were carefully removed. The cortices were transferred on ice to fresh HBSS 1 x, and the tissue was homogenized using a 10 ml pipette. The HBSS was then washed off, and the brains were placed in a dissociation solution containing DNAse for 30 min at 37 °C, and the remaining tissue pieces were further dissociated by pipetting. After centrifugation at 800 rpm for 7 min, the supernatant was removed and the cells were resuspended in culture medium (DMEM supplemented with 10% FCS, 1% penicillin/streptomycin) and placed on a 40 µm cell strainer and finally transferred to a T-75 flask coated with poly-D-lysine. When cells reached confluence, they were shaken overnight at 220 rpm to remove other glial cells, and then astrocytes were passaged. The cells were passaged three times until the experiments were performed. Experiments were performed on day in vitro (DIV) 15–19. Astrocytes were plated in a 12-well plate (1×10<sup>5</sup> cells/well) and maintained for 24 hr followed by a 100 ng/ml LPS stimulus.</p></sec><sec id="s4-6"><title>Cytokine measurement of pro-inflammatory IL-6, IL-1β, and TNF-α</title><p>Enzyme-linked immunosorbent assay (ELISA) was used to quantify cytokines in either brain homogenates or supernatants of treated primary microglia cells. Mice were deeply anesthetized with CO<sub>2</sub> and killed via decapitation. Brains were isolated and homogenized in STKM buffer (250 mM Sucrose, 50 mM Tris-HCl, 25 mM KCl, 5 mM MgCl<sub>2</sub>) using the GentleMACS (Miltenyi Biotec) program Protein_01. After centrifugation at 4000 g for 5 min at 4 °C the supernatant was again centrifuged for 10 min at 13,000 g at 4 °C. Brain homogenates (1:2) (diluted in 1% BSA solution) were analyzed using R&amp;D systems ELISA Kits.</p></sec><sec id="s4-7"><title>IL-37 mRNA measurement</title><p>To quantify the expression of IL-37 in primary microglia, cells were treated with 100 ng/mL LPS for 24 hr for seven different time periods (5 Min, 10 Min, 20 Min, 40 Min, 1 hr, 4 hr and 24 hr). Total RNA was isolated using peqGOLD TriFast. cDNA was prepared using BioLabs ProtoScript II First Strand cDNA Synthesis Kit.</p><p>For tissue extraction the RNA purification Kit (Macherey-Nagel) was used. cDNA was prepared by using the High Capacity cDNA Reverse Transcription Kit (Thermofisher).</p><p>Then, real-time quantitative PCR (qPCR) was performed using BlueProbe qPCR Mix (Biozym) and the following primer pairs: <italic>IL-37</italic>: 5´-GGG AGT TTT GTC TCT ACT GTG AC-3´(forward) and 5´-CCC ACC TGA GCC CTA TAA AAG-3´(reverse); <italic>GAPDH</italic> 5´-GCC TTC CGT GTT CCT ACC-3´(forward) and 5´-CCT CAG TGT AGC CCA AGA TG-3´(reverse). Expression levels of target mRNA was analyzed using the ∆∆Ct method and were normalized to the expression level of the house keeping gene GAPDH, which was used as an internal control.</p></sec><sec id="s4-8"><title>Immunohistochemistry</title><p>To check the amount and morphology of microglial cells in the brain tissue, brains were isolated and fixed in 4% paraformaldehyde (PFA) for 24 hr and then cryoprotected in 30% sucrose solution in phosphate buffered saline (PBS 1 x) for 24 hr. Samples were stored in Tissue-Tek O.C.T. compound (A. Hartenstein Laborversand) at –70 °C. 30 µm brains sections were cut using the Cryostat. Using the free floating method these slices were washed in 1 x PBS and blocked in 1 x PBS solution containing 0.2% Triton X-100, 10% goat serum and 1% BSA for 1 hr at room temperature (RT). Slices were incubated overnight at 4 °C with anti-ionized calcium-binding adaptor molecule 1 (IBA-1) (1:1000; rabbit polyclonal, Synaptic System) primary antibody diluted in 1 X PBS, 0.2% Triton X-100 and 10% goat serum. Cy3-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (1:500; Jackson ImmunoResearch) was used as secondary antibody diluted in 1 X PBS. Sections were washed as before and stained with 4’,6-diamidino-2-phenylindole (DAPI) (SIGMA) followed by cover-slipping with Fluoro-gel with Tris buffer (Electron Microscopy Sciences).</p></sec><sec id="s4-9"><title>FACS analysis</title><p>Microglia activation was analyzed by measuring the marker CD68 with the FACS method (<xref ref-type="bibr" rid="bib90">Lonnemann et al., 2020</xref>). Single cell isolation was performed using the Adult Brain Dissociation Kit (Miltenyi Biotec Order no. 130-107-677) from Miltenyi and the GentleMACS to homogenize the fresh isolated brains. Briefly, brain tissue was homogenized enzymatically and mechanistically for 30 min at 37 °C using the GentleMACS. In the following steps, the debris and the red blood cells were removed using the manufactory manual and products including a percoll based gradient and red blood cell lysis buffer. The cells were resuspended in FACS staining buffer (1xPBS +1% FCS+0.1% Na-Azide) and plated in V-bottom 96-well plate. Cells were stained for 30 min with CD11b-PerCP (1:50), CD45-APC (1:50), CD68-PE (1:50). The flowcytometry was measured using the BD LRS II SORP and analyzed with FlowJo Software.</p></sec><sec id="s4-10"><title>Methoxy-XO4 staining</title><p>The phagocytic activity regarding Aβ uptake in microglial cells of APP/PS1 and APP/PS1-IL37tg animals was analyzed by FACS. Here, WT, APP/PS1 and APP/PS1-IL37tg animals was used and crossed with the Cx3Cr1-GFP mouse line. The Cx3cr1-GFP transgenic mice express a microglia-specific (or monocytic-specific) green fluorescent protein in the CNS. To visualize Aβ particles animals were injected intraperitoneal with 10 mg/kg methoxy-XO4 (Abcam; ab142818; blood-brain barrier permeable amyloid-β fluorescent marker) in 50% DMSO/ 50% NaCl (0.9%) 3 hr prior to the start of experiments. After the brain was removed, the procedure was as in section ‘FACS analysis’.</p></sec><sec id="s4-11"><title>Y-Maze test</title><p>There are several methods to evaluate cognitive function in rodents. Of these, one method is called ‘Y-Maze’ in which a mouse is placed in a maze with three equal arms (hence the term ‘Y’) each 32 cm from the center. First the mouse is free to explore the first two arms while the third arm is blocked. After the mouse get to know the existence of the two arms during 3 min training, the mouse was returned to its cage for 1.5 hr. Then the mouse is placed back to the Y-Maze with all three arms available. The observer records how often the mouse enters an arm. Due to animal’s natural tendency to explore a newly introduced environment it is expected to be expressed by a high frequency of spontaneous alteration performance (SAP). The SAP score is a triplet of three successive different arm visits (ABC, BCA, CAB, BAC, ACB, CBA).</p></sec><sec id="s4-12"><title>Morris water maze test</title><p>The Morris water maze (MWM) test is an assay to analyze spatial memory formation and retention (<xref ref-type="bibr" rid="bib102">Morris, 1984</xref>). A circular plastic pool (160 cm in diameter and 60 deep) filled up to 30 cm with opaque water (titanium dioxide, Euro OTC Pharma; water temperature 19–20°C) was used including a 10 cm escape platform submerged 1 cm below the water surface and three visual cues on the walls around the pool. Each day the test was performed in the same conditions (dim light and the same time of the day) by the same experimenter blind to all groups. The ANY-maze software (Stoelting, USA) with a camera above the center of the maze was used to track each trial. A pre-training with a visible platform was performed to guarantee the visual and swimming ability in all experimental groups and in addition to get the animal used to the test situation. The pre-training lasted for three consecutive days with two trials each day (maximum of 60 s each) to reach the platform.</p><p>The mice were trained in the Morris water maze for 8 days with the invisible platform located in the northwest (NW) quadrant. Each day, animals were placed from randomly starting positions (SW, S, E and NE) for 4 trials in the water with 5-min intervals. The animals had a maximum of 60 s to find the platform otherwise they were guided to the platform and allowed to stay for additional 15 s. The memory retention was measured by performing a reference test. One reference test was performed on day 3 of the training acquisition (prior to the training session) and another reference test 24 hr after the last training day (day 9). The platform was removed during this reference test. The animals were tracked for 45 s (starting position SE).</p></sec><sec id="s4-13"><title>Electrophysiological experiments</title><p>To study learning and memory processes on cellular level, we did electrophysiological recording experiments in CA1 hippocampal neurons as described before (<xref ref-type="bibr" rid="bib62">Hosseini et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Lonnemann et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Hosseini et al., 2020</xref>). Briefly, mice were deeply anesthetized with 100% CO<sub>2</sub>, killed by decapitation following fast brain removal and transfer into ice-cold carbogenated (95% O<sub>2</sub> and 5% CO<sub>2</sub>) artificial CSG (ACSF) containing 124 mM NaCl, 4.9 mM KCl, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 2.0 mM MgSO<sub>4</sub>, 2.0 mM CaCl<sub>2</sub>, 24.6 mM NaHCO<sub>3</sub> and 10 D-glucose, pH 7.4. Acute hippocampal slices were prepared (400 µm) using a tissue chopper. The hippocampal slices were placed into an interface chamber (Scientific System Design) and incubated at 32 °C in a constant flow rate (0.5 ml/min) of carbogenated ACSF for 2 hr. Afterwards the recordings were started and field excitatory post synaptic potentials (fEPSPs) were measured in the stratum radiatum of the hippocampus CA1 sub-region. The Schaffer collateral pathway was stimulated using two monopolar, lacquer-coated stainless-steel electrodes (5 MΩ; AM Systems). Long-term potentiation (LTP) was induced after 20 min baseline recording by theta-burst stiulation (TBS) including four bursts at 100 Hz repeated 10 times in a 200ms interval. This stimulation was repeated three times in a 10 s interval. Only healthy sections with a stable baseline were included in the data set. Using the IntraCell software (version 1.5, LIN) the data set was analyzed.</p></sec><sec id="s4-14"><title>Golgi-Cox staining</title><p>To analyze the morphology of hippocampal neurons, Golgi-Cox staining was performed like previously described (<xref ref-type="bibr" rid="bib62">Hosseini et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Lonnemann et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Hosseini et al., 2020</xref>). Briefly, mice were deeply anesthetized with CO<sub>2</sub> and sacrificed by decapitation. The brain was incubated in FD rapid Golgi-Cox staining kit according to the manufacturer’s protocol. The tissue was incubated in a mixture of solution A (potassium dichromate and mercuric chloride) and B (potassium chromate) for at least 14 days at RT in the dark. After incubation of A-B the tissue was placed for 1 week in solution C (tissue protection) at RT. In the following, the brain was blocked in 2% agar and 200-µm-thick coronal sections were cut using a vibratome (Leica VT 1000 S). The slices were collected on gelatin-coated glass slides and stained with solution D and E before being dehydrated through graded alcohols and mounted using Permount (Thermo Fisher Scientific).</p></sec><sec id="s4-15"><title>Congo-Red staining</title><p>To examine the Aβ-plaques in APP/PS1 and APP/PS1-IL37 mice plaques were analyzed for the amount and size using the Congo-Red staining. Mice were deeply anesthetized with CO<sub>2</sub> and sacrificed via decapitation. Brains were isolated and hemispheres were fixed in 4% PFA for 24 hr and then cryoprotected in 30% sucrose solution in phosphate buffered saline (PBS 1 x). Hemispheres were stored in Tissue-Tek (Hartenstein Laborversand) at –70 °C and cutted using the Leica Cryostat (CM3050 S) in 30 µm slices. The sections were transported on gelatin-coated slides and in the following stained with the Congo-Red manufactorer’s protocol using the FD Congo-Red Solution kit (FD Neurotechnologies, Inc) and mounted with Permount (Thermo Fisher Scientific).</p></sec><sec id="s4-16"><title>Imaging and image analysis</title><p>To analyze the hippocampal neuron morphology, CA1 and dentate gyrus (DG) cells were imaged in the three-dimensions (z-stack thickness of 0.5 µm) using Axioplan 2 imaging microscope (Zeiss) with a 63 x (N.A. 1) oil objective equipped with a digital camera (AxioCam MRm, Zeiss). All selected dendrites were analyzed per spine density via number of spines (counted manually using the ImageJ software) per micrometer of dendritic length more than 50–60 µm which were positioned at least 40–50 µm away from the cell soma.</p><p>To analyze microglia morphology microscopic images of anti-IBA-1 were taken within the area of cortex and hippocampus. Images were taken in 3D (z-stack thickness 1 µm) using Axioplan 2 imaging microscope (Zeiss) equipped with an ApoTome module (Zeiss) with a 20 X objective (NA, 0.8) and digital camera (AxioCam MRm; Zeiss). IBA-1 positive cells were counted with clearly visible nuclei by DAPI staining for microglia density and the processes of IBA-1 positive cells were analyzed to investigate the activation status of these cells by using the ImageJ software (Wane Rasband NIH, USA).</p><p>To survey the Aβ-plaques images from Congo-Red stained slices were taken. Congo-Red staining presents a bright fluorescence emission at 614 nm with excitation at 497 nm. Images of brain sections were taken using an Axioplan 2 imaging microscope (Zeiss) with a 2.5 X objective (N.A. 0.07) connected to a digital camera (Nikon) with the same light exposure time of 1 s in all groups. Plaque load and plaque size were analyzed using the ImageJ software (Wane Rasband NIH, USA) with the analyze particle tool. The polygon selection tool was used to generate the region of interest (ROI) for the area of hippocampus and cortex. Plaque load (number of particles) and plaque size (area of particles) were normalized to the area of hippocampus and cortex and plotted as plaque load and plaque size per mm<sup>2</sup>.</p></sec><sec id="s4-17"><title>Extraction of intracellular Metabolites for Gas Chromatography-Mass Spectrometry (GC-MS)</title><p>Primary microglia cells (5*10<sup>5</sup> cells) were plated onto 12-well plates and incubated for 24 hr. The medium was exchanged with fresh medium or medium mixed with 10 ng/ml LPS for 24 hr. To extract intracellular metabolites cells were washed once with 0.9% NaCl and 500 µL of a cold methanol/water mixture was added. The water fraction contained the internal standard (IS) D6-glutaric-acid (c=1 µg/ml). Cells were scraped and transferred into 250 µL of –20 °C Chloroform. After <underline>vortexing</underline> samples for 20 min at 4 °C with maximal speed in an automatic shaker, samples were centrifuge for 5 min at above 15,000 xg in a table centrifuge (4 °C). A total of 200 µL of the upper phase was transferred in a GC glass vial with micro insert and evaporated to dry under vacuum at 4 °C, overnight. To avoid condensation, the GC glass vials were warmed to room temperature under vacuum and capped afterwards with magnetic caps.</p></sec><sec id="s4-18"><title>Metabolite measurement</title><p>Derivatization of the samples was performed directly before GC-MS measurement. Metabolite extracts were dissolved in 15 µL pyridine, containing 20 mg/mL methoxyamine hydrochloride at 55 °C for 90 min under shaking. After adding 15 µL N-methyl-N-tert-butyldimethylsilyl-trifluoroacetamide samples were incubated at 55 °C for 60 min under continuous shaking. GC/MS analysis was performed using an Agilent 7890B GC coupled to an Agilent 5977B MSD. The gas chromatogram was equipped with a 30 m ZB-35 Phenomenex 5 m Guard capillary column. As carrier gas helium was used at a flow rate of 1.0 ml/min. A sample volume of 1 µL was injected into a split/splitless inlet, operating a splitless mode at 270 °C. The GC oven Temperature was held at 100 °C for 2 min and increased to 300 at 10 °C/min and held for further 4 min. Afterwards the temperature was increased to 325 °C. The MSD was operating under electron ionization at 70 eV. The MS source was held at 230 °C and the quadrupole at 150 °C. The total run time of one sample was 26 min. Full scan mass spectra were acquired from m/z 70 to m/z 800. All GC-MS chromatograms were processed using Metabolite Detector, v3.020151231Ra (<xref ref-type="bibr" rid="bib61">Hiller et al., 2009</xref>).</p></sec><sec id="s4-19"><title>RNA sequencing</title><p>Briefly, brain tissue from WT and IL –37tg mice treated with either saline or LPS was homogenized enzymatically and mechanically for 30 min at 37 °C using GentleMACS. Cellular debris and red blood cells were removed using the manufacturer’s manual and products such as a Percoll-based gradient and a red blood cell lysis buffer. Microglia were then isolated by administration of CD11b MicroBeads followed by magnetic bead separation. RNA was then isolated using the Nucleo Spin RNA Isolation Kit (Machery-Nagel). The cDNA synthesis was performed and libraries were prepared using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina at the Genome Analytics of the Helmholtz Center for Infection Research. The libraries were sequenced on Illumina NovaSeq 6000 using NovaSeq 6000 S1 Reagent Kit (100 cycles, paired end run) with an average of 5x107 reads per RNA sample. Before alignment to reference genome (mm10) each sequence in the raw FASTQ files were trimmed on base call quality and sequencing adapter contamination using Trim Galore! wrapper tool. Reads shorter than 20 bp were removed from FASTQ file (<xref ref-type="bibr" rid="bib4">Andrews, 2010</xref>; <xref ref-type="bibr" rid="bib82">Krueger, 2012</xref>). Trimmed reads were aligned to the reference genome using open source short read aligner STAR (<ext-link ext-link-type="uri" xlink:href="https://code.google.com/p/rna-star/">https://code.google.com/p/rna-star/</ext-link>) with settings according to log file (<xref ref-type="bibr" rid="bib42">Dobin et al., 2013</xref>). Feature counts were determined using R package ‘Rsubread’ (<xref ref-type="bibr" rid="bib87">Liao et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Durinck et al., 2005</xref>). Only genes showing counts greater 5 at least two times across all samples were considered for further analysis (data cleansing). Gene annotation was done by R package ‘bioMaRt’ Before starting the statistical analysis steps, expression data was log<sub>2</sub> transform and TMM normalized (edgeR). Differential gene expression was calculated by R package ‘edgeR’. Functional analysis was performed by R package ‘clusterProfiler’ (<xref ref-type="bibr" rid="bib121">Robinson et al., 2010</xref>; <xref ref-type="bibr" rid="bib159">Yu et al., 2012</xref>).</p></sec><sec id="s4-20"><title>Statistical analysis</title><p>Sample size for all experiments were calculated a priory with G*Power software (HHU Düsseldorf). Samples were allocated into the experimental groups randomly.</p><p>Data were analyzed and plotted by GraphPad Prism 8 (GraphPad Software, Inc USA) and presented as mean ± SEM. Statistically analysis were performed with either unpaired t-test, one-way ANOVA (post hoc test Fisher’s LSD or Turkey’s multiple comparisons) or two-way ANOVA (post hoc test Fisher’s LSD or Bonferroni’s multiple comparisons) depending on experiments. The minimum significance value was considered as p&lt;0.05 (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Statistical table.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Figure</th><th align="left" valign="bottom">Name</th><th align="left" valign="bottom">Test</th><th align="left" valign="bottom"/><th align="left" valign="bottom">Multi-comparison</th><th align="left" valign="bottom"/><th align="left" valign="bottom"/></tr></thead><tbody><tr><td align="char" char="." valign="bottom">1B</td><td align="char" char="." valign="bottom">100 ng/ml 6 hr</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,9)=2,428; p=0.1434</td><td align="left" valign="bottom">Tukey’s</td><td align="left" valign="bottom">0,8947</td><td align="left" valign="bottom">WT vs. HET</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0,1460</td><td align="left" valign="bottom">WT vs. HOM</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">100 ng/ml 24 hr</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,11)=7,941; p=0.0073</td><td align="left" valign="bottom">Tukey’s</td><td align="left" valign="bottom">0,0539</td><td align="left" valign="bottom">WT vs. HET</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0,0067</td><td align="left" valign="bottom">WT vs. HOM</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1 µg/ml 6 hr</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,9)=12,74; p=0.0024</td><td align="left" valign="bottom">Tukey’s</td><td align="left" valign="bottom">0,0090</td><td align="left" valign="bottom">WT vs. HET</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0,0037</td><td align="left" valign="bottom">WT vs. HOM</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1 µg/ml 24 hr</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,11)=3,915; p=0.0520</td><td align="left" valign="bottom">Tukey’s</td><td align="left" valign="bottom">0,3586</td><td align="left" valign="bottom">WT vs. HET</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0,0426</td><td align="left" valign="bottom">WT vs. HOM</td></tr><tr><td align="char" char="." valign="bottom">1C</td><td align="left" valign="bottom">IL-6 10 ng/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=1,742 df = 16; p=0.1007</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">IL-6 100 ng/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=3,597 df = 16; p=0.0024</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">IL-6 1 µg/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=5,127 df = 16; p=0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="char" char="." valign="bottom">1D</td><td align="left" valign="bottom">TNF-α 10 ng/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=3,376 df = 16; p=0.0038</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">TNF-α 100 ng/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=6,774 df = 16; p&lt;0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">TNF-α 1 µg/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=6,264 df = 16; p&lt;0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="char" char="." valign="bottom">1E</td><td align="left" valign="bottom">IL-1β 10 ng/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=2,390 df = 16; p=0.0295</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">IL-1β 100 ng/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=5,027 df = 16; p=0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">IL-1β 1 µg/ml</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=5,852 df = 16; p&lt;0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="char" char="." valign="bottom">1F</td><td align="left" valign="bottom">IL-37 mRNA</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(7,15)=2,629; p=0.0550</td><td align="left" valign="bottom">Fisher’s LSD</td><td align="left" valign="bottom">0.0171</td><td align="left" valign="bottom">0 hr vs. 1 hr</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0086</td><td align="left" valign="bottom">0 hr vs. 4 hr</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0238</td><td align="left" valign="bottom">0 hr vs. 24 hr</td></tr><tr><td align="char" char="." valign="bottom">1G</td><td align="left" valign="bottom">IL-6</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=20,39 df = 4; p&lt;0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT vs. IL37tg</td></tr><tr><td align="char" char="." valign="bottom">1H</td><td align="left" valign="bottom">rIL-37 100 ng/ml</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,30)=5,135; p=0.0121</td><td align="left" valign="bottom">Tukey’s</td><td align="left" valign="bottom">0.1675</td><td align="left" valign="bottom">WT vs. 100 ng</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0133</td><td align="left" valign="bottom">WT vs. 500 ng</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">rIL-37 1 µg/ml</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,30)=3,512; p=0.0426</td><td align="left" valign="bottom">Tukey’s</td><td align="left" valign="bottom">0.2457</td><td align="left" valign="bottom">WT vs. 100 ng</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0498</td><td align="left" valign="bottom">WT vs. 500 ng</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">2B</td><td align="left" valign="bottom">Itaconate<break/>Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,20)=174,9; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Itaconate<break/>Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,20)=27,55; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">2C</td><td align="left" valign="bottom">Succinate<break/>Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,20)=98,40; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0005</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Succinate<break/>Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,20)=17,01; p=0.0005</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">3B</td><td align="left" valign="bottom">Body weight<break/>Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,17)=220,5; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Body weight<break/>Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,41)=1,486; p=0.2299</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0139</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">3D</td><td align="left" valign="bottom">CD68<break/>Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,6)=19,52; p=0.0045</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0017</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">CD68<break/>Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,6)=48,42; p=0.0004</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0167</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">3E</td><td align="left" valign="bottom">IL-1β Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,7)=9,399;p=0.0182</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0244</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.7541</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">IL-1β Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,7)=3,182;p=0.0935</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0366</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">3F</td><td align="left" valign="bottom">Iba1 CA1 Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,25)=5,222;p=0.0311</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0024</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Iba1 CA1 Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,34)=4,951;p=0.0328</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0027</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">3G</td><td align="left" valign="bottom">Processes CA1 Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,46)=1,066; p=0.3073</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.6229</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Processes CA1 Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,58)=1,238; p=0.2704</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.5670</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">3H</td><td align="left" valign="bottom">Iba1 Cortex Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,25)=15,97; p=0.0005</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0002</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.3234</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Iba1 Cortex Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,34)=5,159; p=0.0296</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0054</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">3I</td><td align="left" valign="bottom">Processes Cortex Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,104)=9,865; p=0.0022</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.1401</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0232</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Processes Cortex Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,104)=0,119; p=0.7308</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.8147</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">4A</td><td align="left" valign="bottom">LTP WT</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,28)=4,459; p=0.0438</td><td align="left" valign="bottom">Fisher’s LSD<break/>Time point 43–80</td><td align="left" valign="bottom">&lt;0.05</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="char" char="." valign="bottom">4B</td><td align="left" valign="bottom">LTP IL37</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,23)=0,085; p=0.7734</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="char" char="." valign="bottom">4C</td><td align="left" valign="bottom">LTP last 5 min Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,22)=7,887;p=0.0102</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0043</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">LTP last 5 min Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,29)=1,552; p=0.2228</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">4D</td><td align="left" valign="bottom">Spines CA1 Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,32)=22,81; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.1145</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Spines CA1 Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,44)=26,68; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0657</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">4E</td><td align="left" valign="bottom">Spines DG Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,26)=3,307; p=0.0805</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0062</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Spines DG Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,36)=0,529; p=0.4718</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.5222</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0295</td><td align="left" valign="bottom">LPS WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">4G</td><td align="left" valign="bottom">LTP WT</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,30)=4,925; p=0.0342</td><td align="left" valign="bottom">Fisher’s LSD<break/>Time point 39–80</td><td align="left" valign="bottom">&lt;0.05</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="char" char="." valign="bottom">4H</td><td align="left" valign="bottom">LTP IL37</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,26)=0,01395; p=0.9069</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="char" char="." valign="bottom">4I</td><td align="left" valign="bottom">LTP last 5 min Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,27)=4,613; p=0.0409</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0285</td><td align="left" valign="bottom">WT NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">IL37 NIL vs. LPS</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">LTP last 5 min Genotype</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,29)=1,747; p=0.1966</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">5A</td><td align="left" valign="bottom">Y-Maze Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,6)=18,25; p=0.0052</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0046</td><td align="left" valign="bottom">WT NIL vs. IL1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.7313</td><td align="left" valign="bottom">IL37 NIL vs. IL1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Y-Maze pre-treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,6)=9,899; p=0.0199</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0024</td><td align="left" valign="bottom">IL1 WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">5B</td><td align="left" valign="bottom">IL-6 Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,16)=264,6; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">WT NIL vs. IL1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">IL37 NIL vs. IL1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">IL-6 pre-treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,16)=10,27; p=0.0055</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.8327</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0004</td><td align="left" valign="bottom">IL1 WT vs. IL37</td></tr><tr><td align="char" char="." valign="bottom">5C</td><td align="left" valign="bottom">IL-1α Treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,16)=132,0; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">WT NIL vs. IL1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">IL37 NIL vs. IL1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">IL-1α pre-treatment</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(1,16)=17,47; p=0.0007</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">&gt;0.9999</td><td align="left" valign="bottom">NIL WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0003</td><td align="left" valign="bottom">IL1 WT vs. IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">6B</td><td align="left" valign="bottom">IL-1β</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,19)=5,224; p=0.0156</td><td align="left" valign="bottom">Fisher’s LSD</td><td align="left" valign="bottom">0.0903</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.2480</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0046</td><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">6C</td><td align="left" valign="bottom">IL-6</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,21)=3,600; p=0.0452</td><td align="left" valign="bottom">Fisher’s LSD</td><td align="left" valign="bottom">0.0220</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.5264</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0466</td><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">6E</td><td align="left" valign="bottom">CD68 9–12 m</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,11)=14,39; p=0.0008</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0008</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0529</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.04494</td><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">6F</td><td align="left" valign="bottom">CD68 6 m</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,12)=13,45; p=0.0009</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0007</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0263</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0985</td><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">6G</td><td align="left" valign="bottom">CD68 20–23 m</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,12)=13,38; p=0.0009</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0007</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0359</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0383</td><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">6I</td><td align="left" valign="bottom">Plaque load<break/>Hp</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=2,403 df = 74; p=0.0187</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Plaque load<break/>Cx</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=4,953 df = 63; p&lt;0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">6J</td><td align="left" valign="bottom">Plaque size<break/>Hp</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=2,296 df = 74; p=0.0245</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Plaque size<break/>Cx</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=5,949 df = 63; p&lt;0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">6G</td><td align="left" valign="bottom">Abeta uptake</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,22)=136; p&lt;0.0001</td><td align="left" valign="bottom">Bonferroni’s</td><td align="left" valign="bottom">0.0001</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0001</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0026</td><td align="left" valign="bottom">APP vs. APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">7B</td><td align="left" valign="bottom">Latency WT</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(7,88)=5,842; p&lt;0.0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">WT</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Latency APP</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(7,72)=3,477; p=0.0029</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Latency APP-IL37</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(7,80)=4,445; p=0.0003</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">APP-IL37</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Latency</td><td align="char" char="hyphen" valign="bottom">2-way ANOVA</td><td align="left" valign="bottom">F(2,30)=10,50; p=0.0003</td><td align="left" valign="bottom">Fisher’s LSD<break/>Day 1</td><td align="left" valign="bottom">&lt;0.05</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Day 3–6</td><td align="left" valign="bottom">&lt;0.01</td><td align="left" valign="bottom"> </td></tr><tr><td align="char" char="." valign="bottom">7C</td><td align="left" valign="bottom">PT<break/>WT</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=11,45 df = 22; p&lt;0,0001</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">NT vs. TQ</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">PT<break/>APP</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=0,9874 df = 18; p=0.3365</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">NT vs. TQ</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">PT<break/>APP-IL37</td><td align="left" valign="bottom">ttest</td><td align="left" valign="bottom">t=3,705 df = 20; p=0.0014</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"/><td align="left" valign="bottom">NT vs. TQ</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">PT TQs</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,30)=8,415; p=0.0013</td><td align="left" valign="bottom">Turkey‘s</td><td align="left" valign="bottom">0.0009</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0,0505</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">7E</td><td align="left" valign="bottom">LTP</td><td align="char" char="hyphen" valign="bottom">Two-way ANOVA</td><td align="left" valign="bottom">F(2,45)=9,286; p=0.0004</td><td align="left" valign="bottom">Fisher’s LSD<break/>Time point 21–80</td><td align="left" valign="bottom">&lt;0.0005</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Fisher’s LSD<break/>Time point 41–80</td><td align="left" valign="bottom">&lt;0.05</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">7F</td><td align="left" valign="bottom">Mean LTP 20–25 min</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,45)=7,090; p=0.0021</td><td align="left" valign="bottom">Turkey‘s</td><td align="left" valign="bottom">0.0016</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.5444</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">7G</td><td align="left" valign="bottom">Mean LTP 75–80 min</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,45)=9,354; p=0.0004</td><td align="left" valign="bottom">Turkey‘s</td><td align="left" valign="bottom">0.0014</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0023</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr><tr><td align="char" char="." valign="bottom">7I</td><td align="left" valign="bottom">Spine density</td><td align="char" char="hyphen" valign="bottom">One-way ANOVA</td><td align="left" valign="bottom">F(2,63)=6.318;p=0.0032</td><td align="left" valign="bottom">Turkey‘s</td><td align="left" valign="bottom">0.0026</td><td align="left" valign="bottom">WT vs. APP</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">0.0536</td><td align="left" valign="bottom">WT vs. APP-IL37</td></tr></tbody></table></table-wrap></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Supervision, Methodology</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Data curation, Software, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experimental procedures and protocolls were authorized by the animal welfare representative of the TU Braunschweig and the LAVES of the state of Lower Saxony in Germany (Oldenburg, Germany) (33.19-42502-04-16/2170).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-75889-transrepform1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for all Figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was in part supported by the DFG (SFB854), and by the Helmholtz-Gemeinschaft, Zukunftsthema &quot;Immunology and Inflammation&quot; (ZT-0027) to MK, and NIH Grant AI-15614 (to CAD). We acknowledge Philip Bufler, for providing us the hIL-37tg mouse and Andreas Holz for excellent guidance and critical comments to an earlier version of the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amo-Aparicio</surname><given-names>J</given-names></name><name><surname>Sanchez-Fernandez</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Eisenmesser</surname><given-names>EZ</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Lopez-Vales</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Extracellular and nuclear roles of IL-37 after spinal cord injury</article-title><source>Brain, Behavior, and Immunity</source><volume>91</volume><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.09.026</pub-id><pub-id pub-id-type="pmid">33002630</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>GX</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Kawata</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Tsuneyama</surname><given-names>K</given-names></name><name><surname>Leung</surname><given-names>P</given-names></name><name><surname>Lian</surname><given-names>ZX</given-names></name><name><surname>Okazaki</surname><given-names>K</given-names></name><name><surname>Ridgway</surname><given-names>WM</given-names></name><name><surname>Norman</surname><given-names>GL</given-names></name><name><surname>Ansari</surname><given-names>AA</given-names></name><name><surname>He</surname><given-names>XS</given-names></name><name><surname>Coppel</surname><given-names>RL</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice</article-title><source>Hepatology</source><volume>56</volume><fpage>1418</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1002/hep.25803</pub-id><pub-id pub-id-type="pmid">22532156</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>R</given-names></name><name><surname>Lerouet</surname><given-names>D</given-names></name><name><surname>Kimber</surname><given-names>I</given-names></name><name><surname>Pinteaux</surname><given-names>E</given-names></name><name><surname>Rothwell</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulation of expression of the novel IL-1 receptor family members in the mouse brain</article-title><source>Journal of Neurochemistry</source><volume>95</volume><fpage>324</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03364.x</pub-id><pub-id pub-id-type="pmid">16086690</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><source>FastQC: A Quality Control Tool for High Throughput Sequence Data</source><publisher-loc>Cambridge, United Kingdom</publisher-loc><publisher-name>Babraham Bioinformatics, Babraham Institute</publisher-name></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>K</given-names></name><name><surname>Matsuki</surname><given-names>N</given-names></name><name><surname>Ikegaya</surname><given-names>Y</given-names></name><name><surname>Nishiyama</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Deterioration of spatial learning performances in lipopolysaccharide-treated mice</article-title><source>Japanese Journal of Pharmacology</source><volume>87</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1254/jjp.87.195</pub-id><pub-id pub-id-type="pmid">11885968</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardura-Fabregat</surname><given-names>A</given-names></name><name><surname>Boddeke</surname><given-names>EWGM</given-names></name><name><surname>Boza-Serrano</surname><given-names>A</given-names></name><name><surname>Brioschi</surname><given-names>S</given-names></name><name><surname>Castro-Gomez</surname><given-names>S</given-names></name><name><surname>Ceyzériat</surname><given-names>K</given-names></name><name><surname>Dansokho</surname><given-names>C</given-names></name><name><surname>Dierkes</surname><given-names>T</given-names></name><name><surname>Gelders</surname><given-names>G</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Hoeijmakers</surname><given-names>L</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name><name><surname>Iaccarino</surname><given-names>L</given-names></name><name><surname>Jahnert</surname><given-names>S</given-names></name><name><surname>Kuhbandner</surname><given-names>K</given-names></name><name><surname>Landreth</surname><given-names>G</given-names></name><name><surname>Lonnemann</surname><given-names>N</given-names></name><name><surname>Löschmann</surname><given-names>PA</given-names></name><name><surname>McManus</surname><given-names>RM</given-names></name><name><surname>Paulus</surname><given-names>A</given-names></name><name><surname>Reemst</surname><given-names>K</given-names></name><name><surname>Sanchez-Caro</surname><given-names>JM</given-names></name><name><surname>Tiberi</surname><given-names>A</given-names></name><name><surname>Van der Perren</surname><given-names>A</given-names></name><name><surname>Vautheny</surname><given-names>A</given-names></name><name><surname>Venegas</surname><given-names>C</given-names></name><name><surname>Webers</surname><given-names>A</given-names></name><name><surname>Weydt</surname><given-names>P</given-names></name><name><surname>Wijasa</surname><given-names>TS</given-names></name><name><surname>Xiang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting neuroinflammation to treat alzheimer’s disease</article-title><source>CNS Drugs</source><volume>31</volume><fpage>1057</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1007/s40263-017-0483-3</pub-id><pub-id pub-id-type="pmid">29260466</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselin</surname><given-names>L</given-names></name><name><surname>Rivera Alvarez</surname><given-names>J</given-names></name><name><surname>Heide</surname><given-names>S</given-names></name><name><surname>Bonnet</surname><given-names>CS</given-names></name><name><surname>Tilly</surname><given-names>P</given-names></name><name><surname>Vitet</surname><given-names>H</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Bacino</surname><given-names>CA</given-names></name><name><surname>Baranaño</surname><given-names>K</given-names></name><name><surname>Chassevent</surname><given-names>A</given-names></name><name><surname>Dameron</surname><given-names>A</given-names></name><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Hanchard</surname><given-names>NA</given-names></name><name><surname>Mahida</surname><given-names>S</given-names></name><name><surname>McWalter</surname><given-names>K</given-names></name><name><surname>Mignot</surname><given-names>C</given-names></name><name><surname>Nava</surname><given-names>C</given-names></name><name><surname>Rastetter</surname><given-names>A</given-names></name><name><surname>Streff</surname><given-names>H</given-names></name><name><surname>Thauvin-Robinet</surname><given-names>C</given-names></name><name><surname>Weiss</surname><given-names>MM</given-names></name><name><surname>Zapata</surname><given-names>G</given-names></name><name><surname>Zwijnenburg</surname><given-names>PJG</given-names></name><name><surname>Saudou</surname><given-names>F</given-names></name><name><surname>Depienne</surname><given-names>C</given-names></name><name><surname>Golzio</surname><given-names>C</given-names></name><name><surname>Héron</surname><given-names>D</given-names></name><name><surname>Godin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mutations in the KIF21B kinesin gene cause neurodevelopmental disorders through imbalanced canonical motor activity</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2441</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16294-6</pub-id><pub-id pub-id-type="pmid">32415109</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auffret</surname><given-names>A</given-names></name><name><surname>Gautheron</surname><given-names>V</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Rovira</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Progressive age-related impairment of the late long-term potentiation in alzheimer’s disease presenilin-1 mutant knock-in mice</article-title><source>Journal of Alzheimer’s Disease</source><volume>19</volume><fpage>1021</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-1302</pub-id><pub-id pub-id-type="pmid">20157256</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avital</surname><given-names>A</given-names></name><name><surname>Goshen</surname><given-names>I</given-names></name><name><surname>Kamsler</surname><given-names>A</given-names></name><name><surname>Segal</surname><given-names>M</given-names></name><name><surname>Iverfeldt</surname><given-names>K</given-names></name><name><surname>Richter-Levin</surname><given-names>G</given-names></name><name><surname>Yirmiya</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity</article-title><source>Hippocampus</source><volume>13</volume><fpage>826</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1002/hipo.10135</pub-id><pub-id pub-id-type="pmid">14620878</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballak</surname><given-names>DB</given-names></name><name><surname>van Diepen</surname><given-names>JA</given-names></name><name><surname>Moschen</surname><given-names>AR</given-names></name><name><surname>Jansen</surname><given-names>HJ</given-names></name><name><surname>Hijmans</surname><given-names>A</given-names></name><name><surname>Groenhof</surname><given-names>G-J</given-names></name><name><surname>Leenders</surname><given-names>F</given-names></name><name><surname>Bufler</surname><given-names>P</given-names></name><name><surname>Boekschoten</surname><given-names>MV</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Eini</surname><given-names>H</given-names></name><name><surname>Lewis</surname><given-names>EC</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Tilg</surname><given-names>H</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Tack</surname><given-names>CJ</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Stienstra</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>IL-37 protects against obesity-induced inflammation and insulin resistance</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4711</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5711</pub-id><pub-id pub-id-type="pmid">25182023</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Pascual</surname><given-names>V</given-names></name><name><surname>O’Garra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines</article-title><source>Nature Immunology</source><volume>13</volume><fpage>925</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1038/ni.2406</pub-id><pub-id pub-id-type="pmid">22990890</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannerman</surname><given-names>DM</given-names></name><name><surname>Bus</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Sanderson</surname><given-names>DJ</given-names></name><name><surname>Schwarz</surname><given-names>I</given-names></name><name><surname>Jensen</surname><given-names>V</given-names></name><name><surname>Hvalby</surname><given-names>Ø</given-names></name><name><surname>Rawlins</surname><given-names>JNP</given-names></name><name><surname>Seeburg</surname><given-names>PH</given-names></name><name><surname>Sprengel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dissecting spatial knowledge from spatial choice by hippocampal NMDA receptor deletion</article-title><source>Nature Neuroscience</source><volume>15</volume><fpage>1153</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1038/nn.3166</pub-id><pub-id pub-id-type="pmid">22797694</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beattie</surname><given-names>EC</given-names></name><name><surname>Stellwagen</surname><given-names>D</given-names></name><name><surname>Morishita</surname><given-names>W</given-names></name><name><surname>Bresnahan</surname><given-names>JC</given-names></name><name><surname>Ha</surname><given-names>BK</given-names></name><name><surname>Von Zastrow</surname><given-names>M</given-names></name><name><surname>Beattie</surname><given-names>MS</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Control of synaptic strength by glial tnfalpha</article-title><source>Science</source><volume>295</volume><fpage>2282</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.1126/science.1067859</pub-id><pub-id pub-id-type="pmid">11910117</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>MMS</given-names></name><name><surname>Lonnemann</surname><given-names>N</given-names></name><name><surname>Remus</surname><given-names>A</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Enduring changes in neuronal function upon systemic inflammation are NLRP3 inflammasome dependent</article-title><source>The Journal of Neuroscience</source><volume>40</volume><fpage>5480</fpage><lpage>5494</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0200-20.2020</pub-id><pub-id pub-id-type="pmid">32499379</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhaskar</surname><given-names>K</given-names></name><name><surname>Konerth</surname><given-names>M</given-names></name><name><surname>Kokiko-Cochran</surname><given-names>ON</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Lamb</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulation of tau pathology by the microglial fractalkine receptor</article-title><source>Neuron</source><volume>68</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.08.023</pub-id><pub-id pub-id-type="pmid">20920788</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bliss</surname><given-names>TV</given-names></name><name><surname>Collingridge</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A synaptic model of memory: long-term potentiation in the hippocampus</article-title><source>Nature</source><volume>361</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/361031a0</pub-id><pub-id pub-id-type="pmid">8421494</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>ML</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism</article-title><source>Progress in Neurobiology</source><volume>76</volume><fpage>77</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2005.06.004</pub-id><pub-id pub-id-type="pmid">16081203</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchard</surname><given-names>C</given-names></name><name><surname>Pagé</surname><given-names>J</given-names></name><name><surname>Bédard</surname><given-names>A</given-names></name><name><surname>Tremblay</surname><given-names>P</given-names></name><name><surname>Vallières</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions</article-title><source>Glia</source><volume>55</volume><fpage>790</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1002/glia.20506</pub-id><pub-id pub-id-type="pmid">17390309</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulanger</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Immune proteins in brain development and synaptic plasticity</article-title><source>Neuron</source><volume>64</volume><fpage>93</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.09.001</pub-id><pub-id pub-id-type="pmid">19840552</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutajangout</surname><given-names>A</given-names></name><name><surname>Wisniewski</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The innate immune system in alzheimer’s disease</article-title><source>International Journal of Cell Biology</source><volume>2013</volume><elocation-id>576383</elocation-id><pub-id pub-id-type="doi">10.1155/2013/576383</pub-id><pub-id pub-id-type="pmid">24223593</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bufler</surname><given-names>P</given-names></name><name><surname>Gamboni-Robertson</surname><given-names>F</given-names></name><name><surname>Azam</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Interleukin-1 homologues IL-1f7b and IL-18 contain functional mrna instability elements within the coding region responsive to lipopolysaccharide</article-title><source>The Biochemical Journal</source><volume>381</volume><fpage>503</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1042/BJ20040217</pub-id><pub-id pub-id-type="pmid">15046617</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>S</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Micheel</surname><given-names>J</given-names></name><name><surname>Dobrowolny</surname><given-names>H</given-names></name><name><surname>Mawrin</surname><given-names>C</given-names></name><name><surname>Krause</surname><given-names>TJ</given-names></name><name><surname>Adamaszek</surname><given-names>M</given-names></name><name><surname>Bogerts</surname><given-names>B</given-names></name><name><surname>Bommhardt</surname><given-names>U</given-names></name><name><surname>Hartig</surname><given-names>R</given-names></name><name><surname>Busse</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Age-related increase of VGF-expression in T lymphocytes</article-title><source>Aging</source><volume>6</volume><fpage>440</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.18632/aging.100656</pub-id><pub-id pub-id-type="pmid">25013207</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraffa</surname><given-names>A</given-names></name><name><surname>Conti</surname><given-names>C</given-names></name><name><surname>D Ovidio</surname><given-names>C</given-names></name><name><surname>Gallenga</surname><given-names>CE</given-names></name><name><surname>Tettamanti</surname><given-names>L</given-names></name><name><surname>Mastrangelo</surname><given-names>F</given-names></name><name><surname>Ronconi</surname><given-names>G</given-names></name><name><surname>Kritas</surname><given-names>SK</given-names></name><name><surname>Conti</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators</article-title><source>Journal of Biological Regulators and Homeostatic Agents</source><volume>32</volume><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">29921369</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Pro- versus anti-inflammatory cytokines: myth or reality</article-title><source>Cellular and molecular biology</source><volume>47</volume><fpage>695</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">11502077</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Koenders</surname><given-names>M</given-names></name><name><surname>Kalabokis</surname><given-names>V</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>AC</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation</article-title><source>Rheumatology</source><volume>55</volume><fpage>2220</fpage><lpage>2229</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kew325</pub-id><pub-id pub-id-type="pmid">27567100</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Justice</surname><given-names>JN</given-names></name><name><surname>Boyle</surname><given-names>KE</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Eisenmesser</surname><given-names>EZ</given-names></name><name><surname>Herrera</surname><given-names>JJ</given-names></name><name><surname>Hansen</surname><given-names>KC</given-names></name><name><surname>Nemkov</surname><given-names>T</given-names></name><name><surname>Stienstra</surname><given-names>R</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Seals</surname><given-names>DR</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Ballak</surname><given-names>DB</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance</article-title><source>PNAS</source><volume>114</volume><fpage>2313</fpage><lpage>2318</lpage><pub-id pub-id-type="doi">10.1073/pnas.1619011114</pub-id><pub-id pub-id-type="pmid">28193888</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Suppression of inflammation and acquired immunity by IL-37</article-title><source>Immunological Reviews</source><volume>281</volume><fpage>179</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1111/imr.12605</pub-id><pub-id pub-id-type="pmid">29247987</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>E</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name><name><surname>Basile</surname><given-names>MS</given-names></name><name><surname>Mammana</surname><given-names>S</given-names></name><name><surname>Pennisi</surname><given-names>M</given-names></name><name><surname>Fagone</surname><given-names>P</given-names></name><name><surname>Kalfin</surname><given-names>R</given-names></name><name><surname>Martinovic</surname><given-names>V</given-names></name><name><surname>Ivanovic</surname><given-names>J</given-names></name><name><surname>Andabaka</surname><given-names>M</given-names></name><name><surname>Mesaros</surname><given-names>S</given-names></name><name><surname>Pekmezovic</surname><given-names>T</given-names></name><name><surname>Drulovic</surname><given-names>J</given-names></name><name><surname>Nicoletti</surname><given-names>F</given-names></name><name><surname>Petralia</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>In silico and in vivo analysis of il37 in multiple sclerosis reveals its probable homeostatic role on the clinical activity, disability, and treatment with fingolimod</article-title><source>Molecules</source><volume>25</volume><elocation-id>E20</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25010020</pub-id><pub-id pub-id-type="pmid">31861585</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Herkenham</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines</article-title><source>The Journal of Neuroscience</source><volume>25</volume><fpage>1788</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4268-04.2005</pub-id><pub-id pub-id-type="pmid">15716415</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coll-Miró</surname><given-names>M</given-names></name><name><surname>Francos-Quijorna</surname><given-names>I</given-names></name><name><surname>Santos-Nogueira</surname><given-names>E</given-names></name><name><surname>Torres-Espin</surname><given-names>A</given-names></name><name><surname>Bufler</surname><given-names>P</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>López-Vales</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Beneficial effects of IL-37 after spinal cord injury in mice</article-title><source>PNAS</source><volume>113</volume><fpage>1411</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1073/pnas.1523212113</pub-id><pub-id pub-id-type="pmid">26787859</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Commins</surname><given-names>S</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name><name><surname>O’Mara</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The effects of the bacterial endotoxin lipopolysaccharide on synaptic transmission and plasticity in the CA1-subiculum pathway in vivo</article-title><source>Neuroscience</source><volume>102</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/s0306-4522(00)00498-x</pub-id><pub-id pub-id-type="pmid">11166113</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>P</given-names></name><name><surname>Lauritano</surname><given-names>D</given-names></name><name><surname>Caraffa</surname><given-names>A</given-names></name><name><surname>Gallenga</surname><given-names>CE</given-names></name><name><surname>Kritas</surname><given-names>SK</given-names></name><name><surname>Ronconi</surname><given-names>G</given-names></name><name><surname>Martinotti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Microglia and mast cells generate proinflammatory cytokines in the brain and worsen inflammatory state: suppressor effect of IL-37</article-title><source>European Journal of Pharmacology</source><volume>875</volume><elocation-id>173035</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173035</pub-id><pub-id pub-id-type="pmid">32097657</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Beaux</surname><given-names>AC</given-names></name><name><surname>Maingay</surname><given-names>JP</given-names></name><name><surname>Ross</surname><given-names>JA</given-names></name><name><surname>Fearon</surname><given-names>KCH</given-names></name><name><surname>Carter</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Interleukin-4 and interleukin-10 increase endotoxin-stimulated human umbilical vein endothelial cell interleukin-8 release</article-title><source>Journal of Interferon &amp; Cytokine Research</source><volume>15</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1089/jir.1995.15.441</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Filippo</surname><given-names>M</given-names></name><name><surname>Chiasserini</surname><given-names>D</given-names></name><name><surname>Gardoni</surname><given-names>F</given-names></name><name><surname>Viviani</surname><given-names>B</given-names></name><name><surname>Tozzi</surname><given-names>A</given-names></name><name><surname>Giampà</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>C</given-names></name><name><surname>Tantucci</surname><given-names>M</given-names></name><name><surname>Zianni</surname><given-names>E</given-names></name><name><surname>Boraso</surname><given-names>M</given-names></name><name><surname>Siliquini</surname><given-names>S</given-names></name><name><surname>de Iure</surname><given-names>A</given-names></name><name><surname>Ghiglieri</surname><given-names>V</given-names></name><name><surname>Colcelli</surname><given-names>E</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Fusco</surname><given-names>FR</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Effects of central and peripheral inflammation on hippocampal synaptic plasticity</article-title><source>Neurobiology of Disease</source><volume>52</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2012.12.009</pub-id><pub-id pub-id-type="pmid">23295855</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Biologic basis for interleukin-1 in disease</article-title><source>Blood</source><volume>87</volume><fpage>2095</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1182/blood.V87.6.2095.bloodjournal8762095</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Immunological and inflammatory functions of the interleukin-1 family</article-title><source>Annual Review of Immunology</source><volume>27</volume><fpage>519</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132612</pub-id><pub-id pub-id-type="pmid">19302047</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Anti-inflammatory agents: present and future</article-title><source>Cell</source><volume>140</volume><fpage>935</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.043</pub-id><pub-id pub-id-type="pmid">20303881</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases</article-title><source>Nature Reviews. Drug Discovery</source><volume>11</volume><fpage>633</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1038/nrd3800</pub-id><pub-id pub-id-type="pmid">22850787</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Nold-Petry</surname><given-names>C</given-names></name><name><surname>Nold</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Bufler</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Suppression of innate inflammation and immunity by interleukin-37</article-title><source>European Journal of Immunology</source><volume>46</volume><fpage>1067</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1002/eji.201545828</pub-id><pub-id pub-id-type="pmid">27060871</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Overview of the IL-1 family in innate inflammation and acquired immunity</article-title><source>Immunological Reviews</source><volume>281</volume><fpage>8</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/imr.12621</pub-id><pub-id pub-id-type="pmid">29247995</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dionisio-Santos</surname><given-names>DA</given-names></name><name><surname>Olschowka</surname><given-names>JA</given-names></name><name><surname>O’Banion</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exploiting microglial and peripheral immune cell crosstalk to treat alzheimer’s disease</article-title><source>Journal of Neuroinflammation</source><volume>16</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s12974-019-1453-0</pub-id><pub-id pub-id-type="pmid">30953557</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drew</surname><given-names>WG</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name><name><surname>Baugh</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>Effects of delta9-THC, LSD-25 and scopolamine on continuous, spontaneous alternation in the Y-maze</article-title><source>Psychopharmacologia</source><volume>32</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/BF00428688</pub-id><pub-id pub-id-type="pmid">4753532</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dugan</surname><given-names>LL</given-names></name><name><surname>Ali</surname><given-names>SS</given-names></name><name><surname>Shekhtman</surname><given-names>G</given-names></name><name><surname>Roberts</surname><given-names>AJ</given-names></name><name><surname>Lucero</surname><given-names>J</given-names></name><name><surname>Quick</surname><given-names>KL</given-names></name><name><surname>Behrens</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>IL-6 mediated degeneration of forebrain gabaergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e5518</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005518</pub-id><pub-id pub-id-type="pmid">19436757</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>De Moor</surname><given-names>B</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>BioMart and bioconductor: a powerful link between biological databases and microarray data analysis</article-title><source>Bioinformatics</source><volume>21</volume><fpage>3439</fpage><lpage>3440</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti525</pub-id><pub-id pub-id-type="pmid">16082012</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedotcheva</surname><given-names>NI</given-names></name><name><surname>Sokolov</surname><given-names>AP</given-names></name><name><surname>Kondrashova</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Nonezymatic formation of succinate in mitochondria under oxidative stress</article-title><source>Free Radical Biology &amp; Medicine</source><volume>41</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2006.02.012</pub-id><pub-id pub-id-type="pmid">16781453</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiala</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>QN</given-names></name><name><surname>Sayre</surname><given-names>J</given-names></name><name><surname>Pop</surname><given-names>V</given-names></name><name><surname>Brahmandam</surname><given-names>V</given-names></name><name><surname>Graves</surname><given-names>MC</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cyclooxygenase-2-positive macrophages infiltrate the alzheimer’s disease brain and damage the blood-brain barrier</article-title><source>European Journal of Clinical Investigation</source><volume>32</volume><fpage>360</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2362.2002.00994.x</pub-id><pub-id pub-id-type="pmid">12027877</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabay</surname><given-names>C</given-names></name><name><surname>Lamacchia</surname><given-names>C</given-names></name><name><surname>Palmer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>IL-1 pathways in inflammation and human diseases</article-title><source>Nature Reviews. Rheumatology</source><volume>6</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2010.4</pub-id><pub-id pub-id-type="pmid">20177398</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><name><surname>Robbins</surname><given-names>EM</given-names></name><name><surname>Zhang-Nunes</surname><given-names>SX</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Betensky</surname><given-names>RA</given-names></name><name><surname>Raju</surname><given-names>S</given-names></name><name><surname>Prada</surname><given-names>C</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Bacskai</surname><given-names>BJ</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization of amyloid deposition in the appswe/ps1de9 mouse model of alzheimer disease</article-title><source>Neurobiology of Disease</source><volume>24</volume><fpage>516</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2006.08.017</pub-id><pub-id pub-id-type="pmid">17029828</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The interleukin-1 family: back to the future</article-title><source>Immunity</source><volume>39</volume><fpage>1003</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.11.010</pub-id><pub-id pub-id-type="pmid">24332029</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glabe</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Amyloid accumulation and pathogensis of alzheimer’s disease: significance of monomeric, oligomeric and fibrillar Aβ</article-title><source>Alzheimer’s Disease</source><volume>2005</volume><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1007/b100942</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>P</given-names></name><name><surname>Machado</surname><given-names>I</given-names></name><name><surname>Vilcaes</surname><given-names>A</given-names></name><name><surname>Caruso</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Schiöth</surname><given-names>H</given-names></name><name><surname>Lasaga</surname><given-names>M</given-names></name><name><surname>Scimonelli</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular mechanisms involved in interleukin 1-beta (IL-1β)-induced memory impairment. modulation by alpha-melanocyte-stimulating hormone (α-MSH)</article-title><source>Brain, Behavior, and Immunity</source><volume>34</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2013.08.007</pub-id><pub-id pub-id-type="pmid">23968970</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>PM</given-names></name><name><surname>Hutchinson</surname><given-names>MR</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pathological pain and the neuroimmune interface</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1038/nri3621</pub-id><pub-id pub-id-type="pmid">24577438</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanisch</surname><given-names>UK</given-names></name><name><surname>Kettenmann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microglia: active sensor and versatile effector cells in the normal and pathologic brain</article-title><source>Nature Neuroscience</source><volume>10</volume><fpage>1387</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1038/nn1997</pub-id><pub-id pub-id-type="pmid">17965659</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The amyloid hypothesis of alzheimer’s disease: progress and problems on the road to therapeutics</article-title><source>Science</source><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Heinz</surname><given-names>A</given-names></name><name><surname>Jahn</surname><given-names>D</given-names></name><name><surname>Hiller</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Complexity of macrophage metabolism in infection</article-title><source>Current Opinion in Biotechnology</source><volume>68</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2021.01.020</pub-id><pub-id pub-id-type="pmid">33610128</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hein</surname><given-names>AM</given-names></name><name><surname>Stasko</surname><given-names>MR</given-names></name><name><surname>Matousek</surname><given-names>SB</given-names></name><name><surname>Scott-McKean</surname><given-names>JJ</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Olschowka</surname><given-names>JA</given-names></name><name><surname>Costa</surname><given-names>ACS</given-names></name><name><surname>O’Banion</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice</article-title><source>Brain, Behavior, and Immunity</source><volume>24</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2009.10.002</pub-id><pub-id pub-id-type="pmid">19825412</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneka</surname><given-names>M.T</given-names></name><name><surname>Kummer</surname><given-names>MP</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Innate immune activation in neurodegenerative disease</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>463</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nri3705</pub-id><pub-id pub-id-type="pmid">24962261</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>El Khoury</surname><given-names>J</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name><name><surname>Brosseron</surname><given-names>F</given-names></name><name><surname>Feinstein</surname><given-names>DL</given-names></name><name><surname>Jacobs</surname><given-names>AH</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Vitorica</surname><given-names>J</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Herrup</surname><given-names>K</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name><name><surname>Finsen</surname><given-names>B</given-names></name><name><surname>Brown</surname><given-names>GC</given-names></name><name><surname>Verkhratsky</surname><given-names>A</given-names></name><name><surname>Yamanaka</surname><given-names>K</given-names></name><name><surname>Koistinaho</surname><given-names>J</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Halle</surname><given-names>A</given-names></name><name><surname>Petzold</surname><given-names>GC</given-names></name><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Morgan</surname><given-names>D</given-names></name><name><surname>Shinohara</surname><given-names>ML</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Bazan</surname><given-names>NG</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Hunot</surname><given-names>S</given-names></name><name><surname>Joseph</surname><given-names>B</given-names></name><name><surname>Deigendesch</surname><given-names>N</given-names></name><name><surname>Garaschuk</surname><given-names>O</given-names></name><name><surname>Boddeke</surname><given-names>E</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Breitner</surname><given-names>JC</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name><name><surname>Golenbock</surname><given-names>DT</given-names></name><name><surname>Kummer</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuroinflammation in alzheimer’s disease</article-title><source>The Lancet. Neurology</source><volume>14</volume><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmid">25792098</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennigan</surname><given-names>A</given-names></name><name><surname>Trotter</surname><given-names>C</given-names></name><name><surname>Kelly</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lipopolysaccharide impairs long-term potentiation and recognition memory and increases p75ntr expression in the rat dentate gyrus</article-title><source>Brain Research</source><volume>1130</volume><fpage>158</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.10.066</pub-id><pub-id pub-id-type="pmid">17174281</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiller</surname><given-names>K</given-names></name><name><surname>Hangebrauk</surname><given-names>J</given-names></name><name><surname>Jäger</surname><given-names>C</given-names></name><name><surname>Spura</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>K</given-names></name><name><surname>Schomburg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>MetaboliteDetector: comprehensive analysis tool for targeted and nontargeted GC/MS based metabolome analysis</article-title><source>Analytical Chemistry</source><volume>81</volume><fpage>3429</fpage><lpage>3439</lpage><pub-id pub-id-type="doi">10.1021/ac802689c</pub-id><pub-id pub-id-type="pmid">19358599</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseini</surname><given-names>S</given-names></name><name><surname>Wilk</surname><given-names>E</given-names></name><name><surname>Michaelsen-Preusse</surname><given-names>K</given-names></name><name><surname>Gerhauser</surname><given-names>I</given-names></name><name><surname>Baumgärtner</surname><given-names>W</given-names></name><name><surname>Geffers</surname><given-names>R</given-names></name><name><surname>Schughart</surname><given-names>K</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Long-term neuroinflammation induced by influenza A virus infection and the impact on hippocampal neuron morphology and function</article-title><source>The Journal of Neuroscience</source><volume>38</volume><fpage>3060</fpage><lpage>3080</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1740-17.2018</pub-id><pub-id pub-id-type="pmid">29487124</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseini</surname><given-names>S</given-names></name><name><surname>Michaelsen-Preusse</surname><given-names>K</given-names></name><name><surname>Grigoryan</surname><given-names>G</given-names></name><name><surname>Chhatbar</surname><given-names>C</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Type I interferon receptor signaling in astrocytes regulates hippocampal synaptic plasticity and cognitive function of the healthy CNS</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107666</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107666</pub-id><pub-id pub-id-type="pmid">32433975</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory</article-title><source>Neuroscience and Biobehavioral Reviews</source><volume>28</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2004.06.006</pub-id><pub-id pub-id-type="pmid">15465137</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>JM</given-names></name><name><surname>Kwan</surname><given-names>J</given-names></name><name><surname>Malek-Ahmadi</surname><given-names>M</given-names></name><name><surname>Maarouf</surname><given-names>CL</given-names></name><name><surname>Kokjohn</surname><given-names>TA</given-names></name><name><surname>Belden</surname><given-names>C</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Roher</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Morphological and pathological evolution of the brain microcirculation in aging and alzheimer’s disease</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e36893</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0036893</pub-id><pub-id pub-id-type="pmid">22615835</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikegaya</surname><given-names>Y</given-names></name><name><surname>Delcroix</surname><given-names>I</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Matsuki</surname><given-names>N</given-names></name><name><surname>Nishiyama</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Interleukin-1beta abrogates long-term depression of hippocampal CA1 synaptic transmission</article-title><source>Synapse</source><volume>47</volume><fpage>54</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1002/syn.10154</pub-id><pub-id pub-id-type="pmid">12422373</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowsky</surname><given-names>JL</given-names></name><name><surname>Slunt</surname><given-names>HH</given-names></name><name><surname>Gonzales</surname><given-names>V</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name><name><surname>Borchelt</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1</article-title><source>Neurobiology of Aging</source><volume>25</volume><fpage>885</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2003.09.008</pub-id><pub-id pub-id-type="pmid">15212842</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>KA</given-names></name><name><surname>Eu</surname><given-names>MY</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Gwag</surname><given-names>BJ</given-names></name><name><surname>Jou</surname><given-names>I</given-names></name><name><surname>Joe</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex</article-title><source>Glia</source><volume>56</volume><fpage>1039</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1002/glia.20677</pub-id><pub-id pub-id-type="pmid">18381656</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>RR</given-names></name><name><surname>Xu</surname><given-names>ZZ</given-names></name><name><surname>Gao</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Emerging targets in neuroinflammation-driven chronic pain</article-title><source>Nature Reviews. Drug Discovery</source><volume>13</volume><fpage>533</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/nrd4334</pub-id><pub-id pub-id-type="pmid">24948120</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Aliberti</surname><given-names>J</given-names></name><name><surname>Graemmel</surname><given-names>P</given-names></name><name><surname>Sunshine</surname><given-names>MJ</given-names></name><name><surname>Kreutzberg</surname><given-names>GW</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Analysis of fractalkine receptor cx(3)cr1 function by targeted deletion and green fluorescent protein reporter gene insertion</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>4106</fpage><lpage>4114</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.11.4106-4114.2000</pub-id><pub-id pub-id-type="pmid">10805752</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurga</surname><given-names>AM</given-names></name><name><surname>Paleczna</surname><given-names>M</given-names></name><name><surname>Kuter</surname><given-names>KZ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Overview of general and discriminating markers of differential microglia phenotypes</article-title><source>Frontiers in Cellular Neuroscience</source><volume>14</volume><elocation-id>198</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2020.00198</pub-id><pub-id pub-id-type="pmid">32848611</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasai</surname><given-names>T</given-names></name><name><surname>Inada</surname><given-names>K</given-names></name><name><surname>Takakuwa</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Taniguchi</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Wakabayashi</surname><given-names>G</given-names></name><name><surname>Endo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Anti-inflammatory cytokine levels in patients with septic shock</article-title><source>Research Communications in Molecular Pathology and Pharmacology</source><volume>98</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">9434313</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kettenmann</surname><given-names>H</given-names></name><name><surname>Hanisch</surname><given-names>UK</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Verkhratsky</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Physiology of microglia</article-title><source>Physiological Reviews</source><volume>91</volume><fpage>461</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1152/physrev.00011.2010</pub-id><pub-id pub-id-type="pmid">21527731</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kigerl</surname><given-names>KA</given-names></name><name><surname>Gensel</surname><given-names>JC</given-names></name><name><surname>Ankeny</surname><given-names>DP</given-names></name><name><surname>Alexander</surname><given-names>JK</given-names></name><name><surname>Donnelly</surname><given-names>DJ</given-names></name><name><surname>Popovich</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>13435</fpage><lpage>13444</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3257-09.2009</pub-id><pub-id pub-id-type="pmid">19864556</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WG</given-names></name><name><surname>Mohney</surname><given-names>RP</given-names></name><name><surname>Wilson</surname><given-names>B</given-names></name><name><surname>Jeohn</surname><given-names>GH</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia</article-title><source>The Journal of Neuroscience</source><volume>20</volume><fpage>6309</fpage><lpage>6316</lpage><pub-id pub-id-type="pmid">10934283</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Cho</surname><given-names>JJ</given-names></name><name><surname>Choi</surname><given-names>DH</given-names></name><name><surname>Hwang</surname><given-names>O</given-names></name><name><surname>Shin</surname><given-names>DH</given-names></name><name><surname>Chun</surname><given-names>HS</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name><name><surname>Joh</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia</article-title><source>The Journal of Neuroscience</source><volume>25</volume><fpage>3701</fpage><lpage>3711</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4346-04.2005</pub-id><pub-id pub-id-type="pmid">15814801</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kwak</surname><given-names>A</given-names></name><name><surname>Ryoo</surname><given-names>S</given-names></name><name><surname>Bae</surname><given-names>SH</given-names></name><name><surname>Azam</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>391</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00391</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitazawa</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Tsukamoto</surname><given-names>MR</given-names></name><name><surname>Koike</surname><given-names>MA</given-names></name><name><surname>Wes</surname><given-names>PD</given-names></name><name><surname>Vasilevko</surname><given-names>V</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an alzheimer’s disease model</article-title><source>Journal of Immunology</source><volume>187</volume><fpage>6539</fpage><lpage>6549</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100620</pub-id><pub-id pub-id-type="pmid">22095718</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkinidis</surname><given-names>L</given-names></name><name><surname>Anisman</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Interaction between cholinergic and catecholaminergic agents in a spontaneous alternation task</article-title><source>Psychopharmacology</source><volume>48</volume><fpage>261</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1007/BF00496859</pub-id><pub-id pub-id-type="pmid">823581</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Kohsaka</surname><given-names>S</given-names></name><name><surname>Okabe</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Long-term changes of spine dynamics and microglia after transient peripheral immune response triggered by LPS in vivo</article-title><source>Molecular Brain</source><volume>4</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1186/1756-6606-4-27</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyasu</surname><given-names>S</given-names></name><name><surname>Moro</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Type 2 innate immune responses and the natural helper cell</article-title><source>Immunology</source><volume>132</volume><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2011.03413.x</pub-id><pub-id pub-id-type="pmid">21323663</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Trim Galore: a wrapper tool around Cutadapt and FastQC to consistently apply quality and adapter trimming to FastQ files, with some extra functionality for MspI-digested RRBS-type (Reduced Representation Bisufite-Seq) libraries</article-title><ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.org/babraham/ac/uk/projects/trim_galore">https://www.bioinformatics.org/babraham/ac/uk/projects/trim_galore</ext-link><date-in-citation iso-8601-date="2022-07-01">July 1, 2022</date-in-citation></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laflamme</surname><given-names>N</given-names></name><name><surname>Echchannaoui</surname><given-names>H</given-names></name><name><surname>Landmann</surname><given-names>R</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cooperation between toll-like receptor 2 and 4 in the brain of mice challenged with cell wall components derived from gram-negative and gram-positive bacteria</article-title><source>European Journal of Immunology</source><volume>33</volume><fpage>1127</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1002/eji.200323821</pub-id><pub-id pub-id-type="pmid">12672079</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>MC</given-names></name><name><surname>Casabona</surname><given-names>JC</given-names></name><name><surname>Puntel</surname><given-names>M</given-names></name><name><surname>Pitossi</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in parkinson’s disease?</article-title><source>Frontiers in Cellular Neuroscience</source><volume>7</volume><elocation-id>53</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2013.00053</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemstra</surname><given-names>AW</given-names></name><name><surname>Groen in’t Woud</surname><given-names>JCM</given-names></name><name><surname>Hoozemans</surname><given-names>JJM</given-names></name><name><surname>van Haastert</surname><given-names>ES</given-names></name><name><surname>Rozemuller</surname><given-names>AJM</given-names></name><name><surname>Eikelenboom</surname><given-names>P</given-names></name><name><surname>van Gool</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Microglia activation in sepsis: a case-control study</article-title><source>Journal of Neuroinflammation</source><volume>4</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-4-4</pub-id><pub-id pub-id-type="pmid">17224051</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Neff</surname><given-names>CP</given-names></name><name><surname>Barber</surname><given-names>K</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Azam</surname><given-names>T</given-names></name><name><surname>Palmer</surname><given-names>BE</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8</article-title><source>PNAS</source><volume>112</volume><fpage>2497</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1073/pnas.1424626112</pub-id><pub-id pub-id-type="pmid">25654981</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LPS‑induced proinflammatory cytokine expression in human airway epithelial cells and macrophages via NF‑κB, STAT3 or AP‑1 activation</article-title><source>Molecular Medicine Reports</source><volume>17</volume><fpage>5484</fpage><lpage>5491</lpage><pub-id pub-id-type="doi">10.3892/mmr.2018.8542</pub-id><pub-id pub-id-type="pmid">29393460</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Osipovitch</surname><given-names>M</given-names></name><name><surname>Benraiss</surname><given-names>A</given-names></name><name><surname>Huynh</surname><given-names>NPT</given-names></name><name><surname>Foti</surname><given-names>R</given-names></name><name><surname>Bates</surname><given-names>J</given-names></name><name><surname>Chandler-Militello</surname><given-names>D</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Tesar</surname><given-names>PJ</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name><name><surname>Windrem</surname><given-names>MS</given-names></name><name><surname>Goldman</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dysregulated glial differentiation in schizophrenia may be relieved by suppression of SMAD4- and REST-dependent signaling</article-title><source>Cell Reports</source><volume>27</volume><fpage>3832</fpage><lpage>3843</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.05.088</pub-id><pub-id pub-id-type="pmid">31242417</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonnemann</surname><given-names>N</given-names></name><name><surname>Hosseini</surname><given-names>S</given-names></name><name><surname>Marchetti</surname><given-names>C</given-names></name><name><surname>Skouras</surname><given-names>DB</given-names></name><name><surname>Stefanoni</surname><given-names>D</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of alzheimer’s disease</article-title><source>PNAS</source><volume>117</volume><fpage>32145</fpage><lpage>32154</lpage><pub-id pub-id-type="doi">10.1073/pnas.2009680117</pub-id><pub-id pub-id-type="pmid">33257576</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucin</surname><given-names>KM</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Immune activation in brain aging and neurodegeneration: too much or too little?</article-title><source>Neuron</source><volume>64</volume><fpage>110</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.08.039</pub-id><pub-id pub-id-type="pmid">19840553</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunding</surname><given-names>L</given-names></name><name><surname>Webering</surname><given-names>S</given-names></name><name><surname>Vock</surname><given-names>C</given-names></name><name><surname>Schröder</surname><given-names>A</given-names></name><name><surname>Raedler</surname><given-names>D</given-names></name><name><surname>Schaub</surname><given-names>B</given-names></name><name><surname>Fehrenbach</surname><given-names>H</given-names></name><name><surname>Wegmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL-37 requires IL-18Rα and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice</article-title><source>Allergy</source><volume>70</volume><fpage>366</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1111/all.12566</pub-id><pub-id pub-id-type="pmid">25557042</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marie</surname><given-names>C</given-names></name><name><surname>Pitton</surname><given-names>C</given-names></name><name><surname>Fitting</surname><given-names>C</given-names></name><name><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Regulation by anti-inflammatory cytokines (IL-4, IL-10, IL-13, tgfbeta)of interleukin-8 production by LPS- and/ or tnfalpha-activated human polymorphonuclear cells</article-title><source>Mediators of Inflammation</source><volume>5</volume><fpage>334</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1155/S0962935196000488</pub-id><pub-id pub-id-type="pmid">18475727</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>Klegeris</surname><given-names>A</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Inflammation, the complement system and the diseases of aging</article-title><source>Neurobiology of Aging</source><volume>26 Suppl 1</volume><fpage>94</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.08.008</pub-id><pub-id pub-id-type="pmid">16198446</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamee</surname><given-names>EN</given-names></name><name><surname>Masterson</surname><given-names>JC</given-names></name><name><surname>Jedlicka</surname><given-names>P</given-names></name><name><surname>McManus</surname><given-names>M</given-names></name><name><surname>Grenz</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>CB</given-names></name><name><surname>Nold</surname><given-names>MF</given-names></name><name><surname>Nold-Petry</surname><given-names>C</given-names></name><name><surname>Bufler</surname><given-names>P</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Rivera-Nieves</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Interleukin 37 expression protects mice from colitis</article-title><source>PNAS</source><volume>108</volume><fpage>16711</fpage><lpage>16716</lpage><pub-id pub-id-type="doi">10.1073/pnas.1111982108</pub-id><pub-id pub-id-type="pmid">21873195</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlini</surname><given-names>M</given-names></name><name><surname>Kirabali</surname><given-names>T</given-names></name><name><surname>Kulic</surname><given-names>L</given-names></name><name><surname>Nitsch</surname><given-names>RM</given-names></name><name><surname>Ferretti</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Extravascular CD3+ T cells in brains of alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study</article-title><source>Neuro-Degenerative Diseases</source><volume>18</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1159/000486200</pub-id><pub-id pub-id-type="pmid">29402847</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelucci</surname><given-names>A</given-names></name><name><surname>Cordes</surname><given-names>T</given-names></name><name><surname>Ghelfi</surname><given-names>J</given-names></name><name><surname>Pailot</surname><given-names>A</given-names></name><name><surname>Reiling</surname><given-names>N</given-names></name><name><surname>Goldmann</surname><given-names>O</given-names></name><name><surname>Binz</surname><given-names>T</given-names></name><name><surname>Wegner</surname><given-names>A</given-names></name><name><surname>Tallam</surname><given-names>A</given-names></name><name><surname>Rausell</surname><given-names>A</given-names></name><name><surname>Buttini</surname><given-names>M</given-names></name><name><surname>Linster</surname><given-names>CL</given-names></name><name><surname>Medina</surname><given-names>E</given-names></name><name><surname>Balling</surname><given-names>R</given-names></name><name><surname>Hiller</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production</article-title><source>PNAS</source><volume>110</volume><fpage>7820</fpage><lpage>7825</lpage><pub-id pub-id-type="doi">10.1073/pnas.1218599110</pub-id><pub-id pub-id-type="pmid">23610393</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>E</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Succinate: a metabolic signal in inflammation</article-title><source>Trends in Cell Biology</source><volume>24</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.11.008</pub-id><pub-id pub-id-type="pmid">24361092</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EL</given-names></name><name><surname>Ryan</surname><given-names>DG</given-names></name><name><surname>Prag</surname><given-names>HA</given-names></name><name><surname>Dikovskaya</surname><given-names>D</given-names></name><name><surname>Menon</surname><given-names>D</given-names></name><name><surname>Zaslona</surname><given-names>Z</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Costa</surname><given-names>ASH</given-names></name><name><surname>Higgins</surname><given-names>M</given-names></name><name><surname>Hams</surname><given-names>E</given-names></name><name><surname>Szpyt</surname><given-names>J</given-names></name><name><surname>Runtsch</surname><given-names>MC</given-names></name><name><surname>King</surname><given-names>MS</given-names></name><name><surname>McGouran</surname><given-names>JF</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>Hughes</surname><given-names>MM</given-names></name><name><surname>Carroll</surname><given-names>RG</given-names></name><name><surname>Booty</surname><given-names>LM</given-names></name><name><surname>Knatko</surname><given-names>EV</given-names></name><name><surname>Meakin</surname><given-names>PJ</given-names></name><name><surname>Ashford</surname><given-names>MLJ</given-names></name><name><surname>Modis</surname><given-names>LK</given-names></name><name><surname>Brunori</surname><given-names>G</given-names></name><name><surname>Sévin</surname><given-names>DC</given-names></name><name><surname>Fallon</surname><given-names>PG</given-names></name><name><surname>Caldwell</surname><given-names>ST</given-names></name><name><surname>Kunji</surname><given-names>ERS</given-names></name><name><surname>Chouchani</surname><given-names>ET</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name><name><surname>Hartley</surname><given-names>RC</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Itaconate is an anti-inflammatory metabolite that activates nrf2 via alkylation of KEAP1</article-title><source>Nature</source><volume>556</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nature25986</pub-id><pub-id pub-id-type="pmid">29590092</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minhas</surname><given-names>PS</given-names></name><name><surname>Latif-Hernandez</surname><given-names>A</given-names></name><name><surname>McReynolds</surname><given-names>MR</given-names></name><name><surname>Durairaj</surname><given-names>AS</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Rubin</surname><given-names>A</given-names></name><name><surname>Joshi</surname><given-names>AU</given-names></name><name><surname>He</surname><given-names>JQ</given-names></name><name><surname>Gauba</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Linde</surname><given-names>M</given-names></name><name><surname>Sugiura</surname><given-names>Y</given-names></name><name><surname>Moon</surname><given-names>PK</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Suematsu</surname><given-names>M</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Longo</surname><given-names>FM</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Andreasson</surname><given-names>KI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Restoring metabolism of myeloid cells reverses cognitive decline in ageing</article-title><source>Nature</source><volume>590</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-03160-0</pub-id><pub-id pub-id-type="pmid">33473210</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moretti</surname><given-names>S</given-names></name><name><surname>Bozza</surname><given-names>S</given-names></name><name><surname>Oikonomou</surname><given-names>V</given-names></name><name><surname>Renga</surname><given-names>G</given-names></name><name><surname>Casagrande</surname><given-names>A</given-names></name><name><surname>Iannitti</surname><given-names>RG</given-names></name><name><surname>Puccetti</surname><given-names>M</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Romani</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004462</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004462</pub-id><pub-id pub-id-type="pmid">25375146</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Developments of a water-maze procedure for studying spatial learning in the rat</article-title><source>Journal of Neuroscience Methods</source><volume>11</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/0165-0270(84)90007-4</pub-id><pub-id pub-id-type="pmid">6471907</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>C</given-names></name><name><surname>Carlet</surname><given-names>J</given-names></name><name><surname>Fitting</surname><given-names>C</given-names></name><name><surname>Misset</surname><given-names>B</given-names></name><name><surname>Blériot</surname><given-names>JP</given-names></name><name><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Dysregulation of in vitro cytokine production by monocytes during sepsis</article-title><source>The Journal of Clinical Investigation</source><volume>88</volume><fpage>1747</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1172/JCI115493</pub-id><pub-id pub-id-type="pmid">1939659</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>C</given-names></name><name><surname>Sanderson</surname><given-names>DJ</given-names></name><name><surname>Barkus</surname><given-names>C</given-names></name><name><surname>Deacon</surname><given-names>RMJ</given-names></name><name><surname>Rawlins</surname><given-names>JNP</given-names></name><name><surname>Bannerman</surname><given-names>DM</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Systemic inflammation induces acute working memory deficits in the primed brain: relevance for delirium</article-title><source>Neurobiology of Aging</source><volume>33</volume><fpage>603</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.04.002</pub-id><pub-id pub-id-type="pmid">20471138</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadeau</surname><given-names>S</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Regulation of the gene encoding tumor necrosis factor alpha (TNF-alpha) in the rat brain and pituitary in response in different models of systemic immune challenge</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>58</volume><fpage>61</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1097/00005072-199901000-00008</pub-id><pub-id pub-id-type="pmid">10068315</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>K</given-names></name><name><surname>Quirk</surname><given-names>MC</given-names></name><name><surname>Chitwood</surname><given-names>RA</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Yeckel</surname><given-names>MF</given-names></name><name><surname>Sun</surname><given-names>LD</given-names></name><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Carr</surname><given-names>CA</given-names></name><name><surname>Johnston</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>MA</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Requirement for hippocampal CA3 NMDA receptors in associative memory recall</article-title><source>Science</source><volume>297</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1126/science.1071795</pub-id><pub-id pub-id-type="pmid">12040087</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizami</surname><given-names>S</given-names></name><name><surname>Hall-Roberts</surname><given-names>H</given-names></name><name><surname>Warrier</surname><given-names>S</given-names></name><name><surname>Cowley</surname><given-names>SA</given-names></name><name><surname>Di Daniel</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Microglial inflammation and phagocytosis in alzheimer’s disease: potential therapeutic targets</article-title><source>British Journal of Pharmacology</source><volume>176</volume><fpage>3515</fpage><lpage>3532</lpage><pub-id pub-id-type="doi">10.1111/bph.14618</pub-id><pub-id pub-id-type="pmid">30740661</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nold</surname><given-names>MF</given-names></name><name><surname>Nold-Petry</surname><given-names>CA</given-names></name><name><surname>Zepp</surname><given-names>JA</given-names></name><name><surname>Palmer</surname><given-names>BE</given-names></name><name><surname>Bufler</surname><given-names>P</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>IL-37 is a fundamental inhibitor of innate immunity</article-title><source>Nature Immunology</source><volume>11</volume><fpage>1014</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1038/ni.1944</pub-id><pub-id pub-id-type="pmid">20935647</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nold-Petry</surname><given-names>CA</given-names></name><name><surname>Lo</surname><given-names>CY</given-names></name><name><surname>Rudloff</surname><given-names>I</given-names></name><name><surname>Elgass</surname><given-names>KD</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Gantier</surname><given-names>MP</given-names></name><name><surname>Lotz-Havla</surname><given-names>AS</given-names></name><name><surname>Gersting</surname><given-names>SW</given-names></name><name><surname>Cho</surname><given-names>SX</given-names></name><name><surname>Lao</surname><given-names>JC</given-names></name><name><surname>Ellisdon</surname><given-names>AM</given-names></name><name><surname>Rotter</surname><given-names>B</given-names></name><name><surname>Azam</surname><given-names>T</given-names></name><name><surname>Mangan</surname><given-names>NE</given-names></name><name><surname>Rossello</surname><given-names>FJ</given-names></name><name><surname>Whisstock</surname><given-names>JC</given-names></name><name><surname>Bufler</surname><given-names>P</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Nold</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction</article-title><source>Nature Immunology</source><volume>16</volume><fpage>354</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1038/ni.3103</pub-id><pub-id pub-id-type="pmid">25729923</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Leary</surname><given-names>TP</given-names></name><name><surname>Brown</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Visuo-spatial learning and memory deficits on the barnes maze in the 16-month-old appswe/ps1de9 mouse model of alzheimer’s disease</article-title><source>Behavioural Brain Research</source><volume>201</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2009.01.039</pub-id><pub-id pub-id-type="pmid">19428625</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Neill</surname><given-names>LAJ</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Metabolism of inflammation limited by AMPK and pseudo-starvation</article-title><source>Nature</source><volume>493</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/nature11862</pub-id><pub-id pub-id-type="pmid">23325217</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Neill</surname><given-names>LAJ</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Itaconate: the poster child of metabolic reprogramming in macrophage function</article-title><source>Nature Reviews. Immunology</source><volume>19</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0128-5</pub-id><pub-id pub-id-type="pmid">30705422</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papageorgiou</surname><given-names>IE</given-names></name><name><surname>Fetani</surname><given-names>AF</given-names></name><name><surname>Lewen</surname><given-names>A</given-names></name><name><surname>Heinemann</surname><given-names>U</given-names></name><name><surname>Kann</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Widespread activation of microglial cells in the hippocampus of chronic epileptic rats correlates only partially with neurodegeneration</article-title><source>Brain Structure &amp; Function</source><volume>220</volume><fpage>2423</fpage><lpage>2439</lpage><pub-id pub-id-type="doi">10.1007/s00429-014-0802-0</pub-id><pub-id pub-id-type="pmid">24878824</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polazzi</surname><given-names>E</given-names></name><name><surname>Contestabile</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Reciprocal interactions between microglia and neurons: from survival to neuropathology</article-title><source>Reviews in the Neurosciences</source><volume>13</volume><fpage>221</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1515/revneuro.2002.13.3.221</pub-id><pub-id pub-id-type="pmid">12405226</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Prince</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><source>World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends</source><publisher-loc>London, United Kingdom</publisher-loc><publisher-name>Alzheimer’s Disease International</publisher-name></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Priller</surname><given-names>J</given-names></name><name><surname>Sisodia</surname><given-names>SS</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Heterogeneity of CNS myeloid cells and their roles in neurodegeneration</article-title><source>Nature Neuroscience</source><volume>14</volume><fpage>1227</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1038/nn.2923</pub-id><pub-id pub-id-type="pmid">21952260</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Block</surname><given-names>ML</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Breese</surname><given-names>GR</given-names></name><name><surname>Hong</surname><given-names>J-S</given-names></name><name><surname>Knapp</surname><given-names>DJ</given-names></name><name><surname>Crews</surname><given-names>FT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration</article-title><source>Glia</source><volume>55</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1002/glia.20467</pub-id><pub-id pub-id-type="pmid">17203472</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintanilla</surname><given-names>RA</given-names></name><name><surname>Orellana</surname><given-names>DI</given-names></name><name><surname>González-Billault</surname><given-names>C</given-names></name><name><surname>Maccioni</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Interleukin-6 induces alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway</article-title><source>Experimental Cell Research</source><volume>295</volume><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2004.01.002</pub-id><pub-id pub-id-type="pmid">15051507</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rachal Pugh</surname><given-names>C</given-names></name><name><surname>Fleshner</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Rudy</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The immune system and memory consolidation: a role for the cytokine IL-1beta</article-title><source>Neuroscience and Biobehavioral Reviews</source><volume>25</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/s0149-7634(00)00048-8</pub-id><pub-id pub-id-type="pmid">11166076</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivest</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of innate immune responses in the brain</article-title><source>Nature Reviews. Immunology</source><volume>9</volume><fpage>429</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/nri2565</pub-id><pub-id pub-id-type="pmid">19461673</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>EdgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudloff</surname><given-names>I</given-names></name><name><surname>Cho</surname><given-names>SX</given-names></name><name><surname>Lao</surname><given-names>JC</given-names></name><name><surname>Ngo</surname><given-names>D</given-names></name><name><surname>McKenzie</surname><given-names>M</given-names></name><name><surname>Nold-Petry</surname><given-names>CA</given-names></name><name><surname>Nold</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells</article-title><source>Journal of Leukocyte Biology</source><volume>101</volume><fpage>901</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1189/jlb.3MA0616-287R</pub-id><pub-id pub-id-type="pmid">27881605</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Fernández</surname><given-names>A</given-names></name><name><surname>Zandee</surname><given-names>S</given-names></name><name><surname>Amo-Aparicio</surname><given-names>J</given-names></name><name><surname>Charabati</surname><given-names>M</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Eisenmesser</surname><given-names>EZ</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>López-Vales</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8</article-title><source>Theranostics</source><volume>11</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.7150/thno.47435</pub-id><pub-id pub-id-type="pmid">33391457</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>DP</given-names></name><name><surname>Lehrman</surname><given-names>EK</given-names></name><name><surname>Kautzman</surname><given-names>AG</given-names></name><name><surname>Koyama</surname><given-names>R</given-names></name><name><surname>Mardinly</surname><given-names>AR</given-names></name><name><surname>Yamasaki</surname><given-names>R</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner</article-title><source>Neuron</source><volume>74</volume><fpage>691</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.026</pub-id><pub-id pub-id-type="pmid">22632727</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname><given-names>PZ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cytokines &amp; their physiologic and pharmacologic functions in inflammation: A review</article-title><source>Int J Pharm Life Sci</source><volume>2</volume><elocation-id>10</elocation-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Kulk</surname><given-names>N</given-names></name><name><surname>Nold</surname><given-names>MF</given-names></name><name><surname>Gräf</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Reinhardt</surname><given-names>D</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Bufler</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines</article-title><source>Journal of Immunology</source><volume>180</volume><fpage>5477</fpage><lpage>5482</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.8.5477</pub-id><pub-id pub-id-type="pmid">18390730</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>KN</given-names></name><name><surname>Commins</surname><given-names>S</given-names></name><name><surname>O’Mara</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus</article-title><source>Behavioural Brain Research</source><volume>124</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/s0166-4328(01)00232-7</pub-id><pub-id pub-id-type="pmid">11423165</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>JE</given-names></name><name><surname>Smith</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The IL-1 family: regulators of immunity</article-title><source>Nature Reviews. Immunology</source><volume>10</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/nri2691</pub-id><pub-id pub-id-type="pmid">20081871</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MJ</given-names></name><name><surname>Koch</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Differential expression of murine macrophage surface glycoprotein antigens in intracellular membranes</article-title><source>Journal of Cell Science</source><volume>87 (Pt 1)</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1242/jcs.87.1.113</pub-id><pub-id pub-id-type="pmid">3312248</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparkman</surname><given-names>NL</given-names></name><name><surname>Martin</surname><given-names>LA</given-names></name><name><surname>Calvert</surname><given-names>WS</given-names></name><name><surname>Boehm</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Effects of intraperitoneal lipopolysaccharide on morris maze performance in year-old and 2-month-old female C57BL/6J mice</article-title><source>Behavioural Brain Research</source><volume>159</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2004.10.011</pub-id><pub-id pub-id-type="pmid">15795008</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephan</surname><given-names>AH</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The complement system: an unexpected role in synaptic pruning during development and disease</article-title><source>Annual Review of Neuroscience</source><volume>35</volume><fpage>369</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113810</pub-id><pub-id pub-id-type="pmid">22715882</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>B</given-names></name><name><surname>Allen</surname><given-names>NJ</given-names></name><name><surname>Vazquez</surname><given-names>LE</given-names></name><name><surname>Howell</surname><given-names>GR</given-names></name><name><surname>Christopherson</surname><given-names>KS</given-names></name><name><surname>Nouri</surname><given-names>N</given-names></name><name><surname>Micheva</surname><given-names>KD</given-names></name><name><surname>Mehalow</surname><given-names>AK</given-names></name><name><surname>Huberman</surname><given-names>AD</given-names></name><name><surname>Stafford</surname><given-names>B</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Litke</surname><given-names>AM</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Smith</surname><given-names>SJ</given-names></name><name><surname>John</surname><given-names>SWM</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The classical complement cascade mediates CNS synapse elimination</article-title><source>Cell</source><volume>131</volume><fpage>1164</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.036</pub-id><pub-id pub-id-type="pmid">18083105</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strehl</surname><given-names>A</given-names></name><name><surname>Lenz</surname><given-names>M</given-names></name><name><surname>Itsekson-Hayosh</surname><given-names>Z</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Deller</surname><given-names>T</given-names></name><name><surname>Maggio</surname><given-names>N</given-names></name><name><surname>Vlachos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Systemic inflammation is associated with a reduction in synaptopodin expression in the mouse hippocampus</article-title><source>Experimental Neurology</source><volume>261</volume><fpage>230</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2014.04.033</pub-id><pub-id pub-id-type="pmid">24837317</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Current understanding of IL-37 in human health and disease</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>696605</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.696605</pub-id><pub-id pub-id-type="pmid">34248996</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swonger</surname><given-names>AK</given-names></name><name><surname>Rech</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Serotonergic and cholinergic involvement in habituation of activity and spontaneous alternation of rats in a y maze</article-title><source>Journal of Comparative and Physiological Psychology</source><volume>81</volume><fpage>509</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1037/h0033690</pub-id><pub-id pub-id-type="pmid">4265289</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>ZS</given-names></name><name><surname>Beiser</surname><given-names>AS</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Roubenoff</surname><given-names>R</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Au</surname><given-names>R</given-names></name><name><surname>Kiel</surname><given-names>DP</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inflammatory markers and the risk of alzheimer disease: the framingham study</article-title><source>Neurology</source><volume>68</volume><fpage>1902</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000263217.36439.da</pub-id><pub-id pub-id-type="pmid">17536046</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannahill</surname><given-names>GM</given-names></name><name><surname>Curtis</surname><given-names>AM</given-names></name><name><surname>Adamik</surname><given-names>J</given-names></name><name><surname>Palsson-McDermott</surname><given-names>EM</given-names></name><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>Goel</surname><given-names>G</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Bernard</surname><given-names>NJ</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>NH</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Gardet</surname><given-names>A</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Jany</surname><given-names>SS</given-names></name><name><surname>Corr</surname><given-names>SC</given-names></name><name><surname>Haneklaus</surname><given-names>M</given-names></name><name><surname>Caffrey</surname><given-names>BE</given-names></name><name><surname>Pierce</surname><given-names>K</given-names></name><name><surname>Walmsley</surname><given-names>S</given-names></name><name><surname>Beasley</surname><given-names>FC</given-names></name><name><surname>Cummins</surname><given-names>E</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Whyte</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>CT</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>VP</given-names></name><name><surname>Clish</surname><given-names>C</given-names></name><name><surname>Auron</surname><given-names>PE</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Succinate is an inflammatory signal that induces IL-1β through HIF-1α</article-title><source>Nature</source><volume>496</volume><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nature11986</pub-id><pub-id pub-id-type="pmid">23535595</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thériault</surname><given-names>P</given-names></name><name><surname>ElAli</surname><given-names>A</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The dynamics of monocytes and microglia in alzheimer’s disease</article-title><source>Alzheimer’s Research &amp; Therapy</source><volume>7</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s13195-015-0125-2</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Prieto</surname><given-names>GA</given-names></name><name><surname>Kramár</surname><given-names>EA</given-names></name><name><surname>Smith</surname><given-names>ED</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><name><surname>Lynch</surname><given-names>G</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>17714</fpage><lpage>17724</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1253-12.2012</pub-id><pub-id pub-id-type="pmid">23223292</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Mullan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>T-cells in alzheimer’s disease</article-title><source>Neuromolecular Medicine</source><volume>7</volume><fpage>255</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1385/NMM:7:3:255</pub-id><pub-id pub-id-type="pmid">16247185</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsilioni</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>AB</given-names></name><name><surname>Pantazopoulos</surname><given-names>H</given-names></name><name><surname>Berretta</surname><given-names>S</given-names></name><name><surname>Conti</surname><given-names>P</given-names></name><name><surname>Leeman</surname><given-names>SE</given-names></name><name><surname>Theoharides</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin</article-title><source>PNAS</source><volume>116</volume><fpage>21659</fpage><lpage>21665</lpage><pub-id pub-id-type="doi">10.1073/pnas.1906817116</pub-id><pub-id pub-id-type="pmid">31591201</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Stolpe</surname><given-names>A</given-names></name><name><surname>van der Saag</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Intercellular adhesion molecule-1</article-title><source>Journal of Molecular Medicine</source><volume>74</volume><fpage>13</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/BF00202069</pub-id><pub-id pub-id-type="pmid">8834767</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbeek</surname><given-names>MM</given-names></name><name><surname>Otte-Höller</surname><given-names>I</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Van Nostrand</surname><given-names>WE</given-names></name><name><surname>Sorg</surname><given-names>C</given-names></name><name><surname>Ruiter</surname><given-names>DJ</given-names></name><name><surname>de Waal</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A lysosomal marker for activated microglial cells involved in alzheimer classic senile plaques</article-title><source>Acta Neuropathologica</source><volume>90</volume><fpage>493</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1007/BF00294811</pub-id><pub-id pub-id-type="pmid">8560983</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vukic</surname><given-names>V</given-names></name><name><surname>Callaghan</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>Lue</surname><given-names>L-F</given-names></name><name><surname>Liu</surname><given-names>QY</given-names></name><name><surname>Couraud</surname><given-names>P-O</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Weksler</surname><given-names>B</given-names></name><name><surname>Stanimirovic</surname><given-names>DB</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in alzheimer’s brain is mediated by the JNK-AP1 signaling pathway</article-title><source>Neurobiology of Disease</source><volume>34</volume><fpage>95</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2008.12.007</pub-id><pub-id pub-id-type="pmid">19162185</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WY</given-names></name><name><surname>Tan</surname><given-names>MS</given-names></name><name><surname>Yu</surname><given-names>JT</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Role of pro-inflammatory cytokines released from microglia in alzheimer’s disease</article-title><source>Annals of Translational Medicine</source><volume>3</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.3978/j.issn.2305-5839.2015.03.49</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>JD</given-names></name><name><surname>Huang</surname><given-names>M-H</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name><name><surname>Rowe</surname><given-names>JW</given-names></name><name><surname>Seeman</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Interleukin-6 and risk of cognitive decline: macarthur studies of successful aging</article-title><source>Neurology</source><volume>59</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1212/wnl.59.3.371</pub-id><pub-id pub-id-type="pmid">12177370</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widmann</surname><given-names>CN</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Long-term cerebral consequences of sepsis</article-title><source>The Lancet. Neurology</source><volume>13</volume><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70017-1</pub-id><pub-id pub-id-type="pmid">24849863</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>G</given-names></name><name><surname>Lotan</surname><given-names>A</given-names></name><name><surname>Lifschytz</surname><given-names>T</given-names></name><name><surname>Ben-Ari</surname><given-names>H</given-names></name><name><surname>Kreisel Merzel</surname><given-names>T</given-names></name><name><surname>Tatarskyy</surname><given-names>P</given-names></name><name><surname>Valitzky</surname><given-names>M</given-names></name><name><surname>Mernick</surname><given-names>B</given-names></name><name><surname>Avidan</surname><given-names>E</given-names></name><name><surname>Koroukhov</surname><given-names>N</given-names></name><name><surname>Lerer</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differentially severe cognitive effects of compromised cerebral blood flow in aged mice: association with myelin degradation and microglia activation</article-title><source>Frontiers in Aging Neuroscience</source><volume>9</volume><elocation-id>191</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2017.00191</pub-id><pub-id pub-id-type="pmid">28670274</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>TT</given-names></name><name><surname>Chen</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Lipopolysaccharide triggers macrophage activation of inflammatory cytokine expression, chemotaxis, phagocytosis, and oxidative ability via a toll-like receptor 4-dependent pathway: validated by RNA interference</article-title><source>Toxicology Letters</source><volume>191</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2009.08.025</pub-id><pub-id pub-id-type="pmid">19735705</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S-Y</given-names></name><name><surname>Wang</surname><given-names>T-F</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Jen</surname><given-names>CJ</given-names></name><name><surname>Chuang</surname><given-names>J-I</given-names></name><name><surname>Wu</surname><given-names>F-S</given-names></name><name><surname>Wu</surname><given-names>C-W</given-names></name><name><surname>Kuo</surname><given-names>Y-M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway</article-title><source>Brain, Behavior, and Immunity</source><volume>25</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2010.09.006</pub-id><pub-id pub-id-type="pmid">20851176</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Meng</surname><given-names>K</given-names></name><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Tony</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice</article-title><source>Clinical and Experimental Immunology</source><volume>176</volume><fpage>438</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1111/cei.12284</pub-id><pub-id pub-id-type="pmid">24527881</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ACOD1 in immunometabolism and disease</article-title><source>Cellular &amp; Molecular Immunology</source><volume>17</volume><fpage>822</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0489-5</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Propson</surname><given-names>NE</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Autophagy deficiency modulates microglial lipid homeostasis and aggravates tau pathology and spreading</article-title><source>PNAS</source><volume>118</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2023418118</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>TT</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>TF</given-names></name><name><surname>Ke</surname><given-names>FY</given-names></name><name><surname>Kuo</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differential distribution and activation of microglia in the brain of male C57BL/6J mice</article-title><source>Brain Structure &amp; Function</source><volume>218</volume><fpage>1051</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1007/s00429-012-0446-x</pub-id><pub-id pub-id-type="pmid">22886465</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity</article-title><source>Journal of Translational Medicine</source><volume>12</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/1479-5876-12-69</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>RD</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emerging functions of serum amyloid A in inflammation</article-title><source>Journal of Leukocyte Biology</source><volume>98</volume><fpage>923</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1189/jlb.3VMR0315-080R</pub-id><pub-id pub-id-type="pmid">26130702</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yirmiya</surname><given-names>R</given-names></name><name><surname>Goshen</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Immune modulation of learning, memory, neural plasticity and neurogenesis</article-title><source>Brain, Behavior, and Immunity</source><volume>25</volume><fpage>181</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2010.10.015</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousif</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yousif</surname><given-names>F</given-names></name><name><surname>Ao</surname><given-names>L</given-names></name><name><surname>Nold</surname><given-names>M</given-names></name><name><surname>Nold-Petry</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Expression of IL-37 in mouse protects the myocardium against ischemic injury via modulation of NF-κB activation</article-title><source>Circulation</source><volume>124</volume><elocation-id>A8603</elocation-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ClusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>Omics</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Kannisto</surname><given-names>K</given-names></name><name><surname>Curbo</surname><given-names>S</given-names></name><name><surname>von Döbeln</surname><given-names>U</given-names></name><name><surname>Hultenby</surname><given-names>K</given-names></name><name><surname>Isetun</surname><given-names>S</given-names></name><name><surname>Gåfvels</surname><given-names>M</given-names></name><name><surname>Karlsson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Thymidine kinase 2 deficiency-induced mtdna depletion in mouse liver leads to defect β-oxidation</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e58843</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0058843</pub-id><pub-id pub-id-type="pmid">23505564</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zilka</surname><given-names>N</given-names></name><name><surname>Kazmerova</surname><given-names>Z</given-names></name><name><surname>Jadhav</surname><given-names>S</given-names></name><name><surname>Neradil</surname><given-names>P</given-names></name><name><surname>Madari</surname><given-names>A</given-names></name><name><surname>Obetkova</surname><given-names>D</given-names></name><name><surname>Bugos</surname><given-names>O</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Who fans the flames of alzheimer’s disease brains? misfolded tau on the crossroad of neurodegenerative and inflammatory pathways</article-title><source>Journal of Neuroinflammation</source><volume>9</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/1742-2094-9-47</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75889.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Xiaoyu</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Tsinghua University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.11.26.470085" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.26.470085"/></front-stub><body><p>In this manuscript, the authors demonstrated that acute and chronic neuroinflammation was attenuated in human IL-37 (hIL-37) transgenic mice, thus revealing the effects of an anti-inflammatory cytokine hIL-37 in the central nervous system of mice. This study will be of interest to scientists studying neuroinflammation and searching for potential therapeutic targets.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75889.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hu</surname><given-names>Xiaoyu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Tsinghua University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.11.26.470085">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.11.26.470085v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer's disease mouse model&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Jeannie Chin as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The expression profile of hIL-37 receptors on different cell types under different conditions should be shown. The phenotype seen in microglia in vitro was attributed to hIL-37 acting on microglia themselves, but it is not clear this is the only possibility.</p><p>2. Experiments using human cell lines or patient samples would provide additional validation.</p><p>3. The authors mentioned that in acute inflammation, little LPS is likely to enter the brain because of an intact blood-brain barrier (BBB). It is also possible that the peripherally-induced inflammation may contribute to the neuroinflammation centrally. Due to the systemic overexpression of hIL-37, to exclude the peripheral effects of hIL-37, the experiments of direct injection of hIL-37 into the brain would help clarify the conclusion.</p><p>4. Background, Lines 87,88: The overall premise that anti-inflammatory therapies will be beneficial in AD is overly simplistic. The inflammatory activation of glial cells is required as a protective immune response, including pro-inflammatory activation. Also, retrospective studies that have demonstrated that NSAIDs are not a successful therapeutic strategy go against this notion. Please consider rephrasing.</p><p>5. What is known about IL-37 expression in humans? Since it is expressed by all cells in the current model, will this hamper biological interpretation, since the brain RNAseq database suggests that it is highly enriched specifically in microglia? This confounding factor makes biological interpretation of the in-vivo data a little difficult.</p><p>6. Results, Page 4, Lines 148-152: Description of Figure 1C-1E is confusing and unclear as written. Please consider rephrasing.</p><p>7. Results, Page 5: The points about the TCA cycle metabolites is raised in this section for the first time. Please consider introducing this concept in relation to AD / related immune responses in the introduction.</p><p>8. Figure 3C: Please include what the X-axis is plotting? As a supplemental figure, please include your initial gating strategy used for all flow cytometry data. Are there any CD68+CD11b+ CD45 high cells in these animals? If an effect of IL-37 is seen in filtration of peripheral inflammatory macrophages into the brain, this is a very strong data set to improve the impact of this figure.</p><p>9. Results, page 7: The authors make the statement that IL-37 signaling has a significant impact on the pro-inflammatory activation of microglia in the brain. However, this is based on just the measurement of IL-1b and microglial numbers. The authors should measure other markers of inflammation that are known to go up in the brain upon LPS challenge. Maybe using an Elisa based multiplex assay such as MSD or Luminex to measure brain inflammatory cytokines will add to this data set.</p><p>10. Results, page 7: Figure 4A-4B: Was the LPS injection used for these experiments the same as outlined for figure 3? Please clarify this in the method section, especially since 2 different LPS treatment paradigms have been used for 4A-4B and 4G-4H.</p><p>11. The paradigm for the Y-maze testing (pre-treatment with IL-37, followed by IL1b), though in-line with the current study, is not biologically relevant. Since IL-37 will be upregulated as part of the neuroinflammatory response, have the authors tried to treat animals with IL-37 after IL-1b or concurrently with IL-1B?</p><p>12. Figure 1B: This figure suggests that 1 i.p injection with rIL-1B completely abolishes any working memory In WT mice. This is surprising. Please clarify.</p><p>13. For Figures6 and 7: Were both sexes used for APPPS1 studies? If so, please clarify in the methods section as to the number of males and females, given that female APPPS1 mice show more aggressive disease as compared to males.</p><p>14. Figure 6. Please show all gating strategies as well as relevant gates drawn to identify CD11b+ CD45low microglia, as well as the methoxy X-04+ vs methoxy X-04- microglia. Is there a CD11b+ CD45high microglial subset at this age, since at earlier timepoints, these distinct microglial subsets are evident and have different activation profiles.</p><p>15. Please include details of how brain tissue was processed to prepare single-cell suspension for all FACS data. i.e: percoll based density gradients or myelin removal beads etc?</p><p>16. Authors discuss their methoxy-X04 data as indicative of &quot;increased clearance&quot; of plaques. Careful interpretation of this data set is required as this assay only measures Abeta &quot;uptake&quot;. Since no measures of clearance have been assessed, please reword and/ reinterpret this in the results and Discussion section.</p><p>17. Please include representative images for plaque loads in the cortex that correlate with quantification in 6I. Also, please include a representative image for differences in plaque size.</p><p>18. Figure 7A: Please mention the average age of the animals used in the 3 animal groups for MW testing. 9-12 months is a big age range for these animals and results will be skewed if one cohort is largely composed of older animals vs. younger.</p><p>19. The Discussion section is rather long and largely used to re-summarize results. The authors should reconsider using this section to put their data into context for the big-picture field of neurodegeneration. Some suggestions – How do the authors picture IL-37 signaling to play a role in human AD?</p><p>a. Given the detailed description of distinct microglial subsets associated with amyloid vs. tau pathology in AD, do the authors anticipate IL-37 to have distinct effects depending on pathological outcomes?</p><p>b. Literature has demonstrated that IL-1b, IL-6 and TNFa from reactive microglia may play a role in exacerbating tau-spread. The authors should discuss the implications of their findings in this light</p><p>c. Is anything is known about IL-37 signaling in other neuroinflammatory models (injury, MS etc)? A possible discussion of these in the context of neuroprotection may strengthen this section.</p><p>20. in vitro phenotypes in Figure 1 were not closely connected with the following in vivo neuroinflammation phenotypes. Although three different neuroinflammation models were used, the detailed mechanisms for how IL-37 reduced neuroinflammation were not well addressed.</p><p>21) Figure 3 and Figure 5 showed reduced pro-inflammatory cytokine production in brain lysates. However, glial cells other than microglia, such as astrocytes and infiltrating leukocytes could be sources of inflammatory cytokines. There was no evidence supporting that reduced cytokine levels were intrinsic to microglia as modelled in the in vitro system. Thus, in vitro and in vivo phenotypes appeared somewhat disconnected.</p><p>22) In Figure 5, IL-1β-induced neuroinflammation model was used to demonstrate the beneficial effects of IL-37 on cognition and synaptic function. Could injection of recombinant IL-37 display similar effects for LPS challenge model in Figure 3 and Figure 4?</p><p>23) Reduced IL-37-mediated neuroinflammation was shown in both chronic and acute models in the manuscript. Did microglia or other cells play a major role in those models? The detailed mechanisms regarding cell type contribution were largely missing in the manuscript.</p><p>24. Figure 2 showed differential metabolomic profiling of microglial cells between WT and IL-37tg mice. However, there was no further evidence demonstrating that the metabolic function of microglial cells was indeed altered by IL-37 expression. It would be better to show the results of seahorse or other metabolic functional assays.</p><p>25. The models for acute neuroinflammation including LPS and IL-1β challenge were systematic inflammation. It might be reasonable to propose that reduced neuroinflammation was a secondary effect to reduced inflammation response in the periphery. In addition, in Figure 3, would injection of LPS twice induce tolerance responses?</p><p>26. In Figure 3 and Figure 6, CD68 was used as an activation marker for microglia. However, CD68 expression by itself is not enough to define microglia to be in the activation state. The phenotypic changes of microglial cells would also depend on specific models used. Additional experimental evidence is needed for defining the reduced activation status of microglia in IL-37tg mice.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.75889.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The expression profile of hIL-37 receptors on different cell types under different conditions should be shown. The phenotype seen in microglia in vitro was attributed to hIL-37 acting on microglia themselves, but it is not clear this is the only possibility.</p></disp-quote><p>It has been shown that IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to exert its versatile anti-inflammatory effects in innate signal transduction. Based on the previous studies now listed in the revised manuscript, astrocytes are also capable of expressing the required receptors for IL-37. However, in the new experiments we performed, we stimulated primary astrocytes with LPS and then measured the levels of IL-6 and TNF-α (see Sup. Figure 1). In contrast to primary microglia from IL-37tg mice (Figure 1C-D), levels of pro-inflammatory cytokines were not reduced in primary astrocytes from IL-37tg mice after 100ng/ml LPS stimulation for 24 hours (see Sup. Figure 1A-B). Therefore, we can assume that although astrocytes also express receptors for IL-37, IL-37 signalling may not occur via them because the anti-inflammatory consequences are not expressed. These new experiments are added in the supplementary section and discussed in the revised manuscript.</p><p>A new supplementary Figure 1 is added. The changes can be found in lines 118-124 and 171-175, respectively.</p><disp-quote content-type="editor-comment"><p>2. Experiments using human cell lines or patient samples would provide additional validation.</p></disp-quote><p>Although the suggestion to use human material could significantly strengthen the results of this manuscript, performing new experiments with human cell lines requires a large time window because our laboratory currently has no experience with this. In addition, obtaining patient samples requires official ethical approval, which takes a lot of time. Therefore, in the revised manuscript, in the Introduction and Discussion, we try to refer to the recent human studies on the role of IL-37 in various human diseases such as autism and multiple sclerosis.</p><p>The changes can be found in lines 120-124 and 731-734, respectively.</p><disp-quote content-type="editor-comment"><p>3. The authors mentioned that in acute inflammation, little LPS is likely to enter the brain because of an intact blood-brain barrier (BBB). It is also possible that the peripherally-induced inflammation may contribute to the neuroinflammation centrally. Due to the systemic overexpression of hIL-37, to exclude the peripheral effects of hIL-37, the experiments of direct injection of hIL-37 into the brain would help clarify the conclusion.</p></disp-quote><p>In this study, we used IL-37tg mice that received i.p. injection of LPS to investigate the potential anti-inflammatory effects of IL-37 on the acute deleterious inflammatory response induced by LPS in the brain. We agree with the comment that containment of the inflammatory response in the periphery by IL-37 could prevent the inflammatory consequences in the brain, and we were not sure whether local expression of IL-37 in the brain could be beneficial in blocking the effects of LPS. Therefore, in a separate ex vivo approach, we treated the acute hippocampal slices of IL-37tg mice with LPS and then measured long-term potentiation (LTP) using electrophysiological experiments. Although LTP was impaired when acute slices from WT mice were treated with LPS, this was not the case for slices from IL-37tg mice. Subsequent mRNA expression in acute slices showed that IL-37 expression was higher in slices from IL-37tg mice after LPS stimulation (Data not shown because n was low due to the small amount of materials). Thus, we can conclude that in addition to peripheral IL-37, local induction in the brain during LPS administration may be part of the rescue mechanisms. In our revised manuscript, we have made this point more explicit.</p><p>The information can be found in lines 291-308.</p><disp-quote content-type="editor-comment"><p>4. Background, Lines 87,88: The overall premise that anti-inflammatory therapies will be beneficial in AD is overly simplistic. The inflammatory activation of glial cells is required as a protective immune response, including pro-inflammatory activation. Also, retrospective studies that have demonstrated that NSAIDs are not a successful therapeutic strategy go against this notion. Please consider rephrasing.</p></disp-quote><p>As the editor mentioned, although acute inflammation is part of the body's response to tissue damage and is critical to the healing process, a prolonged inflammatory response can be harmful. Chronic inflammation has been shown to affect and accelerate each of the three hallmarks of AD pathology, including Aβ accumulation, tau phosphorylation, and cognitive decline associated with loss of synapses and neurons. Therefore, attenuating chronic inflammatory processes may be a useful way to treat or prevent the progression of AD. NSAIDs are generally used for their anti-inflammatory, analgesic, and antipyretic effects. NSAIDs work by blocking the production of prostaglandins by inhibiting two cyclooxygenase enzymes. However, prostaglandins contribute to the development of the major signs of acute inflammation. Therefore, as the editor mentioned, they are not a useful therapy to prevent the progression of AD as a result of a chronic inflammatory response.</p><p>We have taken this point into consideration and reworded the mentioned part in the introduction to make it clearer.</p><p>The information can be found in lines 89-91.</p><disp-quote content-type="editor-comment"><p>5. What is known about IL-37 expression in humans? Since it is expressed by all cells in the current model, will this hamper biological interpretation, since the brain RNAseq database suggests that it is highly enriched specifically in microglia? This confounding factor makes biological interpretation of the in-vivo data a little difficult.</p></disp-quote><p>Previously, IL-37 was shown to be constitutively expressed in various human tissues and cells, which may help in maintaining immune homeostasis. IL-37 is expressed in human immune cells mainly in circulating monocytes, tissue macrophages, dendritic cells, tonsil B cells, and plasma cells. In addition, IL-1β and TNF-α were shown to increase the expression of IL-37 in cultured human microglia. Review of the expression profile of human iPSC derived microglia after LPS treatment using the GEO database also reveals the presence of IL-37</p><p>(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE186301), but it is still not clear which cell types in the human brain produce IL-37 abundantly. In the revised manuscript, the previously known information about IL-37 in humans was added in the Introduction and Discussion sections.</p><p>The information can be found in lines 123-127 and 550-554.</p><disp-quote content-type="editor-comment"><p>6. Results, Page 4, Lines 148-152: Description of Figure 1C-1E is confusing and unclear as written. Please consider rephrasing.</p></disp-quote><p>We followed the editor’s advice and rephrased this part.</p><disp-quote content-type="editor-comment"><p>7. Results, Page 5: The points about the TCA cycle metabolites is raised in this section for the first time. Please consider introducing this concept in relation to AD / related immune responses in the introduction.</p></disp-quote><p>The relevant information was added in the revised manuscripts. The information can be found in lines 131-136.</p><disp-quote content-type="editor-comment"><p>8. Figure 3C: Please include what the X-axis is plotting? As a supplemental figure, please include your initial gating strategy used for all flow cytometry data. Are there any CD68+CD11b+ CD45 high cells in these animals? If an effect of IL-37 is seen in filtration of peripheral inflammatory macrophages into the brain, this is a very strong data set to improve the impact of this figure.</p></disp-quote><p>All detailed information on plot axis and gating strategies was added to the revised manuscript. In addition, the FACS data were reanalyzed to verify the populations of infiltrating macrophages expressing CD68 in the brains of WT and IL-37tg mice after LPS challenge. Supplementary Figure 3 is included in the manuscript. The corresponding information can be found in lines 227-238.</p><disp-quote content-type="editor-comment"><p>9. Results, page 7: The authors make the statement that IL-37 signaling has a significant impact on the pro-inflammatory activation of microglia in the brain. However, this is based on just the measurement of IL-1b and microglial numbers. The authors should measure other markers of inflammation that are known to go up in the brain upon LPS challenge. Maybe using an Elisa based multiplex assay such as MSD or Luminex to measure brain inflammatory cytokines will add to this data set.</p></disp-quote><p>In this study, we specifically analyzed IL-1ꞵ because the production of this cytokine depends on the activation of the NLRP3 inflammasome, which also includes IL-18 and the closely related IL-37; all of these cytokines belong to the IL-1 family. This cytokine is an important mediator of the inflammatory response, particularly upon LPS stimulation (Lopez-Castejon and Brough, 2011). Therefore, we focused on this selected known cytokine.</p><p>However, in the new experiment, we also measured the levels of other cytokines, including IL-6 and TNF-α, using Elisa and added the data to the revised manuscript in supplementary Figure 2.</p><p>For microglia, we also analyzed CD68 expression, which in combination with proinflammatory cytokines (IL-1ꞵ) in brain and cultures represent features of high activation and neuroinflammatory processes.</p><p>These points have been highlighted in the revised manuscript. The information can be found in lines 227-230.</p><disp-quote content-type="editor-comment"><p>10. Results, page 7: Figure 4A-4B: Was the LPS injection used for these experiments the same as outlined for figure 3? Please clarify this in the method section, especially since 2 different LPS treatment paradigms have been used for 4A-4B and 4G-4H.</p></disp-quote><p>Because Figure 4A-C are the electrophysiological experiments after LPS challenge in vivo, the timing of the experiment is the same as in Figure 3, but we have made this clearer in the revised manuscript. The methods and information for Figure 4G-I have been included in the Methods and Results sections. The information can be found in lines 291308 and 909-914.</p><disp-quote content-type="editor-comment"><p>11. The paradigm for the Y-maze testing (pre-treatment with IL-37, followed by IL1b), though in-line with the current study, is not biologically relevant. Since IL-37 will be upregulated as part of the neuroinflammatory response, have the authors tried to treat animals with IL-37 after IL-1b or concurrently with IL-1B?</p></disp-quote><p>Although we agree with the comment that the best therapeutic regimen for the anti-inflammatory agent is to use it after the onset of symptoms, in this part of the study we focused on recommending rIL-37 as a preventive strategy rather than as a therapeutic agent for acute inflammation. In addition, pro-inflammatory members of the IL-1 family were hypothesized to play an important role in the pathophysiology of sepsis, as serum levels of these cytokines were greatly increased in patients with sepsis. Moreover, injection of IL-1β elicits an acute and rapid response in the body (similar to septic shock), making the search for preventive strategies for these conditions of great importance compared with therapeutic strategies, because the immune response is very rapid and not gradual. We have tried to make this point clearer in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>12. Figure 1B: This figure suggests that 1 i.p injection with rIL-1B completely abolishes any working memory In WT mice. This is surprising. Please clarify.</p></disp-quote><p>Acute systemic inflammation has been shown to cause deficits in working memory early in the disease course in dementia models. Moreover, systemic inflammation primarily impairs attention and cognitive flexibility, including working memory, rather than associative learning. Therefore, short-term memory formation may be more vulnerable to even mild inflammatory responses, as it has been shown that a low-dose injection of LPS, which elicits a very mild immune response and small changes (&lt; 1 °C) in core body temperature, severely impairs working memory (Murray et al., 2012). This is not the case for long-term memory formation. We therefore hypothesized that a systemic injection of IL-1β, which induces strong systemic inflammation, can completely abolish working memory, which is also confirmed by our results. These points have been carefully highlighted in the Discussion section. The information can be found in lines 590-597.</p><disp-quote content-type="editor-comment"><p>13. For Figures6 and 7: Were both sexes used for APPPS1 studies? If so, please clarify in the methods section as to the number of males and females, given that female APPPS1 mice show more aggressive disease as compared to males.</p></disp-quote><p>Mainly male mice were used in this study. All detailed information about the sexes of the mice was clarified in the revised manuscript. The information can be found in lines 885886.</p><disp-quote content-type="editor-comment"><p>14. Figure 6. Please show all gating strategies as well as relevant gates drawn to identify CD11b+ CD45low microglia, as well as the methoxy X-04+ vs methoxy X-04- microglia. Is there a CD11b+ CD45high microglial subset at this age, since at earlier timepoints, these distinct microglial subsets are evident and have different activation profiles.</p></disp-quote><p>All detailed information on gating strategies is included in the revised manuscript (lines 382-393). Cx3cr1GFP mice were used in this particular experiment. Therefore, the gating strategies were performed for the positive FITC cell population. The detailed information on this and supplementary Figure 6 are included in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>15. Please include details of how brain tissue was processed to prepare single-cell suspension for all FACS data. i.e: percoll based density gradients or myelin removal beads etc?</p></disp-quote><p>All detailed information on the preparation of single cell suspensions for FACS data has been accurately added to the revised manuscript. The information can be found in lines 994-997.</p><disp-quote content-type="editor-comment"><p>16. Authors discuss their methoxy-X04 data as indicative of &quot;increased clearance&quot; of plaques. Careful interpretation of this data set is required as this assay only measures Abeta &quot;uptake&quot;. Since no measures of clearance have been assessed, please reword and/ reinterpret this in the results and Discussion section.</p></disp-quote><p>We fully agree with this comment. The explanation and interpretation of this experiment was adjusted accordingly in the revised manuscript. The information can be found in lines 382-393 and 682-684.</p><disp-quote content-type="editor-comment"><p>17. Please include representative images for plaque loads in the cortex that correlate with quantification in 6I. Also, please include a representative image for differences in plaque size.</p></disp-quote><p>All the representative images mentioned for specific brain regions and different plaque sizes were added to the revised manuscript. The information can be found in Supplementary Figure 5.</p><disp-quote content-type="editor-comment"><p>18. Figure 7A: Please mention the average age of the animals used in the 3 animal groups for MW testing. 9-12 months is a big age range for these animals and results will be skewed if one cohort is largely composed of older animals vs. younger.</p></disp-quote><p>Carefully age-matched mice were used in all experimental groups. Detailed information on the average age of the animals was included in the revised manuscript. The information can be found in Supplementary Figure 8.</p><disp-quote content-type="editor-comment"><p>19. The Discussion section is rather long and largely used to re-summarize results. The authors should reconsider using this section to put their data into context for the big-picture field of neurodegeneration. Some suggestions – How do the authors picture IL-37 signaling to play a role in human AD?</p><p>a. Given the detailed description of distinct microglial subsets associated with amyloid vs. tau pathology in AD, do the authors anticipate IL-37 to have distinct effects depending on pathological outcomes?</p><p>b. Literature has demonstrated that IL-1b, IL-6 and TNFa from reactive microglia may play a role in exacerbating tau-spread. The authors should discuss the implications of their findings in this light</p><p>c. Is anything is known about IL-37 signaling in other neuroinflammatory models (injury, MS etc)? A possible discussion of these in the context of neuroprotection may strengthen this section.</p></disp-quote><p>All of the above valuable points were included in the Discussion section of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>20. in vitro phenotypes in Figure 1 were not closely connected with the following in vivo neuroinflammation phenotypes. Although three different neuroinflammation models were used, the detailed mechanisms for how IL-37 reduced neuroinflammation were not well addressed.</p></disp-quote><p>Although this study suggests the positive role of IL-37 in modulating microglial activations as a possible key mechanism in controlling neuroinflammation, the detailed mechanisms are not addressed in this manuscript. However, we believe that our findings obtained in various inflammatory models clearly demonstrate the beneficial role of IL-37 and thus may pave the way for future studies to discover the detailed mechanisms and possible neuroprotective potential of IL-37, especially with regard to therapy in humans. The detailed possible underlying mechanisms of the neuroinflammatory potential of IL37 were proposed in the Discussion section of the revised manuscript based on the recent literature examining the beneficial role of IL-37 in autism, MS and spinal cord injury.</p><p>In addition, we performed a single-cell RNA sequencing experiment in the microglial cell population of both WT and IL-37tg mice after LPS challenge. We selected several differentially expressed candidate genes that may be important as key molecules to decipher the IL-37 underlying mechanisms in the future. Figure 8 and supplementary Figure 7 are included in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>21) Figure 3 and Figure 5 showed reduced pro-inflammatory cytokine production in brain lysates. However, glial cells other than microglia, such as astrocytes and infiltrating leukocytes could be sources of inflammatory cytokines. There was no evidence supporting that reduced cytokine levels were intrinsic to microglia as modelled in the in vitro system. Thus, in vitro and in vivo phenotypes appeared somewhat disconnected.</p></disp-quote><p>As noted by the reviewer, the role of other cells in the brain, including astrocytes, brain infiltrating macrophages, and lymphocytes, is not evident in the cytokine assay of brain lysate. However, reanalysis of our FACS data with gating strategies for infiltrating macrophages and lymphocytes revealed no differences between groups, suggesting a smaller population and no significant activation profile compared with microglia. Moreover, based on the new experiment performed with primary astrocyte cultures (see answer to question 1), the key role of microglia in this scenario is suggested. The relevant information was added to the manuscript (lines 171-175) and can be found in supplementary Figure 1 and 3.</p><disp-quote content-type="editor-comment"><p>22) In Figure 5, IL-1β-induced neuroinflammation model was used to demonstrate the beneficial effects of IL-37 on cognition and synaptic function. Could injection of recombinant IL-37 display similar effects for LPS challenge model in Figure 3 and Figure 4?</p></disp-quote><p>As mentioned by the editor, confirmation of the potential anti-inflammatory role of IL-37 in our in vivo model with LPS challenge is of great importance. We performed new experiments and pre-treated the mice with rIL-37 followed by LPS challenge. Subsequently, the level of pro-inflammatory cytokines in the brain was measured using Elisa. The new data were added to the revised manuscript. The information can be found in the manuscript (lines 335-346) and in supplementary Figure 4.</p><disp-quote content-type="editor-comment"><p>23) Reduced IL-37-mediated neuroinflammation was shown in both chronic and acute models in the manuscript. Did microglia or other cells play a major role in those models? The detailed mechanisms regarding cell type contribution were largely missing in the manuscript.</p></disp-quote><p>The detailed information on the importance of microglial function in neuroinflammatory processes and in the progression of Alzheimer's disease, based on the most recent findings, was added to the revised manuscript.</p><p>In addition, the new experiments on the role of astrocytes and other infiltrating immune cells in this scenario were added to the revised manuscript. Please see the answers to questions 1 and 21.</p><disp-quote content-type="editor-comment"><p>24. Figure 2 showed differential metabolomic profiling of microglial cells between WT and IL-37tg mice. However, there was no further evidence demonstrating that the metabolic function of microglial cells was indeed altered by IL-37 expression. It would be better to show the results of seahorse or other metabolic functional assays.</p></disp-quote><p>In this study, we focused on the two metabolites that have been shown to be associated with inflammation in macrophages. We fully agree with the reviewers that further experiments showing metabolic alterations could be useful to address the subsequent changes in more detail. However, it has already been pointed out that itaconate and succinate in particular are involved in inflammation, especially in macrophages. Further data on the expression level of the <italic>Acod1</italic> gene specifically in microglia, which is responsible for itaconate production, was also added to the revised manuscript. There was no significant differences in <italic>Acod1</italic> expression after LPS challenge between WT and IL-37tg mice, which may be due to the degradation of this transcript that has already occurred (although <italic>Acod1</italic> was still slightly less expressed in the IL-37tg mice). The information can be found in the manuscript (lines 622-636) and in supplementary Figure 7.</p><disp-quote content-type="editor-comment"><p>25. The models for acute neuroinflammation including LPS and IL-1β challenge were systematic inflammation. It might be reasonable to propose that reduced neuroinflammation was a secondary effect to reduced inflammation response in the periphery. In addition, in Figure 3, would injection of LPS twice induce tolerance responses?</p></disp-quote><p>We agree with the reviewer that containment of the inflammatory response in the periphery by IL-37 could prevent the inflammatory consequences in the brain (please see the answer to question 3).</p><p>As mentioned in the comment, the immune tolerance phenomenon is very important in this study. The protocol for 2-times LPS injection was adopted from the study by Wendeln et al. 2018. Their results clearly showed that tolerance in the peripheral immune response occurred after the 2-times LPS injection, as indicated by the cytokine expression levels in the serum. Remarkably, however, this was not the case for the CNS, as cytokine levels in the brain were significantly increased after the second LPS injection.</p><disp-quote content-type="editor-comment"><p>26. In Figure 3 and Figure 6, CD68 was used as an activation marker for microglia. However, CD68 expression by itself is not enough to define microglia to be in the activation state. The phenotypic changes of microglial cells would also depend on specific models used. Additional experimental evidence is needed for defining the reduced activation status of microglia in IL-37tg mice.</p></disp-quote><p>CD68 is a lysosomal protein that is highly expressed by activated macrophages and activated microglia and expressed to a very low extent by resting microglia, as evidenced by much of the literature (Urga et al. 2020, Kettenmann et al. 2011 or Yang et al. 2013). Therefore, CD68 can be considered a well-established activation marker for microglia. However, in this study, our results additionally showed a lower number of IBA-1-positive cells and lower IL-1β expression in the brain of IL-37tg mice after LPS challenge, which may confirm the reduced activation status of microglia in IL-37tg mice. The relevant literature on CD68 as an activation marker for microglia were added to the revised manuscript.</p></body></sub-article></article>